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Classification of influenza viruses
Influenza viruses are very small pathogens (typically 80-120 nm) belonging to the family of the 
Orthomyxoviridae together with four other genera: Thogoto virus, Isavirus and influenza B and C 
viruses.  The influenza viruses are distinguished based on the membrane channel protein, genome 
size and surface glycoproteins. The influenza A viruses are further subdivided into subtypes based 
on the surface glycoproteins hemagglutinin (HA) and neuraminidase (NA) (Figure 1). At present, 16 
subtypes of the HA and 9 subtypes of the NA are known (1).
Structure of influenza A viruses and their proteins 
Influenza A viruses are enveloped single stranded negative sense RNA viruses with a genome 
consisting of eight gene segments encoding eleven different proteins. These eight RNA segments 
are independently encapsidated by the nucleoprotein (NP) and associated with the polymerase 
proteins PB1, PB2 and PA, which together form the ribonucleoprotein (RNP) complex (2). The 
polymerase proteins are responsible for replication and transcription of vRNA and mRNA 
respectively (3). The matrix protein M1 functions as a spacer between the RNP complexes and the 
viral envelope and interacts with both. The viral envelope is derived from the host cell membrane. 
Two major surface glycoproteins (HA and NA) are inserted and protrude from the viral envelope. 
The HA is the receptor binding protein, facilitating attachment of the virus particle to the host cell. 
The HA is synthesized as a precursor polypeptide HA0 which requires proteolytic cleavage into HA1 
and HA2 subunits before it becomes functional and virus particles can infect cells. The HA1 subunit 
contains the receptor-binding pocket and the relatively conserved HA2 unit constitutes the stem 
region containing the fusion peptide. This fusion peptide plays an important role in pH-dependent 
fusion of the viral envelope with the endosomal vesicle. 
By acting as a receptor-destroying enzyme, the NA plays an important role in the virus replication 
cycle after budding of new viruses from the infected cell. NA cleaves sialic acid residues, which 
promotes release of newly produced virus particles from the infected cell. The minor envelope 
protein, M2, is the result of alternative splicing of mRNA encoding M1. It functions as an ion channel 
and facilitates the influx of H+ ions into the virus particle. M2 is the target for the antiviral drug 
amantadine. Two non-structural (NS) proteins are also expressed in the infected cell, NS1 and NS2. 
NS1 is a multifunctional protein and is known for antagonizing the host cell IFN production and 
its activity (3). NS2 is involved in nuclear transport of RNP complexes. Recently, the eleventh viral 
protein was identified which is transcribed from an alternative reading frame of PB1 (PB1-F2) (4). 
Most likely, this protein plays a role in promoting apoptosis of the infected cell.
As for other virus infections, influenza viral proteins are degraded in the cytosol of the infected cell 
by the proteasome into peptides. These peptides are transported to the endoplasmatic reticulum 
where they can bind to MHC class I molecules. The MHC class I peptide complexes are subsequently 
transported to the surface of the infected cells where they can be recognized by virus specific CD8+ 
T cells (see below).
Influenza A virus replication cycle
To start virus replication, the virus needs to attach to host cells first. Therefore, attachment of the 
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virus to the host cell is crucial and is thought to be the major determinant for the host range of 
influenza A viruses (5). After binding of the HA of the influenza virus particle to the sialic acid 
residues on the host cell surface, the virus enters the cell through receptor-mediated endocytosis. 
The low pH in the endocytic compartments activates fusion of the viral membrane with the cell 
membrane which releases the RNPs into the cytoplasm. After transport of the RNP to the nucleus, 
the viral RNA is transcribed in the nucleus into messenger RNA and copy RNA. Messenger RNA is 
used for the translation of viral proteins and copy RNA serves as a template for viral RNA synthesis. 
Viral RNA and newly formed proteins together constitute new RNPs, which are packaged into new 
virions. Subsequently, the NA cleaves sialic acid residues from the cell surface to facilitate efficient 
release of the viral particles.
Natural hosts of influenza viruses
Wildfowl and shorebirds are the natural reservoir of all subtypes of influenza A viruses (6).  Low 
pathogenic influenza viruses have been isolated from at least 105 wild bird species (7).  Also 
influenza viruses have been isolated from a number of mammalian species, including horses, swine, 
marine mammals, mink and ferrets. The fact that influenza A viruses cross the species barrier easily 
is not only demonstrated by the recent influenza A/H5N1 and influenza A/H1N1(2009) infections 
of humans, but also by the recent isolation of equine influenza A/H3N8 from dogs with severe 
pneumonia (8). In addition to infection of humans with avian influenza A/H5N1 viruses, a number of 
animal species have been infected with these viruses. This includes tigers, leopards, cats, dogs, other 
free-living wild carnivores and a number of bird species (9-11).
A
C
B
Figure 1. Electron Microscope (EM) images and 
schematic overview of nfluenza A virus particle. 
A. EM images of influenza A virus particles besides 
the membrane and cytoplasm of a 293T cell. B. 
EM picture of clustered influenza A virus particles 
(images kindly provided by Dr. S. Herfst and T. de 
Jong). C. Schematic overview of an influenza A 
virus particle with the outer surface proteins and 
the eight RNA segments.
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Influenza A virus in humans 
Influenza-like illness in humans was already recorded more than 2000 years ago by Hypocrates, 
while the first human influenza A virus was isolated in during the 1932/1933 epidemic by Smith, 
Andrewes and Laidlaw. At present, influenza A and B viruses continue to circulate among humans, 
mainly during the winter season of both hemispheres. Clinical signs after infection of humans with 
epidemic influenza A virus and after infection with influenza A/H1N1(2009) viruses strains include 
nasal obstruction, cough, fever, anorexia and headache but complications with severe pneumonia 
do occur. Mainly the young, elderly and immunocompromised people are at risk for developing 
severe disease after infection with seasonal influenza virus either due to viral pneumonia or 
secondary bacterial pneumonia causing approximately 250,000 to 500,000 deaths annually (12). In 
addition to influenza epidemics caused by seasonal influenza viruses, pandemics occur occasionally. 
Influenza pandemics are caused by influenza A viruses of novel subtypes that emerge after genetic 
reassortment (antigenic shift) or adaptation to replication in humans of non-human influenza 
viruses. In the absence of virus-neutralizing antibodies to these novel subtypes of influenza A virus 
in the human population, these viruses can affect a substantial proportion of the human population 
when transmitted efficiently from human-to-human. In the last century, three pandemics occurred, 
which were caused by influenza A viruses of the H1N1, H2N2 and H3N2 subtypes. Recently, 
influenza A viruses of swine origin have caused the first pandemic of the 21st century (13, 14). These 
newly emerged pandemic viruses are the result of the exchange of gene segments originating from 
human, classical swine and avian-like swine influenza viruses and have spread worldwide within 
a few months (15, 16). In contrast to the efficient human-to-human transmission and the rapid 
spread of the new influenza A/H1N1 viruses, the highly pathogenic avian influenza A viruses of the 
H5N1 subtype, first detected in humans in 1997 (17, 18) are transmitted from human-to-human 
inefficiently so far, although clusters of human-to-human transmission have been reported (19, 
20). However, over 500 human cases that have been reported since 2003 of which 60% had a fatal 
outcome and therefore it is feared that these viruses may adapt and become pandemic in the future 
(21). In addition to avian A/H5N1 viruses and the new A/H1N1 viruses of swine origin also influenza 
A viruses of other subtypes have crossed the species barrier and have infected humans recently. In 
2000, an avian influenza A/H9N2 virus infected two children in Hong Kong causing only mild disease 
(22) whereas during an outbreak of highly pathogenic avian influenza A/H7N7 in poultry in the 
Netherlands, 89 humans were infected of which one died (23).
Clinical symptoms after infection with the highly pathogenic influenza A/H5N1 virus develop in 
most cases 2-4 days after the last exposure to affected poultry. Clinical signs include fever, cough 
and shortness of breath. On chest radiographs, evidence of pneumonia is present. The pneumonia 
seems in most cases of primary viral origin without evidence of bacterial supra infection. Other 
symptoms are diarrhea, vomiting and abdominal pain. In more severe cases a progressive bilateral 
pneumonia develops rapidly, with complications that include acute respiratory distress syndrome, 
renal dysfunction and multiorgan failure. Indications of involvement of the central nervous system 
were only present in one case. Progressive respiratory failure is in most cases the cause of death, but 
there is evidence that influenza A/H5N1 viruses can disseminate to other organs (24). 
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Immunity to influenza viruses
The immune system of mammals has developed several lines of defence to prevent the invasion of 
pathogens or to limit their replication. Before attachment and infection of the host cells is possible, 
there are several hurdles to be taken. The innate immune response creates the first line of defence, 
is broadly-reactive and plays a crucial role in the induction and direction of the adaptive immune 
response. In addition, the innate immune system is essential for the host during the first 4-7 days 
after infection until the adaptive response can have an effect. In contrast to the innate immune 
response, the adaptive immune response is very specific and is able to provide an increased level of 
protection against reinfection with a certain pathogen.
Innate immune response
The innate immune system recognizes pathogen-associated molecular patterns (PAMP) and 
endogenous danger signals (25). The major PAMP of the influenza virus is thought to be 
cytoplasmatic viral RNA species that contain triphosphate groups at their 5’ ends (26). Host cells 
detect the presence of an infecting virus by pattern recognition receptors (PRR) that recognize 
the PAMP. PRRs are divided into several families, including nucleotide-binding oligomerization 
domain (NOD)-like receptors, Toll-like receptors (TLRs), and retinoic acid-inducible gene-I (RIG-I)-
like helicases. Recognition of PAMP leads to initiation of antiviral signaling cascades that induces an 
antiviral response, the infected tissue is in an ‘alerted state’. This alerted state results in the secretion 
of cytokines (e.g. type I and III interferons) and secretion of chemokines to attract and activate 
inflammatory cells (e.g. natural killer cells) and antigen presenting cells (dendritic cells). Especially 
dendritic cells play a crucial role in the induction of the adaptive immune response as they migrate 
to the afferent lymph node to present their antigen to T cells.
Table 1. Viral targets for the induction of protective antibody responses
Viral antigen Mode of action Comments
HA Prevents virus attachment to host 
cells
• Antibodies must have proper specificity
• Strain specific
NA Inhibits enzymatic activity of NA 
and spread of virus
• Antibodies must have proper specificity
M2 Induction of antibody-dependent 
cell-mediated cytotoxicity (ADCC) 
and elimination of infected cells
• M2 is highly conserved
• Hyperimmunization induces cross-protective 
immunity
NP Largely unknown, complex 
formation?
• Non-neutralizing
• Mode of action and effectiveness unknown
Adaptive immune response
In contrast to the innate immune response, the adaptive immune response is highly specific and 
is characterized by the development of memory for a specific pathogen. This indicates that upon 
re-encounter of the host with a certain pathogen the immune response is stronger and more 
rapidly. The adaptive immune response consists of the humoral antibody-mediated response 
and the cellular T-lymphocyte-mediated response. Upon recognition of their antigen and specific 
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stimulation signals, B-lymphocytes start to proliferate and differentiate into plasma cells that are 
able to secrete antibodies. Multiple isotypes of antibodies exist. For the protection against influenza 
viruses, mainly antibodies of isotypes IgA, IgG and IgM are important. IgA antibodies can play an 
important role in the protection against influenza viruses as they are the main class of antibodies 
in the secretions of the mucous epithelium of the respiratory tract, while IgG antibodies are the 
prinicipal isotype of blood and extracellular fluid and thought to be the most effective antibodies 
against infection with influenza A viruses. 
T cells can be further subdivided into the CD4+ and CD8+ T cells. CD4+ T cells recognize antigen 
presented by the MHC-class II molecules and play a crucial role in the regulation of the immune 
response. CD4+ T cells are divided into various subsets, of which especially T helper 1 and T helper 
2 cells are thought to play an essential role in the control of virus infections. T helper 1 cell stimulate 
the CD8+ T cells by secretion of certain cytokines (27-30), while T helper 2 cells are important for the 
virus-specific antibody response since they play a role in the optimal activation and early expansion 
of B cells, the initiation and maintenance of germinal center reaction and the generation of long-
lived plasma and memory B-cells (31-34). Furthermore, it has been suggested that CD4+ T cells also 
can attack virus-infected host cells directly (35).
The latter function is especially executed by virus-specific cytotoxic T lymphocytes (CTL). After 
initial stimulation and differentiation into CTL with an effector phenotype, CD8+ T cell are able to 
recognize and kill virus-infected cells that present certain epitopes on the surface of the cell by the 
MHC class I molecules. CTL can eliminate virus-infected cells through the release of perforin and 
granzyme or Fas/FasL interaction. In addition, activated CD8+ T cells produce cytokines like IFN-γ 
and TNF-α which can modulate the immune response
Table 2. Viral targets for the induction of protective T cell responses.
Viral antigens Type of response Comments
All viral proteins CD4+ T helper 
cell response
• Polarization (Th1/Th2) dependent on antigen  delivery
• Essential for B-cell and CD8+ CTL responses
• Direct action against infected cells
• HLA restricted
PB1/PB2/PA/NP/
M1/M2/ NS1
CD8+ CTL 
response
• Key role in elimination of infected cells
• Cytokine production
• HLA restriction dictates magnitude of response
• Only marginal response to HA
Viral targets for the induction of immunity against influenza A viruses
The envelope proteins are the most important targets for the induction of virus-specific antibodies 
(Table 1 and Figure 2). The induction of sufficiently high titers of HA-specific antibodies affords 
sterilizing immunity against infection provided that these antibodies have the proper specificity 
for the strains causing the infection. The induction of NA specific antibodies also contributes to 
protective immunity, but since these antibodies interfere with a late step in the virus replication 
cycle they cannot prevent infection. Furthermore, NA-specific antibodies need to have specificity 
for the strain causing the infection, like HA-specific antibodies. In contrast, M2-specific antibodies 
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induced after hyperimmunization or passively administered, afford protection against multiple 
influenza virus strains and even against multiple subtypes of influenza A virus, since this protein is 
highly conserved. Also M2-specific antibodies do not afford sterilizing immunity since their most 
important mode of action is through ADCC after binding to infected cells expressing M2 on their 
surface. The mode of action and the effectiveness of non-neutralizing NP-specific antibodies are 
not fully understood although it has been demonstrated after hyperimmunization that they afford 
some protection (36). 
In addition to the systemic and/or mucosal antibody responses, also virus-specific T cells contribute 
to protective immunity against infection (Table 2). T helper cells are directed to virtually all viral 
structural proteins and polymerases, while virus-specific CTL preferentially recognize internal 
structural proteins like NP and M1. Since these proteins are highly conserved between subtypes, 
CTL responses are cross-reactive and are tought to contribute to heterosubtypic immunity.
Figure 2. Overview of the targets of the immune system for the induction of protective immunity against influenza. 
(A) HA-specific antibodies can bind to the HA on viruses and prevent infection of cells. (B) M2e specific antibodies can 
bind to M2e on virus-infected cells and induce antibody-dependent cell-mediated cytotoxicity (ADCC). (C) NA specific 
antibodies inhibit enzymatic activity of NA and thus further spread of newly produced virus particles. (D) Pathogens 
and proteins are broken down into peptides within acidified endosomes and these peptides bind to MHC Class II, 
MHC Class II peptide complexes are subsequently transported to the surface of the cell for recognition by CD4+ T 
cells. (E) The mode of action of NP-specific antibodies is largely unknown. (F) Influenza viral proteins are degraded in 
the cytosol of the infected cell by the proteasome into peptides that are transported to the endoplasmatic reticulum 
where they can bind to MHC class I molecules. The MHC class I peptide complexes are transported to the surface of the 
infected cells for recognition by CD8+ T cells, which subsequently eliminate the infected cell.
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Heterosubtypic immunity
Infection with influenza virus does not induce lifelong protective immunity against influenza 
infection in humans, even not against infection with the same subtype. The main reason for this 
is that influenza A viruses continue to circulate as antigenic drift variants, that have accumulated 
mutations in antigenic sites of the HA molecule that are recognized by virus neutralizing antibodies. 
However, the induction of antibodies of the proper specificity will afford strain-specific protection 
and this strain-specific immunity can be very long lasting (37, 38).
Since subtypes of the influenza viruses are defined by the absence of mutual cross-reactivity of 
subtype specific antibodies (39), antibodies to one subtype will not afford protection against infection 
with an influenza virus of another subtype. However, it has been demonstrated that infection with 
an influenza A virus can induce a certain degree of protective immunity against infection with an 
influenza A virus of another subtype, although infection cannot be prevented (40). This so-called 
heterosubtypic immunity was first described more than four decades ago (41). Heterosubtypic 
immunity induced by infection has shown to be long-lasting (18 months) in the ferret model, which 
is the gold standard model for human influenza A virus infections (42). The immunologic basis 
underlying heterosubtypic immunity has been the topic of numerous studies (40). Experiments 
in multiple knock-out and transgenic mouse models have shown that virus-specific CD4+ T cells 
(T helper cells), CD8+ Cytotoxic T cells (CTL), mucosal antibodies (IgA) and B cells can contribute 
to heterosubtypic immunity (36, 43-47). Especially cell-mediated immune responses directed to 
conserved proteins of influenza A viruses are believed to play an important role (48-51). Indeed, 
human cytotoxic T lymphocytes (CTLs) responses directed to human influenza A viruses display 
considerable cross-reactivity with HPAI viruses of the A/H5N1 subtype.(51-53). Consequently, also in 
humans the presence of cross-reactive CTLs inversely correlated with the amount of viral shedding 
in the absence of antibodies specific for the virus used for experimental infection.(50) Thus, cross-
reactive T cell responses induced after previous infection may afford some degree of protection 
against influenza A viruses of novel subtypes. There is also evidence that indeed infection with 
influenza A virus can induce heterosubtypic immunity in humans. Individuals that had experienced 
an infection with an influenza A/H1N1 virus before 1957 less likely developed flu during the H2N2 
pandemic of 1957 (54). In this respect, the disproportional age distribution of severe human H5N1 
cases and the relatively high mortality rates new H1N1 influenza virus infections among younger 
individuals is of interest and at present a matter of debate (55-57). Especially younger individuals are 
at risk and although other confounding factors cannot be excluded, it is tempting to speculate that 
young subjects have been infected with seasonal influenza viruses less frequently and therefore 
have not developed protective heterosubtypic immune responses against infection with the new 
influenza A/H1N1 virus and the highly pathogenic avian A/H5N1 viruses. 
Influenza A virus vaccines
Since seasonal influenza A viruses of the H3N2 and H1N1 subtypes and influenza B viruses cause 
epidemics annually associated with excess morbidity and mortality mainly among the elderly, 
immuno-compromised and other high-risk groups, influenza vaccination is recommended for 
these high-risk groups. Furthermore, due to the higher risk of complications and hospitalizations 
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secondary to influenza in children (58, 59), annual vaccination of all healthy children 6 to 59 months 
of age was recommended in various countries including the United States since 2007 (60). Also 
in Europe, vaccination of children is currently considered and a number of countries already 
recommend vaccination of healthy children (61). Annual vaccination against epidemic flu has been 
shown to be (cost-) effective in children since it decreases the burden of disease and the number 
of hospitalizations due to infection with influenza A viruses (62-66).  Most influenza virus vaccines 
that are currently used against seasonal influenza viruses and against the influenza A/H1N1(2009) 
virus are prepared by infecting embryonated chicken eggs with influenza virus vaccine strains. 
Subsequently allantoic fluids of infected eggs are harvested and the egg-derived virus is purified. 
Depending on the vaccine manufacturer, influenza viruses are inactivated with formaldehyde or 
ß-propiolactone to prepare a whole inactivated influenza virus vaccine or treated with a detergent to 
prepare a split or subunit influenza vaccine. Subunit vaccines are, after treatment with a detergent, 
further purified to remove all viral proteins and lipids except the HA and NA. Live attenuated viruses 
are typically attenuated by adapting viruses to replicate at lower temperatures, while cold-adapted 
vaccine strains are subsequently prepared by reassortment with selected epidemic strains to ensure 
that the vaccine strains contain the proper HA and NA. 
To increase the immunogenicity of influenza A virus vaccines, adjuvants can be used. At present, 
many of these non-specific stimulators of the immune system have been developed for use in 
influenza A virus vaccines. The value of adjuvants has been especially demonstrated for weak 
immunogens, like the influenza A/H5N1 virus. Furthermore, it has been demonstrated that the 
use of adjuvants allows dose sparing of the antigen and broadens the specificity of the antibody 
responses that are induced (67, 68). In addition to the use of adjuvants, alternative formulations 
and methods to prepare influenza virus vaccines are in various stages of development or already 
licensed. Examples are the production of vaccine strains by reverse genetics, the use of virosomes 
and virus-like particles and the expression of viral genes in recombinant baculoviruses or modified 
vaccinia viruses (69-74).
Figure 3. Stages in the development of novel influenza A virus vaccines
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Use of animal models for influenza virus vaccine research
Ideally, the effectiveness of novel seasonal influenza vaccines is assessed in clinical trials. However, 
in most cases large numbers of study subjects are required considering the attack rate (5-10%) 
of influenza viruses, which makes these studies very costly. Therefore, there should be a good 
justification for studies like this and preclinical evaluation of candidate vaccines is essential for the 
selection of promising candidates to be tested in clinical trials. For pandemic influenza vaccines it 
is not possible to assess their effectiveness in humans for obvious reasons: the pandemic viruses 
are not yet circulating and experimental infections are potentially very dangerous. In those cases 
only the immunogenicity of candidate vaccines can be determined, but not the protective efficacy 
of vaccine-induced immune responses. Therefore, to assess their protective efficacy, the preclinical 
testing of candidate pandemic influenza vaccines in appropriate animal models is essential. In table 
3, advantages and disadvantages of various animal species that are commonly used for influenza 
vaccine research are listed (Table 3) and in Figure 3 stages in the development of novel influenza A 
virus vaccines are shown.
Table 3. Advantages and disadvantages of animal models most commonly used for the evaluation 
of candidate vaccines.
Species Advantages Disadvantages
Mouse • Cheap
• Short reproduction time
• Good availability of immunological 
reagents
• Allows mechanistic studies (inbred 
species and genetically modified mice)
• Genomics approach possible
• Evaluation of vaccines in elderly mice 
possible
• Predictive value not always clear
• Most seasonal strains need to be adapted
• Pathogenesis does not resembles that of 
humans
• Most strains used are inbred strains
• Not suitable for the evaluation of live 
attenuated influenza A virus vaccines
Guinea pig Suitable for transmission studies • Pathogenesis does not resemble that of 
humans
• No clinical signs after infection 
Ferret • Pathogenesis resembles that of humans
• Suitable for transmission studies
• Pattern of virus attachment resembles 
that of humans
• Poor availability of immunological 
reagents
• Perhaps more susceptible to influenza A 
viruses than humans (especially newborn 
ferrets), sometimes difficult to obtain 
specified pathogen free animals
Macaque • Good predictive value of vaccine 
immunogenicity and protective efficacy
• Immune system resembles that of 
humans
• Genomics approach possible
• Expensive
• Ethical issues
• Need of experienced personnel
18
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Outline of this thesis
In this thesis, the impact of the use of seasonal and pandemic influenza A vaccines was evaluated 
in the light of the pandemic threat of the highly pathogenic avian influenza A/H5N1 viruses. In 
chapter 2, the presence of heterosubtypic immunity against influenza A/H5N1 virus after infection 
with influenza A/H3N2 virus was evaluated in the mouse model and immunological assays were 
performed to assess the correlation between survival and the CD8+ T cell response.
Based on these findings and the recent recommendation of public health authorities of a number 
of countries, including the USA and some European countries, to vaccinate all healthy children 
6-59 months of age against seasonal influenza it was questioned whether annual vaccination 
of young children against seasonal influenza may have a potential downside. Since annual 
vaccination against seasonal influenza is effectively preventing infection, it also may prevent the 
induction of immune responses that otherwise could have been induced by infection. To test this 
hypothesis, mice were vaccinated with either a influenza A/H3N2 subunit vaccine (chapter 3) or 
a whole inactivated influenza A/H3N2 virus (chapter 4) vaccine before mice were inoculated with 
influenza A/H3N2 virus. Four weeks after inoculation with the influenza A/H3N2 virus, mice were 
challenged with an influenza A/H5N1 virus and clinical symptoms, viral load in the lungs and CD8+ 
T cell immunity were  assessed after challenge. In addition to studies in the mouse model, the ferret 
model was used to demonstrate the presence of heterosubtypic immunity induced by infection 
with an influenza A/H3N2 virus and to evaluate the effect of vaccination against seasonal influenza 
viruses on the development of heterosubtypic immunity in this species (chapter 5). Since it can be 
of great importance for the implementation of adequate vaccination strategies to know at which 
age children will have antibodies against multipe influenza viruses, the presence of antibodies 
against seasonal influenza viruses in children in the Netherlands was evaluated to assess the 
proportion of children that had experienced an influenza virus infection between 0 and 7 years of 
age. To this end, sera were used from children 0-7 years of age collected during a nation-wide sero-
epidomological study (chapter 6). In addition, virus-specific antibody and CD4+ and CD8+ T cell 
responses of children with cystic fibrosis that were vaccinated against seasonal influenza annually 
were compared with unvaccinated healthy control children in chapter 7 to evaluate the difference 
in the virus-specific immune responses between these two groups.
Besides studies involving the impact of the use of seasonal influenza virus vaccines on the 
development of heterosubtypic immunity, the immunogenicity and protective efficacy of the novel 
adjuvant CoVaccine HT™ in combination with a whole inactivated influenza A/H5N1 virus vaccine 
was assessed in chapters 8 and 9 . To this end,  in vitro experiments with dendritic cells  and in vivo 
vaccination experiments were performed in mice and ferrets. 
In addition, in chapter 10 the pathogenicity of influenza A/H5N1 virus after intranasal and 
intratracheal inoculation of ferrets are described.
Collectively, studies presented in this thesis demonstrate the role of infection with seasonal 
influenza viruses and the use of seasonal inactivated influenza virus vaccines on the development 
of heterosubtypic immunity and show that the novel adjuvant CoVaccine HT™ in combination 
with a low dose of antigen can establish protection against influenza A/H5N1 virus after a single 
vaccination. The potential implications of these findings are discussed in chapter 11.
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ABSTRACT
The transmission of highly pathogenic avian influenza (HPAI) A viruses of the H5N1 subtype from 
poultry to man and the high case fatality rate fuels the fear for a pandemic outbreak caused by 
these viruses. However, prior infections with seasonal influenza A/H1N1 and A/H3N2 viruses induce 
heterosubtypic immunity that could afford a certain degree of protection against infection with 
the HPAI A/H5N1 viruses, which are distantly related to the human influenza A viruses. To assess 
the protective efficacy of such heterosubtypic immunity mice were infected with human influenza 
virus A/Hong Kong/2/68 (H3N2) four weeks prior to a lethal infection with HPAI virus A/Indone-
sia/5/05 (H5N1).
Prior infection with influenza virus A/Hong Kong/2/68 reduced clinical signs, body weight loss, 
mortality and virus replication in the lungs as compared to naïve mice infected with HPAI virus A/
Indonesia/5/05. Priming by infection with respiratory syncytial virus, a non-related virus did not 
have a beneficial effect on the outcome of A/H5N1 infections, indicating that adaptive immune 
responses were responsible for the protective effect. In mice primed by infection with influenza A/
H3N2 virus cytotoxic T lymphocytes (CTL) specific for NP366-374 epitope ASNENMDAM and PA224-233 
SCLENFRAYV were observed. A small proportion of these CTL was cross-reactive with the peptide 
variant derived from the influenza A/H5N1 virus (ASNENMEVM and SSLENFRAYV respectively) and 
upon challenge infection with the influenza A/H5N1 virus cross-reactive CTL were selectively ex-
panded. These CTL, in addition to those directed to conserved epitopes, shared by the influenza 
A/H3N2 and A/H5N1 viruses, most likely contributed to accelerated clearance of the influenza A/
H5N1 virus infection. Although also other arms of the adaptive immune response may contribute 
to heterosubtypic immunity, the induction of virus-specific CTL may be an attractive target for de-
velopment of broad protective vaccines. Furthermore the existence of pre-existing heterosubtypic 
immunity may dampen the impact a future influenza pandemic may have.
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INTRODUCTION
Highly pathogenic avian influenza A viruses of the H5N1 subtype continue to cause outbreaks in 
domestic birds and are transmitted regularly from infected poultry to humans. Since 2003, 409 
human cases have been reported of which >60% had a fatal outcome (75). It is feared that these 
viruses adapt to their new host and become transmissible from human to human. Since neutral-
izing antibodies against these viruses are absent in the human population at large, this may spark 
a pandemic outbreak.
However, previous infections with influenza A virus of the H1N1 and H3N2 subtypes responsible for 
seasonal influenza activity, can induce heterosubtypic immunity, which may afford a certain degree 
of protection against viruses of a novel subtype e.g. H5N1. The induction of heterosubtypic immu-
nity by primary influenza virus infection was already recognized more than four decades ago (41) 
and has been demonstrated in various animal models including mice (76, 77), pigs (78, 79), ferrets 
(42), chickens (80) and cotton rats (81), using various combinations of influenza A virus subtypes 
for priming and challenge infection. There is also direct and indirect evidence for the existence of 
heterosubtypic immunity in humans. It was demonstrated that individuals that experienced an in-
fection with influenza A(H1N1) virus in preceding years were partially protected from infection with 
the pandemic H2N2 virus in 1957 (54).
Several lines of evidence indicate that cell-mediated immunity and in particular CD8+ cytotoxic 
T lymphocytes contribute to heterosubtypic immunity (82, 83). The majority of CTL is directed to 
conserved epitopes located within the relatively conserved proteins of the virus (84) like the nu-
cleoprotein (NP) and the matrix (M1) protein. The cross-reactive nature of CTL not only has been 
demonstrated in various animal models but also in man. Human CTL directed to human influenza 
A virus of the H1N1 or H3N2 subtype can recognize and eliminate cells infected with highly patho-
genic avian influenza viruses of the H5N1 subtype (51-53).
A protective effect of virus-specific CTL was demonstrated after adoptive transfer of these cells to 
naive mice or in mice from which CTL were depleted (42, 47, 83). Also the use of vaccine prepara-
tions that induce (cross-reactive) CTL responses supported a protective role of virus specific CTL in 
heterosubtypic immunity. In humans evidence is sparse, but it was demonstrated that in the ab-
sence of virus-specific antibodies, the presence of cross-reactive CTL correlated with reduced viral 
shedding after experimental infection (50).
Recently we confirmed in a mouse model that a prior infection with influenza A virus X-31 (H3N2) 
protected against a lethal challenge infection with influenza virus A/Puerto Rico/8/34 (A/PR/8/34) 
(H1N1), which correlated with anamnestic CTL responses (77). However, influenza virus X-31 and A/
PR/8/34 share the gene segments that encode the internal viral proteins which, of course, favors 
the induction of cross-reactive CTL responses. Therefore, we wished to investigate the protective 
efficacy of heterosubtypic immunity, induced by infection with a human influenza A virus, against 
infection with a highly pathogenic avian influenza virus of the H5N1 subtype to mimic the natu-
ral situation and the order of infections more closely. For this purpose, influenza viruses A/Hong 
Kong/2/68 (H3N2) and A/Indonesia/5/05 (H5N1) were used. Again, prior infection with a heterosub-
typic strain (H3N2) had a beneficial effect on the clinical outcome of the H5N1 challenge infection 
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and control of virus replication. The CTL response against the H-2Db restricted CTL epitopes NP366-
374 and PA224-233 primed for an anamnestic CTL response to the H5N1-derived peptide variants that 
correlated with the observed protection. 
MATERIAL AND METHODS
Influenza viruses
Influenza viruses A/Hong kong/2/68 (A/HK/2/68) (H3N2) and A/Indonesia/5/05 (A/IND/5/05) (H5N1) 
were propagated in Madin-Darby Canine Kidney (MDCK) cells. Infectious titers of the virus stocks 
were determined in MDCK cells as described previously (85).
Mice
Female specified pathogen free 6-8 weeks old C57BL/6J mice were purchased from Charles River 
(Sulzfeld, Germany) and age-matched at the time point of challenge infection. Mice were infected 
intranasally with 5x102 TCID50 of influenza virus A/HK/2/68 in a volume of 50μl PBS. Control mice 
were mock-infected with PBS or were infected with 5x106 TCID50 of respiratory syncytial virus (RSV) 
in a volume of 50ul. Productive infection with influenza virus A/HK/2/68 and RSV was confirmed 
by virus isolation from the lungs of infected animals on day 4 post infection (p.i.). Four, seven and 
twenty-eight days after infection, mice were euthanized by exsanguination and their lungs and 
spleen were resected. After twenty-eight days, remaining mice were subsequently challenged with 
2x102 TCID50 of influenza virus A/IND/5/05. This is the minimal dose that resulted in a lethal infec-
tion in >90% mice reproducibly. Mice were monitored daily for weight loss and morbidity after in-
fection. Four, seven and fourteen days after challenge infection mice were euthanized and their 
lungs and spleen were resected. Intranasal infections, blood sampling and euthanasia were carried 
out under anesthesia with isoflurane (3%/O2). The animals were housed in filter-top cages and had 
access to food and water ad libitum. During the infection with the influenza A/H5N1 virus, animals 
were housed in bio-safety level 3 containment facilities. The experimental protocol was approved 
by an independent animal ethics committee. 
Serology
Serum samples were obtained before primary infection, four weeks later and four, seven and four-
teen days after challenge infection. After treatment with cholera filtrate and heat-inactivation at 
56oC, the sera were tested for the presence of anti-HA antibodies. For this purpose a hemaggluti-
nation inhibition assay (HI) was used, following a standard protocol using 1% turkey erythrocytes 
and four HA-units of either influenza virus A/HK/2/68 or A/IND/5/05 (86). For this purpose a reverse 
genetics influenza A/IND/5/05 virus was produced from which the basic cleavage site in the HA 
molecule was deleted. The antibody titers obtained with this virus were comparable with those 
obtained with the wild type strain (data not shown). Sera were also tested for the presence of 
virus-neutralizing antibodies specific for the two influenza viruses using a micro virus neutraliza-
tion (VN) assay with 100 TCID50 of the respective viruses (87). Influenza virus A/HK/2/68 specific 
serum was obtained by injecting a rabbit with sucrose gradient purified virus (88). Hyper-immune 
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serum obtained from a swan immunized twice with inactivated influenza H5N2 virus A/Duck/Pots-
dam/1402/86 (Intervet, Boxmeer, the Netherlands) was used as a positive control against the influ-
enza A/H5N1 virus (89).
Lung virus titers
Lungs were snap frozen on dry ice with ethanol and stored at -70oC. Subsequently they were ho-
mogenized with a FastPrep-24® (MP Biomedicals, Eindhoven, the Netherlands) in transport medi-
um (Hanks medium (MEM) containing: 10% Glycerol, 100U/ml penicillin, 100μg/ml streptomycin, 
polymyxin B, Nystatin, Gentamicin, 7,5% NaHCO3, 1M Hepes) and centrifuged briefly. Quintuplicate 
ten-fold serial dilution of these samples were used to determine the virus titers on confluent layers 
of MDCK cells as described previously (85).
Virus-specific T cells
Tetramer staining
Single-cell splenocyte suspensions were obtained using 100μm cell strainers (BD, Alphen a/d Rijn, 
the Netherlands). Red blood cells were removed using erythrocyte lysis buffer (Roche, Almere, the 
Netherlands). The cells were washed with 2% FCS in PBS and stained for flow cytometry with anti-
bodies: CD3e-PerCP, CD8b.2-FITC (BD Pharmingen, Alphen a/d Rijn, the Netherlands) and APC la-
beled H-2Db tetramer with the NP366-374 epitope ASNENMEVM or an PE labelled H-2Db tetramer 
with the NP366-374 epitope ASNENMDAM (Sanquin Research, Amsterdam, the Netherlands). Cells 
were analysed using a FACSCalibur with a high throughput sampler in combination with Plateman-
ager and Cellquest Pro software (BD Pharmingen).
Intracellular cytokine staining of splenocytes after peptide stimulation
Single-cell splenocyte suspensions were obtained as described above. CTL epitopes NP366-374 (AS-
NENMDAM and ASNENMEVM derived from influenza virus A/HK/2/68 and A/IND/5/05 respectively) 
and PA224-233 (SCLENFRAYV and SSLENFRAYV, respectively) were purchased as synthetic peptides 
(immunograde, >70% purity) (from Sanquin Research, Amsterdam, the Netherlands and Eurogen-
tec, Seraing, Belgium, respectively) (90, 91). Four hundred thousand splenocytes were cultured for 
6 h at 37°C in the presence of 5μM of peptide in IMDM (Lonza, Breda, the Netherlands) with 5% FCS 
and Golgistop (BD Pharmingen). The cells were then incubated overnight at 4°C and subsequently 
intracellular IFN-γ staining was performed. In brief, cells were washed with PBS containing 2% FCS 
and Golgistop, stained for flow cytometry with monoclonal antibodies: CD3e-PerCP or CD8b.2-FITC 
(BD Pharmingen), fixed and permeabilized with cytofix and cytoperm (BD Pharmingen) and stained 
with a monoclonal antibody specific for IFN-γ (BD Pharmingen). Cells were analysed on a FACSCali-
bur with HTS module in combination with Platemanager and Cellquest Pro software (BD Pharmin-
gen).
Histopathology and immunohistochemistry
After euthanasia, the lungs of the mice were inflated with 10% neutral buffered formalin. After fixa-
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tion the lungs were embedded in paraffin, sectioned at 4μm and stained with hematoxylin and 
eosin for histological evaluation. Sequential slides were stained using an immunoperoxidase meth-
od with a monoclonal antibody (Clone HB65 IgG2a (American Type Culture Collection)) directed 
against the nucleoprotein of influenza A virus. a Goat-anti-mouse IgG2a HRP (Southern Biotech, 
Birmingham, Alabama, USA) was used as secondary antibody. The peroxidase was revealed using 
diamino-benzidine as a substrate, resulting in a deep red precipitate in the nucleus of influenza 
A virus infected cells and a less intense red staining in the cytoplasm. The sections were counter-
stained with hematoxylin.
Statistical analysis
Data for weight loss, viral titers, antibody titers and virus-specific T cell populations were analyzed 
using the two-sided Student’s t test and differences were considered significant at P<0.05. Cumula-
tive survival was calculated with the Kaplan Meyer log rank test. 
Figure 1. Bodyweight loss after challenge infection with influenza virus A/IND/5/05 in H3N2-primed mice (black 
dots) and mock-infected control mice (grey dots) or RSV-primed mice (white dots) (A,C). Survival of these animals 
after infection with influenza virus A/ IND/5/05 (B,D), which was significantly higher after day 6 for the H3N2-primed 
mice.*(indicates statistical significant difference (p<0.05)
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RESULTS
Clinical outcome of influenza virus A/IND/5/05 infection
To determine whether primary infection with a human influenza A virus can protect against a sub-
sequent infection with a highly pathogenic avian influenza virus two experiments were performed. 
In the first experiment the mice were primed with 5x102 TCID50 of influenza H3N2 virus A/HK/2/68 
or mock-infected with PBS, and four weeks later they were challenged with 2x102 TCID50 of influen-
za H5N1 virus A/IND/5/05. After challenge infection all animals lost weight until day 6. Subsequent-
ly, all but one H3N2-primed animals gained weight and these animals had only mild symptoms 
compared to immunologically naïve control mice (Figure 1A). The proportion survival in the H3N2-
primed group was significantly higher than that in the mock-infected group (p<0.05)(Figure 1B).  
The experiment was repeated with larger groups and an extra control group, primed by infection 
with respiratory syncytial virus (RSV) to exclude non-specific innate immune responses as basis for 
the observed protection. The first two days post challenge infection (p.i.) all groups of mice dis-
played similar weight loss. From day 3 p.i. onwards, the mean body weights between the three 
groups differed. Four days p.i. H3N2-primed mice had lost 12.6% (SD=3.7) of their body weight, 
whereas PBS and RSV inoculated mice lost 16.8% (SD=3.1) and 18.1% (SD=3.2) of their bodyweight, 
respectively (Figure 1C). The weight loss in the H3N2-primed group was significantly lower than in 
the two other groups (p<0.05). On day 6 the mean loss of body weight was 26.5% (SD=1.6) and 27% 
(SD=0.9) for the PBS and RSV inoculated mice and 19.8% (SD=3.4) for the H3N2-primed mice, which 
was significantly lower (p<0.05) (Figure 1D). From day 6 onwards the latter animals gained weight 
and fully recovered within two weeks after challenge infection with influenza virus A/IND/5/05 
(H5N1).
Between day 4 and 6 p.i. one out of eleven H3N2-primed animal and all animals from the PBS and 
RSV control groups became less active, showed reduced muscle strength and started to develop 
respiratory distress, observed as heavy breathing in combination with hunched posture. In combi-
nation with a weight loss of more than 20%, animals had to be euthanized for ethical reasons. The 
survival rate on day 5 p.i. was 100% for the H3N2-primed group and 71.4% and 37.5% for the ani-
mals previously inoculated with PBS and RSV respectively (Figure 1D). Eventually, all animals of the 
PBS and RSV group had to be euthanized (0% survival), whereas only one of the H3N2-primed mice 
had to be taken out of the experiment (91% survival). This difference in survival rate was statistically 
significant (p<0.05).
Serology
Twenty-eight days after primary infection with influenza virus A/HK/2/68, mice developed GMT HI 
antibody titers of 905.1 (SD=1.49) and VN antibody titers of 226.3 (SD=1.49) against the homolo-
gous strain. The sera did not react with influenza virus A/IND/5/05 in either of the assays. 
Lung virus titers
Four and seven days p.i. with influenza virus A/IND/5/05 lung virus titers were assessed. In the first 
experiment lung virus titers of the H3N2-primed mice were significantly lower at these time points 
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p.i. than those of unprimed mice (p<0.05)(Table 1). In the second experiment the lung virus titers on 
day 4 p.i were significantly lower for the H3N2-primed animals: 108.1 TCID50 (SD=10
0.4) than for the 
naïve mice of the PBS group: 109.0 TCID50 (SD=10
0.4) (p<0.05) and RSV group: 108.8 TCID50 (SD=10
0.3) 
(p<0.05) (Table 1). Only the H3N2-primed animals survived the infection post day 7 and the mean 
virus titer in the lungs on that day was 104.6 TCID50 (SD=10
0.7). Fourteen days p.i. infectious virus was 
no longer detectable in the lungs of these animals. 
Table 1: Lung virus titers after infection with influenza virus A/IND/5/05 (H5N1)1 
Days post infection 4 7 14
Experiment 1 HK/2/68  infection 7.7 ± 0.12 4.8 ± 0.52 n.d.3
Mock infection 8.8 ± 0.5 7.0 ± 0.6 n.d.
Experiment 2 HK/2/68  infection 8.1 ± 0.44 4.6 ± 0.7 <1.55
Mock infection 9.0 ± 0.4 † †
RSV infection 8.8 ± 0.3 † †
1 titers are expressed as TCID50 per gram tissue (Log10)
2 significantly lower than the mock-infected mice (p<0.05)
3 n.d. = not done 
4 significantly lower than the mock-infected and RSV-infected mice (p<0.05)
5 average virus titer below the cut-off value, all animals tested negative by virus isolation
† animals did not survive until these time points.
Detection of virus-specific CTL
Tetramers were used to detect CTL specific for the NP366-374 epitope: ASNENMDAM (influenza virus 
A/HK/2/68) and ASNENMEVM (influenza virus A/IND/5/05). Four and seven days after infection with 
influenza virus A/HK/2/68 no tetramer-positive T lymphocytes were detected in the spleen (data 
not shown). However, twelve days p.i. an NP366-374 (ASNENMDAM) specific response was observed 
(Figure 2A). A small fraction of these cells stained positive with both the ASNENMDAM tetramer 
and the tetramer prepared with the NP366-374 epitope (ASNENMEVM) derived from influenza virus A/
IND/5/05 (H5N1). Upon challenge infection with this virus, this double positive fraction was selec-
tively expanded (Figure 2B) in the majority of mice. 
After challenge infection with the influenza A/H5N1 virus, A/IND/5/05-derived NP366-374 
(ASNENMEVM)-specific cells were detected as early as day seven p.i. in both experiments. Of all 
CD8+ T lymphocytes the mean frequency of Tm+ CD8+ cells was 5.3% (SD= 5.7) and 6.2% (SD=4.6) 
respectively (Table 2). In mock-primed mice this frequency was significantly lower. Two weeks p.i. 
the frequency of NP366-374 specific CTL had declined to 3.6% (SD=2.8). 
In addition to tetramer-staining also intracellular IFNγ-staining was used to assess the presence 
of virus-specific CTL in the spleen. In mice that were primed by infection with influenza virus A/
HK/2/68, the stimulation of splenocytes with the NP366-374 peptide resulted in the detection of IFNγ 
in CD8+ T cells in both experiments with mean frequencies of 2.0% (SD=1.1) and 1.8% (SD=0.8), 
respectively (Table 2). The frequency of IFNγ positive cells was significantly higher than in mock-
infected animals (p<0.05). Fourteen days p.i. the frequency had declined to 0.4% (SD=0.5). Also the 
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frequency of IFNγ positive CD8+ T cells specific for the PA224-233 epitope (SSLENFRAYV) was signifi-
cantly higher in H3N2-primed mice than in mock-infected animals (Table 2).
Table 2: NP366-374 specific CD8+ T lymphocytes 7 dpi  with influenza virus A/IND/5/05 (H5N1)
Experiment 1 Experiment 2
epitope group IFN-γ+ Tm+ IFN-γ+ Tm+
NP366-374                  
ASNENMEVM
HK/2/68 infection 2.0 ± 1.11 5.3 ± 5.71 1.8 ± 0.8 6.2 ± 4.6
Mock infection -0.5 ± 0.2 0.9 ± 0.7 † †
RSV infection n.d.2 n.d. † †
PA224-233
SSLENFRAYV
HK/2/68 infection 3.0 ± 1.41  n.d. n.d. n.d.
Mock infection 0.2 ± 0.3 n.d. † n.d.
RSV infection n.d. n.d. † n.d.
1 significantly higher than the mock-infected mice (p<0.05)
2 n.d.= not done
Histopathology
Twenty-eight days after infection with influenza virus A/HK/2/68, multifocal hyperplasia and hyper-
trophy of the bronchiolar epithelium and peribronchiolar lymphocytic infiltrates were visible, but 
not after PBS or RSV inoculation. 
Four days after infection with influenza virus A/IND/5/05, multifocal moderate necrotizing bron-
cho-interstitial pneumonia covering almost complete lobes was observed in the lungs of both 
the mock- and RSV-infected mice. There was loss of bronchiolar epithelium in combination with 
necropurulent material in the bronchiolar lumen. Infiltration of inflammatory cells, mainly neutro-
phils and lymphocytes, was present in the PBS- and RSV-inoculated mice (Figure 3B, C). In contrast, 
multifocal mild to moderate broncho-interstitial pneumonia with marked inflammatory infiltrates 
consisting of predominantly lymphocytes and neutrophils (Figure 3A) was observed in the lungs of 
H3N2-primed mice. The bronchiolar wall was rather conserved although some cellular debris was 
present in the lumen. In the alveoli, hypertrophy of the type II pneumocytes was seen.
Seven days p.i. the lungs of the H3N2-primed animals still displayed mild to moderate broncho-
interstitial pneumonia. The bronchiolar epithelium displayed hyperplasia and hypertrophy (indi-
cation of regeneration) and the peribronchiolar and perivascular infiltration of lymphocytes was 
stronger, also in iBALT formations, compared to day 4.  Regeneration of alveoli was visible and a 
mild lymphocytic infiltrate was found in the alveolar lumen. No data were available for the mock- 
and RSV-primed mice on day seven and fourteen p.i. with influenza virus A/IND/5/05, since none of 
these animals survived past day 6. 
Detection of virus-infected cells in the lungs by immunohistochemistry
The presence of influenza A/IND/5/05 virus-infected cells was assessed by immunohistochemistry 
using a monoclonal antibody directed to the viral NP. Four days p.i. with influenza A/IND/5/05 virus, 
virus-infected cells were abundantly present in the lungs of mock and RSV-primed mice (Figure 
4B, C). The infected cells were located in and around lesions. Almost 50% of the bronchioles was 
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infected with more than 75% of the epithelial cells staining positive for viral antigen. The infected 
cells in the alveoli were predominantly type II like pneumocytes.
In contrast, only a small number of bronchiolar epithelial cells stained positive in mice that were 
primed by infection with influenza virus A/HK/2/68, although especially in the alveoli virus-infected 
cells, mainly type II like pneumocytes, were readily detectable (Figure 4A). Seven days p.i. infected 
cells only were detected sporadically in the lungs of these mice, which resolved the infection com-
pletely by day 14 p.i. (data not shown). 
DISCUSSION
In the present study, the protective efficacy was assessed of heterosubtypic immunity induced af-
ter infection with a human influenza A/H3N2 virus against a lethal challenge infection with a highly 
pathogenic avian influenza A/H5N1 virus. A prior exposure to the human A/H3N2 strain protected 
mice from severe clinical signs and mortality which correlated with control of virus replication in 
the lungs and the induction of anamnestic cross-reactive CTL responses upon influenza A/H5N1 
virus infection.
Inoculation of naive C57BL/6J mice with influenza virus A/IND/5/05 (H5N1) caused a productive 
infection of these animals with infectious virus titers four days p.i. of up to 109 TCID50 per gram of 
lung tissue. These animals developed a severe necrotizing interstitial pneumonia and eventually 
succumb to the infection. Although the kinetics of the development of disease differed somewhat 
between experiment 1 and 2, in both experiments a prior infection with influenza virus A/HK/2/68 
(H3N2) had a significant effect on virus replication rates, loss of body weight and mortality rates. In 
experiment 2 a prior infection with RSV did not prevent influenza A/H5N1 virus-induced disease, 
indicating that the observed protection was dependent on adaptive immune responses induced 
by infection with influenza virus A/HK/2/68 (H3N2) rather than a non-specific innate immune re-
sponse.
In contrast, the protection of H3N2-primed mice against influenza A/H5N1 virus infection corre-
Figure 2. Expansion of a cross-reactive CD8+ T cell population, induced by primary infection, after subsequent infec-
tion with influenza virus A/IND/5/05 (H5N1). On day 12 after infection with influenza virus A/HK/2/68 (H3N2) a CD8+ 
T cell population was detected that recognized both the A/HK/2/68 derived NP366-374 epitope (ASNENMDAM) and 
the A/IND/5/05 derived analog (ASNENMEVM) (A). This cross-reactive population was expanded constituting the ma-
jority of NP366-374 specific CTL on day 7 after infection with influenza virus A/IND/5/05 (H5N1) (B).
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lated with the induction of anamnestic CTL responses specific for the NP366-374 (ASNENMEVM) and 
PA224-233 (SSLENFRAYV) epitopes derived from influenza virus A/IND/5/05 (H5N1). These epitopes 
differ from their counterparts (ASNENMDAM and SCLENFRAYV, respectively) in influenza virus A/
HK/2/68 that was used for priming of the animals. Apparently, infection with influenza virus A/
HK/2/68 primed for cross-reactive CTL against these two epitopes, in addition to epitopes that are 
conserved and shared between influenza viruses A/HK/2/68 and A/IND/5/05. A similar result was 
obtained previously after subsequent infection with influenza viruses A/NT/60/68 (H3N2) (NP366-374 
ASNENMDAM) and A/PR/8/34 (H1N1) (ASNENMETM) (92).
Consecutive infections with these two variant viruses lead to the selective expansion of cross-reac-
tive CTL responses specific for the NP366-374 epitope. After infection with only one of these viruses 
the cross-reactive CTL only form a minor proportion that is expanded after the second infection 
with the variant strain. Thus, also with the combination of viruses we used, cross-reactive CTL were 
selectively expanded after infection with influenza virus A/IND/5/05. A similar result was obtained 
in vitro with human CTL specific for the HLA-B*3501 restricted NP418-426 epitope that differed be-
tween human influenza A/H1N1 and A/H3N2 viruses (93).
Although it has been described that the NP366-374 epitope is more immunodominant than the PA224-
233 epitope in a secondary CTL response (94), a stronger response was observed against the PA224-
233 epitope after infection with influenza virus A/IND/5/05. Possibly, the cross-reactivity of CTL di-
rected to the NP366-374 epitope is lower than that of CTL specific for PA224-233. Thus, the induction of 
memory CTL responses induced by infection with influenza virus A/HK/2/68 (H3N2) correlated with 
protective immunity against infection with influenza A/IND/5/05 virus (H5N1). However, it cannot 
be excluded that other arms of the adaptive immune response contributed to the observed protec-
tion. It is possible that prior infection with an influenza A virus also primed for a secondary T helper 
cell response. 
In addition, it has been demonstrated that antibodies directed to NP (36) or the M2 protein can 
have a protective effect against challenge infection (95-97). However, the protective role of NP-spe-
cific antibodies only could be demonstrated after hyper-immunization of mice with a high dose of 
recombinant NP in combination with LPS. With post-vaccination rNP-immune serum the protective 
effect could be transferred to B-cell deficient µMT mice but not to intact recipient C57BL/6J mice. 
For M2-specific antibodies the protective effect was demonstrated after hyper-immunization or the 
transfer of high doses of M2-specific monoclonal antibodies (96, 98). In addition, transfer of post-
infection serum to naïve recipient mice failed to protect the animals from infection with a hetero-
subtypic strain (44) including influenza virus A/IND/5/05 (H5N1) (data not shown). Therefore, it is 
unlikely that NP or M2 specific antibodies contributed to a great extent to the infection-induced 
heterosubtypic immunity against influenza virus A/IND/5/05 (H5N1) observed in the present study.
Protection of mice against lethal influenza A/H5N1 virus infection induced by primary infection 
with a heterosubtypic influenza virus has been demonstrated before (76). However the internal 
genes of the influenza A/H9N2 and A/H5N1 viruses used for priming and challenge infection re-
spectively were closely related and displayed 98% sequence homology (99). Therefore, this scenar-
io resembled that with the use of influenza X-31 (H3N2) and A/PR/8/34 (H1N1) virus for priming and 
challenge infection respectively since these two viruses share identical internal genes (77). Here we 
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demonstrate for the first time that infection with a human influenza virus induces protective immu-
nity to a highly pathogenic avian influenza virus of the H5N1 subtype. The findings reported may 
have a number of important implications. Although this type of immunity did not protect against 
infection per se, it contributed to control of virus replication and as a result dampened the clinical 
impact of the H5N1 infection. The observed protection against the development of severe disease 
correlated with the induction of cross-reactive CTL responses. Since human CTL raised against sea-
sonal influenza virus strains of the H1N1 and H3N2 subtypes are highly cross-reactive with highly 
pathogenic avian influenza A/H5N1 viruses it is anticipated that they will contribute to protective 
immunity against these viruses, when they might become pandemic (51, 52). Similarly, cross-reac-
tive CTL may have contributed to heterosubtypic immunity and a reduction of lethal influenza A/
H2N2 cases observed during the pandemic in 1957 (54). It even may be speculated that the history 
of infections with seasonal influenza viruses and the cross-reactive CTL responses associated with 
these infections is at the basis of the disproportional age distribution of severe H5N1 cases (100). 
Last but not least, the induction of cross-reactive CTL may be an attractive target for the develop-
ment of vaccines that could induce broad-protective immune response, even against influenza A 
viruses of a novel subtype.
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Figure 3. Histopathology was examined in the lungs of mice after infection with influenza virus A/IND/5/05. Four 
days after infection the lungs of H3N2-primed animals showed a multifocal mild broncho-interstitial pneumonia 
with mild inflammatory infiltrates consisting of predominantly lymphocytes and neutrophils (A).
The mock-infected control mice (B) and RSV-primed mice (C) displayed a multifocal moderate necrotizing broncho-
interstitial pneumonia with marked infiltration, consisting of inflammatory cells, mainly neutrophils and lympho-
cytes, in the alveoli.
Figure 4. Detection of virus-infected cells by immunohistochemistry in the lungs of influenza virus A/IND/5/05 
(H5N1)-infected mice on day 4 p.i. in mice primed by infection with influenza virus A/HK/2/68 (H3N2) (A), mock-infect-
ed mice (B), or RSV-primed mice (C).
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ABSTRACT
Annual vaccination against seasonal influenza viruses is recommended for certain individuals that 
have a high risk for complications resulting from infection with these viruses. Recently it was rec-
ommended in a number of countries including the USA to vaccinate all healthy children between 
6 and 59 months of age as well. However, vaccination of immunologically naïve subjects against 
seasonal influenza may prevent the induction of heterosubtypic immunity against potentially pan-
demic strains of an alternative subtype, otherwise induced by infection with the seasonal strains. 
Here we show in a mouse model that the induction of protective heterosubtypic immunity by in-
fection with a human A/H3N2 influenza virus is prevented by effective vaccination against the A/
H3N2 strain. Consequently, vaccinated mice were no longer protected against a lethal infection 
with an avian A/H5N1 influenza virus. As a result H3N2-vaccinated mice continued to loose body 
weight after A/H5N1 infection, had 100-fold higher lung virus titers on day 7 post infection and 
more severe histopathological changes than mice that were not protected by vaccination against 
A/H3N2 influenza.
The lack of protection correlated with reduced virus-specific CD8+ T cell responses after A/H5N1 
virus challenge infection. These findings may have implications for the general recommendation to 
vaccinate all healthy children against seasonal influenza in the light of the current pandemic threat 
caused by highly pathogenic avian A/H5N1 influenza viruses. 
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INTRODUCTION
Since 2003, more than 380 human cases of infection with highly pathogenic avian influenza A virus 
(IAV) of the H5N1 subtype have been reported to the World Health Organization (WHO) of which 
more than 60% were fatal (101). Because of the continuous spread of these viruses among domes-
tic birds, the frequent introduction into wild birds and the increasing number of human cases, a 
pandemic outbreak caused by influenza A/H5N1 viruses is feared (17, 102, 103).
It has been demonstrated in animal models that prior exposure to an IAV can induce heterosub-
typic immunity to infection with an IAV of an unrelated subtype (for review see(40)). Also in humans 
there is evidence that infection with IAV can induce heterosubtypic immunity (54). Individuals that 
had experienced an infection with an H1N1 IAV before 1957 less likely developed influenza during 
the H2N2 pandemic of 1957 (54). In particular, the induction of cell-mediated immune responses 
after infection contributes to protective immunity against infection with heterosubtypic IAVs. The 
presence of cross-reactive cytotoxic T lymphocytes (CTL) in humans inversely correlated with the 
amount of viral shedding in the absence of antibodies directed against the virus used for experi-
mental infection (50). It is well documented that seasonal human IAVs and avian IAVs share CTL 
epitopes located in the internal viral proteins like the nucleoprotein (51-53). Thus, cell-mediated 
immunity induced by natural infection with seasonal IAVs may confer protection against hetero-
subtypic pandemic influenza viruses. In this respect, the disproportional age distribution of severe 
human H5N1 cases is of interest (57). Especially younger individuals are at risk and although other 
confounding factors cannot be excluded, it is tempting to speculate that young subjects have been 
infected with seasonal influenza viruses less frequently and therefore have not developed protec-
tive heterosubtypic immune responses against infection with the highly pathogenic avian A/H5N1 
viruses. 
Since seasonal IAVs of the H3N2 and H1N1 subtypes cause epidemic outbreaks annually associated 
with excess morbidity and mortality mainly among infants, the elderly, immuno-compromised and 
other high-risk patients, influenza vaccination is recommended for these high-risk groups. In gener-
al, the influenza vaccines most frequently used are inactivated vaccines, including subunit prepara-
tions that consist of the viral hemagglutinin (HA) and neuraminidase (NA). Due to the higher risk of 
complications and hospitalizations secondary to influenza in children (58, 59), annual vaccination 
of all healthy children 6 to 59 months of age was recommended in various countries including the 
United States since 2007 (60).
However, annual vaccination may prevent the induction of heterosubtypic immunity by infection 
with seasonal influenza virus strains. In addition, it is unlikely that seasonal inactivated influenza 
vaccines, unlike live attenuated vaccines, induce heterosubtypic immunity since they induce cross-
reactive CTL responses inefficiently (104, 105).
Thus, we hypothesized that vaccination against seasonal flu prevents the induction of cross-pro-
tective cell-mediated immunity, which consequently may lead to more severe clinical outcome of 
infection with a future pandemic virus. Here we show in a mouse model that protective immunity 
against lethal infection with H5N1 IAV Indonesia/5/05 (IND/05) was induced by infection with H3N2 
IAV HongKong/2/68 (HK/68), which was prevented by effective vaccination against the A/H3N2 vi-
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rus. The lack of protection against IAV IND/05 correlated with reduced virus-specific CTL responses. 
MATERIALS AND METHODS 
Viruses
Virus stocks of influenza viruses A/Hong Kong/2/68 (IAV HK/68) and A/Indonesia/5/05 (H5N1) (IAV 
IND/05) were prepared by infecting confluent Madin-Darby-Canine-Kidney (MDCK) cells. After cy-
topathologic changes were complete, culture supernatants were cleared by low speed centrifuga-
tion and stored at –70°C. Infectious virus titers were determined in MDCK cells as described previ-
ously (85). 
Vaccine preparation 
Influenza subunit antigen derived from IAV X-31 (H3N2) was essentially prepared as described pre-
viously (106).  X-31 is a reassortant vaccine strain of A/Aichi/2/68 and A/PR/8/34, of which the HA 
and NA resemble that of IAV HK/68 closely. The purity of the subunit preparations was tested by 
SDS-polyacrylamide gel electrophoresis and the absence of the nucleoprotein and matrix protein 
of the subunit preparations was tested by western blotting using monoclonal antibodies against 
the influenza A nucleoprotein and the influenza A matrix protein. The protein concentration was 
determined using a BCA Protein Assay Kit (Pierce, Rockford, USA).
Immunization and infection of mice
Female specified pathogens free 6-8 weeks old C57BL/6J (H-2b) mice were purchased from Charles 
River (Sulzfeld, Germany). Mice were immunized twice with an interval of four weeks intramuscular-
ly (i.m.) in both hind legs in a total volume of 100μl. Mice (n=19-40 per group) received PBS (phos-
phate buffered saline) (Groups 1,3 and 4), 15μg subunit vaccine with (Groups 2 and 5) or without 
(Group 6) 1mg Aluminium hydroxide gel (Alum) (Sigma-Aldrich, Zwijndrecht, the Netherlands) or 
Alum only (Group 7). Eight days after the second vaccination, four mice of each group were bled 
and spleens were resected. Four weeks after the second vaccination, mice of groups 2, 3, 6 and 7 
were infected intranasally with 5x102 TCID50 IAV HK/68 in a volume of 50μl. Four and twelve days 
post infection (p.i.), 5-7 mice were bled and lungs and spleens were resected. Four weeks after in-
fection with IAV HK/68, all mice except mice of group 1 were challenged with 2x 102 TCID50 IAV 
IND/05. A dose of 2x 102 TCID50 was used because this was the minimal dose resulting in a lethal 
infection in >90% mice reproducibly. The day before challenge with IAV IND/05, mice of each group 
(n=2-4) were euthanized and lungs and spleens were resected as well as on day four (n=4-6), seven 
(n=2-9) and fourteen (n=3-8) days after challenge. Vaccinations, intranasal infections, orbital punc-
tures and euthanasia were performed under anesthesia with isoflurane in O2. After infection with 
IAV HK/68 and IAV IND/05, mice were monitored for the presence of clinical signs, including weight 
loss. All experiments with IAV IND/05 were performed under Biosafety Level 3 conditions. An inde-
pendent animal ethics committee (DEC consult) approved the experimental protocol before the 
start of the experiments. 
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Table 1. Experimental groups and design of the study
Experimental 
group
Vaccination Infection
Subunit Adjuvant HK/68 IND/05 
1 - - - -
2 + + + +
3 - - + +
4 - - - +
5 + + - +
6 + - + +
7 - + + +
Serology
Serum samples of mice were collected at various time points during the experiment and tested 
for the presence of HA-specific antibodies against IAV HK/68 and IAV IND/05 using the hemagglu-
tination inhibition (HI) assay (107) and virus neutralising (VN) antibodies using the VN assay (87).
To determine the titer of antibodies against IAV IND/05 before infection with IAV IND/05, a reverse 
genetics virus was produced from which the basic cleavage site was removed. Antibody titers ob-
tained with this reverse genetics virus was comparable with that against the wild-type strains (data 
not shown). Positive control serum specific for IAV HK/68 was obtained by injecting a rabbit with 
sucrose gradient purified virus (88). Hyper-immune serum obtained from a swan immunized twice 
with inactivated H5N2 influenza virus A/Duck/Potsdam/1402/86 (Intervet, Boxmeer, the Nether-
lands) was used as a positive control against IAV IND/05(89).
Lung virus titers
Lungs of mice were snap frozen on dry ice with ethanol and stored at –70°C. Lungs were homog-
enized with a FastPrep-24 (MP Biomedicals, Eindhoven, the Netherlands) in medium consisting of 
Hank’s balanced salt solution containing 0.5% lactalbumin, 10% glycerol, 200 U/ml penicillin, 200 
μg/ml streptomycin, 100 U/ml polymyxin B sulfate, 250 μg/ml gentamycin, and 50 U/ml nystatin 
(ICN Pharmaceuticals, Zoetermeer, the Netherlands) and centrifuged briefly. Quintuplicate 10-fold 
serial dilutions of these samples were used to infect MDCK cells as described previously(85). HA 
activity of the culture supernatants collected 5 days post inoculation was used as indicator of infec-
tion. The titers were calculated according Spearman-Karber (108).
Flow cytometry of virus-specific CD8+ T cells
Peptides and intracellular IFN-γ staining
Single cell suspensions of spleens were prepared as described previously (77). CD8+ T cell re-
sponses after infection were measured by incubation with peptides representing two immuno-
dominant epitopes of IAVs in C57BL/6J mice (H2-b), PA224-233 and NP366-374 (91, 109). The peptides 
of the PA224-233 epitope of influenza A virus were manufactured at Eurogentec (Seraing, Belgium), 
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while peptides of the NP366-374 epitope were manufactured at Sanquin Research (Amsterdam, the 
Netherlands). Four hundred thousand splenocytes were cultured for 6 h at 37°C in the presence of 
5μM of either the NP366-374 ASNENMDAM (NPHK), PA224-233 SCLENFRAYV (PAHK) peptides derived from 
IAV HK/68 or the NP366-374 ASNENMEVM  (NPIND) or SSLENFRAYV (PAIND) peptides (derived from IAV 
IND/05) in IMDM (Lonza, Breda, the Netherlands) with 5% FCS and Golgistop (BD). After incuba-
tion, cells were o/n stored at 4°C, stained with monoclonal antibody directed to CD3e-PerCP and 
CD8b.2-FITC, fixate and permeabilized with Cytofix and Cytoperm and stained with monoclonal an-
tibody specific for IFN-γ-PE (all from BD Pharmingen, Alphen a/d Rijn, the Netherlands). Data were 
acquired using a FACSCalibur and analysed with Cellquest Pro Software (BD).
Tetramerstaining
Splenocytes were washed and stained with mAbs CD3e-PerCP, CD8b.2-FITC (BD Pharmingen, Al-
phen a/d Rijn, the Netherlands) and either the Phycoerythrin (PE)-labeled H-2Db tetramer with 
the immunodominant NP366-374 epitope derived from IAV X-31 ASNENMETM (TmX-31) or IAV HK/68 
ASNENMDAM (TmHK) or the APC labeled tetramer derived from IAV IND/05 NP366-374 ASNENMEVM 
(TmIND). All tetramers were purchased from Sanquin Research, Amsterdam, the Netherlands. Fol-
lowing incubation with tetramers and mAbs for 20 minutes, cells were washed twice and analysed 
by flow cytometry using a FACSCanto in combination with FACS Diva software (BD).
Histopathology and immunohistochemistry
After euthanasia, lungs of mice were inflated with 10% neutral buffered formalin. After fixation and 
embedding in paraffin, lungs were sectioned at 4μm and tissue sections were examined by staining 
for hematoxylin and eosin (HE). Using an immunoperoxidase method, sequential slides were also 
stained with a monoclonal antibody directed against the nucleoprotein of IAV (110). 
Statistical analysis
Data for weight loss after infection, viral load in the lungs, tetramerstaining, and peptide pulsing 
were analysed statistically using the two-sided student’s T test. Survival was analysed using the Lo-
grank test. Differences were considered significant at P<0.05.
RESULTS
Antibody responses against IAV HK/68 (H3N2) after vaccination 
Mice were vaccinated with subunit vaccine with or without Alum or were ‘mock’ vaccinated (ta-
ble 1). HI antibody titers were detected 28 days after the first vaccination with subunit and Alum 
(groups 2 and 5) and in 3 out of 26 mice vaccinated with unadjuvanted subunit vaccine (group 6). 
Four weeks after the second vaccination, geometric mean titers (GMTs) increased to 244 and 218 
in mice from group 2 and group 5, respectively. Four mice of group 6 developed detectable HI-
antibody responses with a GMT of 48, the other mice of this group did not seroconvert (figure 1A). 
Sera of mice were also analysed for the presence of virus neutralizing (VN) antibodies. Four weeks 
after the second vaccination, mice vaccinated with adjuvanted subunit vaccine developed VN anti-
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bodies with a GMT of 38 and 29 in group 2 and group 5 respectively, while only two mice of group 6 
developed detectable VN antibody titers (Figure 1B).
Outcome of infection with IAV HK/68 (H3N2)
Mice that developed HI-antibodies against IAV HK/68 (all mice of group 2 and four of group 6) were 
Figure 2. Outcome of infection with IAV HK/68 (H3N2). Mice were inoculated with IAV HK/68 (groups 2 (     ), 3 (    ), 
6 (         ) and 7 (   )) or PBS (groups 1 (     ), 4 (    ) and 5 (    )). (A) Body weight after infection was determined daily and 
expressed as the percentage of the original body weight before infection. (B) Lung virus titers measured on day 4 p.i. 
in mice from the indicated experimental groups. Horizontal bars represent the average titers of five mice. The dotted 
line represents the cut-off value for obtaining a positive result. *This mouse from group 6 had before infection an HI 
antibody titer of 40. (C) Vaccination prevented the induction of iBALT after infection. Twenty-eight days post infec-
tion with IAV HK/68 iBALT was detected in mice from group 3, but not in mice from group 2. Lung tissue sections were 
stained with HE. (D) Virus-specific CD8+ T cell responses detected 28 days post infection. Splenocytes of mice from 
the indicated experimental groups were tested for the presence of CD8+ T cells that bound the H2-Db NPHK Tetramer. 
Horizontal bars represent the average of 2-4 mice. The difference in %CD8+ Tm+ T cells between groups 2 and 3 was 
statistically significant (P=0.030).
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protected from weight loss after infection with IAV HK/68, while mice of other groups lost weight 
until day seven post infection (p.i.) and showed mild clinical symptoms for 2-3 days (Figure 2A). 
Clinical signs and weight loss after infection correlated well with virus titers in the lungs of infected 
mice 4 days p.i.. No virus was detected in lungs of mice vaccinated with adjuvanted subunit vac-
cine, while the average lung virus titer of mock-vaccinated mice was 108.1 TCID50/gram lung. Similar 
titers were observed for the mice in groups 6 and 7 with the exception of one mouse in group 6 
with a HI antibody titer of 40 induced by vaccination with unadjuvanted subunits that had a lung 
virus titer of 105.7 TCID50/gram lung (Figure 2B). The virus titers detected on day 4 p.i. correlated with 
the absence or presence of virus infected cells in the lungs detected by immunohistochemistry 
(data not shown).
Virus-specific CTL and antibody responses after infection with IAV HK/68 (H3N2)
Four days p.i. with IAV HK/68 the frequency of splenic CD8+ T lymphocytes specific for the NP366-374 
epitope of IAV HK/68 (CD8+ TmHK+ T-cells) as determined by tetramer staining remained at back-
ground levels in all groups (data not shown).
In all infected mice a raise in the frequency of CD8+ TmHK+ T-cells was detected twelve days p.i.. 
No statistically significant differences were observed between the experimental groups. Essentially 
the same results were observed using intracellular IFN-γ staining after re-stimulation with peptides 
representing the NP366-374 and PA224-233 epitopes of IAV HK/68 (NPHK and PAHK). The NPHK  and PAHK 
specific CTL induced by infection with IAV HK/68 cross-reacted to various extents with their coun-
terparts derived from IAV IND/05 (NPIND and PAIND). The cross-reactive nature of a proportion of the 
NP366-374 specific CTL was confirmed by double staining with TmHK  and TmIND (data not shown). By 
day 28 p.i. with IAV HK/68, just before challenge infection with IAV IND/05, the frequency of virus-
specific CTL in the spleen had declined and virus-specific CTL were not detectable by intracellular 
Figure 1. Induction of serum antibodies against IAV HK/68 (H3N2) by vaccination. Serum antibody levels were de-
termined before and at the indicated time points after vaccination of mice with PBS (groups 1, 3 and 4;     ), subunit 
vaccine with alum (groups 2 and 5;     ), subunit vaccine only (group 6;    ) and alum only (group 7;    ) by HI assay (A) 
and VN assay (B).
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IFN-γ staining. However, TmHK and TmIND positive cells were detected in mice that were mock vac-
cinated prior to infection (group 3). Strikingly, the frequency of TmHK positive CD8+ T lymphocytes 
was significantly lower in mice of group 2 that were effectively vaccinated against infection with 
IAV HK/68 (p=0.030) (Figure 2D).  
Vaccination prevents induction of iBALT after IAV HK/68 infection 
Following infection with IAV HK/68, no significant lesions were found in lungs of mice vaccinated 
with adjuvanted subunit vaccine (group 2), whereas mice that were mock-vaccinated or vaccinated 
with Alum or subunit preparation only (mice of groups 3, 6 and 7) developed a multifocal mild 
subacute necrotizing bronchopneumonia four days after infection, which on day 12 p.i. progressed 
into a multifocal moderate chronic necrotizing bronchopneumonia. On day 28 p.i., these mice had 
developed perivascular moderate proliferation of inducible Bronchus Associated Lymphoid Tissue 
(iBALT), consisting mainly of mononuclear cells, which was absent in mice effectively vaccinated 
against infection with IAV HK/68 (Figure 2C). 
Effective vaccination prevents heterosubtypic immunity against IAV IND/05 (H5N1)
After infection with IAV IND/05, all mice developed clinical signs (weight loss, ruffled fur, lethargy) 
from day two p.i. onwards. Mice that developed clinical signs p.i. with IAV HK/68 (groups 3, 6 and 
7) lost weight until day 6-7 after infection with IAV IND/05 and then started to gain weight and 
fully recovered, while mice of other groups, not previously infected with IAV HK/68 (groups 4 and 
5) and more strikingly, those effectively vaccinated against infection with IAV HK/68 (group 2) lost 
significantly more weight (group 2 versus group 3: p=0.0001) on day 7 p.i. with IAV IND/05 and 
showed more severe clinical signs (lethargy, ruffled fur, hunched posture) than mice of the other 
groups (Figure 3A). Moribund animals were euthanised when they reached pre-fixed criteria re-
garding weight loss (>20%) and clinical signs, which was used to determine mortality rates. One 
mouse out of 10 (10%) of group 2 survived lethal challenge, while all mice but one (91%) of group 
3 survived lethal challenge (n=11). This difference in survival rate was statistically significant (p= 
0.0003) as was calculated with the Logrank test (Figure 3B). All other mice not previously exposed 
to IAV HK/68 became moribund, whereas all mice not adequately vaccinated against IAV HK/68 
(groups 6 and 7) survived. 
Replication of IAV IND/05 (H5N1) in the lungs
The lung virus titers at days four and seven p.i. were compared between groups of IAV IND/05 in-
fected mice. Four days p.i. no significant differences were found between mice of different groups. 
The average virus titer in mice of group 3 was 107.7 TCID50/gram lung, which was similar to that 
observed in mice from group 2 that were effectively vaccinated against IAV HK/68 (107.6 TCID50/
gram lung). In contrast, there were significant differences in lung viral titers between mice of the 
different groups seven days p.i. (Figure 3C). Group 3 mice, not vaccinated against infection with IAV 
HK/68, had virus titers of 104.8 TCID50/gram lung while mice of group 2, vaccinated with adjuvanted 
subunits, had significantly higher virus titers with an average of 106.5 (p=0.025), which was similar to 
that observed in naïve mice infected with IAV IND/05 virus (group 4) or those that were vaccinated 
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against, but not infected with IAV HK/68 virus (group 5). Mice unsuccessfully vaccinated against IAV 
HK/68 infection with adjuvant or subunits only also displayed lower lung viral titers (groups 6 and 
7). 
Figure 3. Outcome of infection with IAV IND/05 (H5N1). Mice were inoculated with IAV IND/05 (groups 2 (   ), 3 (    ), 
4 (     ), 5 (    ), 6 (    ) and 7 (   )) or PBS (group 1 (   ). (A) Body weight after infection was determined daily and expressed 
as the percentage of the original body weight before infection. (B) Survival rates after infection with IAV IND/05. The 
proportion of mice from the indicated groups that survived infection is shown in a Kaplan-Meier plot. Moribund ani-
mals were euthanized when they reached pre-fixed criteria regarding weight loss (>20%) and disease severity score, 
which was used to determine mortality rates. (C) Lung virus titers measured on 7 days p.i. in mice from the indicated 
groups. Horizontal bars represent the average of 2-6 mice. The difference in virus titers between mice of group 2 and 
group 3 was statistically significant (p=0.025). N.S.: not significant. (D) Virus-specific CD8+ T cell responses on day 7 
p.i.. The frequency of CD3+ CD8+ splenocytes specific for peptide NP366-374 and PA224-233 derived from IAV IND/05 was 
determined by intracellular IFN-γ staining. The horizontal bars represent the average frequency of IFN-γ+ cells in the 
CD8+ T cell population of 2-7 mice in the indicated groups. Differences between group 2 and group 3 were statistically 
significant for both peptides.
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Histopathology and detection of infected cells after infection with IAV IND/05 (H5N1)
On day four p.i. with IAV IND/05, mice developed a multifocal severe subacute necrotizing broncho-
pneumonia, of which the severity was similar for all experimental groups. However, seven days p.i. 
there were marked differences between the groups. The mock-vaccinated mice or those vaccinated 
with adjuvant only prior to infection with IAV HK/68 had a multifocal moderate chronic necrotizing 
Figure 4. Histopathological analysis and 
immunohistochemistry of the lungs of 
mice infected with IAV IND/05. Mouse lung 
sections were stained for influenza A virus 
nucleoprotein. Cytoplasm of infected cells 
stain red, the nuclei of infected cells stain 
deep red. In the groups without a history 
of productive A/H3N2 infection, including 
group 2 (A,B), infection with IAV IND/05 led 
to severe histopathological changes and 
to viral antigen expression in cells of the 
bronchiolar walls and in the alveoli (group 
4: E,F and group 5: G,H). In mice of groups 
3 (C,D) and 7 (I,J) that had experienced a 
productive infection with IAV HK/68 only 
moderate histopathological changes were 
observed and virus infected cells were de-
tected sporadically (see insert in panel D). 
Induction of CD8+ T cell responses 
p.i. with IAV IND/05 (H5N1)
Four and seven days p.i. infection 
with IAV IND/05, splenocytes were 
stained for intracellular IFN-γ af-
ter incubation with peptides NPIND 
and PAIND. Four days p.i., no virus-
specific CD8+ T cell responses were 
detected in any of the IAV IND/05 
infected mice . However, seven days 
p.i., anamnestic NPIND and PAIND 
specific IFN-+CD8+ T-cell responses 
were observed in mice from group 
3, which were significantly lower in 
mice effectively vaccinated against 
IAV HK/68 (group 2)  (p=0.038 and 
p=0.002 respectively) (Figure 3D).
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bronchopneumonia characterized by a perivascular core of lymphocytes and plasma cells, prolif-
eration of bronchiolar epithelium and hyperplasia of pneumocytes with a type II appearance. In 
contrast, mice of groups 4, 5 and especially group 2 had more severe lung pathology characterized 
by a multifocal to coalescing severe subacute necrotizing bronchopneumonia.  
In general, the extent of lung histopathology and the lung virus titers after infection with IAV 
IND/05 correlated with the presence of virus-infected cells in the lungs as determined by immuno-
histochemistry. Four days p.i., virus-infected cells were detected in all IAV IND/05 infected mice. In 
contrast, seven days p.i., antigen positive cells were found sporadically in lungs of mice of groups 3 
(Figures 4C-D) and 7 (Figures 4I-J), whereas in the lungs of mice from group 2 (Figures 4A-B), 4 (Fig-
ures 4E-F) and 5 (Figures 4G-H) virus-infected cells were still abundantly present. 
DISCUSSION
Here we demonstrate that successful vaccination of mice against human IAV HK/68 (H3N2) prevent-
ed the induction of heterosubtypic immunity against a lethal challenge with IAV IND/05 (H5N1). As 
a result, H3N2 vaccinated mice had a fatal clinical outcome of infection with IAV IND/05, associ-
ated with higher virus titers and more severe histopathological lesions in the lungs seven days p.i. 
and reduced virus-specific CD8+ T cell responses compared to mice that experienced a produc-
tive, self-limiting infection with IAV HK/68. It has been well established that infection with IAV can 
induce a certain degree of protective immunity against infection with an heterosubtypic strain of 
IAV (41). This so-called heterosubtypic immunity was not only demonstrated in animal models (41, 
76, 80, 111) but there is also direct and indirect evidence that it exists in humans (50, 54) and that 
cell-mediated immune responses contribute to this type of immunity (for review see (83)). To test 
the hypothesis that successful immunization against seasonal influenza could interfere with the 
induction of heterosubtypic immunity, mice were vaccinated with an Alum-adjuvanted subunit 
vaccine. The use of an adjuvant was necessary since vaccination with subunit alone induced detect-
able antibody responses in a small proportion of mice only and would not provide a useful model 
for successful vaccination against seasonal influenza. Indeed, all mice vaccinated with Alum alone 
and most mice vaccinated with subunits alone were not protected against infection with A/H3N2 
virus. In contrast, all mice vaccinated with adjuvanted subunits, were fully protected against infec-
tion with IAV HK/68. This prevented the induction of heterosubtypic immunity against infection 
with IAV IND/05 normally seen in mice that had experienced a productive IAV HK/68 infection. The 
severity of the clinical signs and histopathological lesions, the extent of weight loss, lung virus titers 
and mortality rates of these mice was comparable of those that were immunologically naïve prior 
to infection with IAV IND/05 (group 4) or that were vaccinated against IAV HK/68 virus, but not sub-
sequently infected with IAV HK/68 virus (group 5). 
Four weeks after infection with IAV HK/68 virus, the number of virus-specific CD8+ T cells in the 
spleen was significantly lower in mice vaccinated against IAV HK/68 than in unvaccinated mice. The 
differences were not observed at earlier time points p.i.. Further evaluation of the CD8+ TmHK+ T 
cells indicated that the numbers of CD62Lhigh and CD127high cells were higher in unvaccinated mice 
than in vaccinated mice on day 28 p.i. (data not shown). This may indicate that the control of IAV 
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HK/68 replication in the lungs had prevented the efficient induction of virus-specific central and 
effector memory CD8+ T cell responses. These results resemble those found in a mouse model for 
Listeria monocytogenes infection, in which shortening of the duration of the infectious period did 
not impact the size of the primary CD8+ T cell response, but diminished the memory population of 
CD8+ T cells (112).  The analysis of the CD8+ T cells responses seven days after challenge infection 
with IAV IND/05 further indicated that indeed prior vaccination against HK/68 (H3N2) prevented 
the efficient induction of memory CTL responses. Both the secondary response to the NPIND and 
the PAIND epitope were reduced compared to the responses observed in un-vaccinated mice. Al-
though it has been described that the NP366-374 is more immunodominant than the PA224-233 epitope 
in secondary CTL responses (91), a stronger response was observed against the PA224-233 epitope 
after infection with IAV IND/05. This could be explained by the lower cross-reactivity of CTL directed 
to the NP366-374 epitope derived from IAV HK/68 (ASNENMDAM) with that derived from IAV IND/05 
virus (ASNENMEVM) compared to the cross-reactivity  of CTL specific for the PA224-233 epitope as 
was observed after the analysis of the CTL measured by tetramerstaining p.i. with IAV HK/68 and 
IND/05 (data not shown). Apart from systemic CTL responses measured in the spleen also local CTL 
responses may contribute to protective immune responses, such as in the draining lymph nodes 
and in the lung tissue itself (113, 114, 117). Since the frequency of virus-specific CD8+ T cells in the 
spleen reflected that in the lymph nodes (45, 115) , we analysed CTL responses in the spleen only. 
It was of interest to note that infection with IAV HK/68 resulted in the formation of iBALT structures. 
Prior vaccination against IAV HK/68 infection prevented the formation of iBALT completely. iBALT 
consists mainly of B cells, T cells and dendritic cells and it has been shown that mice with iBALT but 
without peripheral lymphoid organs can clear virus infection (116).  Although no IAV IND/05 cross-
reactive antibodies were detected by VN or HI assay on the day of challenge infection, it is possible 
that infection with IAV HK/68 induced M2 specific antibodies that potentially cross-reacted with the 
M2 protein of IAV IND/05. However it is unlikely that these antibodies accounted for the heterosub-
typic immunity induced by primary infection with IAV HK/68 (44, 118). 
Thus, prior infection with seasonal influenza viruses, which generally results in a self-limiting up-
per respiratory tract infection, may afford at least partial protection against potentially pandemic 
heterosubtypic influenza virus strains. Altough vaccination is (cost-) effective in this age group (62-
66), it may interfere with the induction of heterosubtypic immunity against potentially pandemic 
strains of a novel subtype, e.g. H5N1, by creating an immunological “blind spot”. Furthermore, the 
use of adjuvants is considered to increase vaccine efficacy in young children(119).  Ideally, seasonal 
influenza vaccines are used that also induce heterosubtypic immunity (105, 120). More research 
is required in this field to define vaccine preparations that not only induce protective immunity 
against seasonal influenza, but also induce heterosubtypic immunity. With the current pandemic 
threat caused by A/H5N1 viruses this would be highly desirable (121).
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ABSTRACT
Recently we have demonstrated that the use of an experimental subunit vaccine protected mice 
against infection with a human A/H3N2 influenza virus, but consequently affected the induction 
of heterosubtypic immunity to a highly pathogenic A/H5N1 influenza virus, otherwise induced 
by the A/H3N2 infection. Since inactivated whole virus (WIV) vaccines are widely used to protect 
against seasonal influenza and also contain inner viral proteins like the nucleoprotein, we tested 
the potential of a WIV vaccine to induce protective immunity against infection with a homologous 
A/H3N2 (A/Hong Kong/2/68) and a heterosubtypic A/H5N1 influenza virus (A/Indonesia/5/05). As 
expected, the vaccine afforded protection against infection with the A/H3N2 virus only. In addition, 
we demonstrated that the use of WIV vaccine for the protection against A/H3N2 infection affected 
the induction of heterosubtypic immunity otherwise afforded by A/H3N2 influenza virus infection. 
The reduction of protective immunity correlated with changes in the immunodominance patterns 
of the CD8+ T cell responses directed to the epitopes located in the acid polymerase (PA224-233) and 
the nucleoprotein (NP366-374). In unvaccinated mice that experienced an infection with the A/H3N2 
influenza virus, the magnitude of the CD8+ T cell response to both peptides was similar upon a 
secondary infection with an A/H5N1 influenza virus. In contrast, prior vaccination with WIV affected 
the immunodominance pattern and skewed the response after infection with influenza virus A/
Indonesia/5/05 towards a dominant NP366-374 specific response. These findings may have implica-
tions for vaccination strategies aiming at the induction of protective immunity to seasonal and/or 
pandemic influenza.
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INTRODUCTION
Influenza viruses are a major cause of respiratory tract infections and responsible for annual excess 
morbidity and mortality mainly in the elderly, infants and patients with underlying disease (12). In 
addition to annual epidemics, influenza A viruses occasionally cause pandemics. New influenza A/
H1N1 viruses of swine origin have caused the recent pandemic that started in Mexico in the spring 
of 2009 (13, 14). Because influenza A viruses of various subtypes can be transmitted to humans 
from animal reservoirs and potentially could cause novel pandemic outbreaks, there is an interest 
in immunity that could protect against multiple subtypes of influenza A viruses, so called hetero-
subtypic immunity, as a basis for the development of universal vaccines (120, 122).
This type of immunity induced by infection with influenza A virus was already recognized in the 
1960’s and has been demonstrated in various animal models (41, 42, 44, 76, 123).  Heterosubtypic 
immunity induced by infection was shown to be long-lasting (42). It does not prevent infection 
since virus neutralizing antibodies against the viral glycoproteins, the hemagglutinin and neur-
aminidase, per definition will not cross-react with those of other subtypes. However, heterosub-
typic immunity does afford a certain degree of protection and reduces morbidity and mortality 
otherwise caused by infection with an influenza virus of an alternative subtype (for review see (40)). 
Evidence for the existence of heterosubtypic immunity in humans is circumstantial but probably 
contributes to protection against infection with (pandemic) influenza viruses of novel subtypes (50, 
54, 124). Heterosubtypic immunity may be relevant especially for protection against infection with 
highly pathogenic avian influenza viruses like those of the H5N1 subtype that have infected more 
than people since 1997 with a case fatality rate of 60% (125).
The elucidation of the mechanism of heterosubtypic immunity has been the subject of numerous 
studies. It has been demonstrated in mice, that multiple arms of the immune system contribute to 
heterosubtypic immunity, including virus specific CD4+ and CD8+ T cells, local virus specific anti-
bodies and B cells (40, 47, 96, 126-129).  Especially CD8+ cytotoxic T lymphocytes (CTL) are thought 
to contribute to heterosubtypic immunity, because they recognize predominantly cross-reactive 
epitopes located in conserved proteins like the nucleoprotein and the matrix protein. The cross-
reactive nature of influenza virus-specific CTL has been confirmed with T cell populations obtained 
from mice (130-132) and humans  (51-53, 133, 134). Furthermore the presence of CTL immunity 
correlated with protection against infection and inversely correlated with the extent and duration 
of viral replication in mice and humans (45, 50, 77).
Since infection with seasonal influenza A viruses induces strong virus-specific CTL responses it 
could be hypothesized that the use of vaccines that induce protective antibody responses to sea-
sonal influenza viruses, subsequently prevents the induction of virus-specific CTL responses.  This 
could affect the induction of heterosubtypic immunity against infection with viruses of novel sub-
types. We recently tested this hypothesis in a mouse model using an alum-adjuvanted subunit 
preparation to protect against infection with an A/H3N2 influenza virus. Consequently, H3N2-vac-
cinated mice did not develop heterosubtypic immunity and were no longer protected against a 
lethal challenge with an A/H5N1 influenza virus (135).
In the present study, we used a whole inactivated influenza A virus vaccine (WIV) based on an A/
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H3N2 virus comparable to vaccine preparations used for the vaccination of human subjects to 
mimic the situation in humans more closely. This vaccine preparation contained also the internal 
viral proteins like NP and M1 protein in addition to HA and NA.  Upon vaccination, this WIV prepara-
tion induced protective immunity to a human seasonal influenza A/H3N2 virus and virus-specific 
CD8+ T cell responses against the conserved proteins, but failed to induce protection against infec-
tion with influenza A/H5N1 virus. Furthermore, vaccination with the WIV preparation affected the 
induction of heterosubtypic immunity induced by experimental infection with a human influenza 
A/H3N2 virus, similar to the use of adjuvanted subunit vaccine. In addition, the use of WIV affected 
the immunodominance pattern of the CD8+ T cell response to the epitopes NP366-374 and PA224-233. 
MATERIALS AND METHODS
Viruses
Virus stocks of influenza viruses A/Hong Kong/2/68 (H3N2) (A/HK/2/68) and A/Indonesia/5/05 
(H5N1) (A/IND/5/05) were prepared by infecting confluent Madin-Darby canine kidney (MDCK) 
cells and infectious virus titers were determined in MDCK cells as described previously (135). 
Vaccine preparation 
Egg-grown concentrated and purified influenza A X-31 virus (a reassortant vaccine strain of A/
Aichi/2/68 and A/PR/8/34 of which the hemagglutinin and neuraminidase resemble that of influ-
enza A/HK/2/68 closely) was inactivated by treatment with 0.05% formaldehyde for seven days un-
der continuous stirring at 4°C. After inactivation, antigen was dialyzed against phosphate buffered 
saline (PBS). The purity of the vaccine preparation was tested by SDS-polyacrylamide gel electro-
phoresis and the inactivation was confirmed by failure to passage on MDCK cells. The protein con-
centration was determined using a BCA Protein Assay Kit (Pierce, Rockford, USA).
Immunization and infection of mice
Six-to-eight weeks old, female, specified pathogens free C57BL/6J (H-2b) mice were purchased from 
Charles River (Sulzfeld, Germany). Mice were divided in five groups and animals of groups 1 (n=42), 
3 (n=35) and 4 (n=17) were mock-immunized intramuscularly twice with an interval of four weeks 
with 100 µl PBS in two hind legs, while mice of groups 2 (n=47) and 5 (n=23) were immunized twice 
with 15μg whole inactivated vaccine (WIV) in PBS (total volume 100μl) (Table 1). Eight and 28 days 
after the first and 28 and 56 days after the second vaccination, four mice of group 1 and 2 were bled 
and spleens were resected. As a positive control group for the induction of virus-specific CD8+ T 
cell responses after vaccination, eight mice were also infected with 2x104 TCID50 influenza A X-31 
intranasally in a total volume of 50μl, which were euthanized eight and 28 dpi.
Four weeks after the second vaccination, mice of groups 2 and 3 were infected intranasally with 
5x102 TCID50 influenza virus A/HK/2/68 (H3N2) in a volume of 50μl. Mice of groups 1, 4 and 5 were 
mock-infected with PBS. Following infection, mice were weighed daily to monitor their weight loss 
as clinical indicator of infection. Four, twelve and 28 dpi six mice of groups 1, 2 and 3 were bled 
and lungs and spleens were resected. Four weeks after infection with influenza virus A/HK/2/68 
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(H3N2), all mice except those of group 1 were infected with 2x102 TCID50 influenza A/IND/5/05 
(H5N1) intranasally. This dose was chosen at it was the minimal dose resulting in a lethal infection 
in >90% mice reproducibly (135, 136). Mice of group 1 were mock-infected with PBS. The day be-
fore infection with influenza virus A/IND/5/05 (H5N1), six mice of each group except group 4 were 
euthanized and lungs and spleens were resected. After infection with influenza virus A/IND/5/05 
(H5N1), mice were weighed daily and monitored for clinical signs. Mice were euthanized four (n=5 
per group), seven (n=8 or more per group) and fourteen (n=4 or less per group) days after chal-
lenge and spleens and lungs were resected. Vaccinations, intranasal infections, blood withdrawal 
and euthanasia were performed under anesthesia with isoflurane in O2. All experiments with in-
fluenza A/H5N1 virus were performed under Biosafety Level 3 (BSL III) conditions. An independent 
animal ethics committee approved the experimental protocol before the start of the experiments. 
Table 1. Overview of experimental groups of mice used in this experiment
Experimental 
group
Treatment of mice
X-31 WIV 
vaccination
Infection with 
A/HK/2/68 (H3N2)
Infection with 
A/IND/5/05 (H5N1)
1 - - -
2 + + +
3 - + +
4 - - +
5 + - +
Serology
Before vaccination, four weeks after the first vaccination, four weeks after the second vaccination 
and four weeks after infection with influenza A/H3N2 virus, serum samples of mice were collected 
and tested for the presence of HA-specific antibodies against influenza viruses A/H3N2 and A/H5N1 
using the hemagglutination inhibition (HI) assay and virus neutralizing (VN) antibodies using the 
VN assay as described previously (87, 107, 135).
Lung virus titers
Lungs of mice collected four and twelve dpi with influenza A/H3N2 and four, seven and fourteen 
days after challenge with influenza A/H5N1 virus were snap frozen and stored at –70°C until further 
processing. Lungs were homogenized and quintuplicate 10-fold serial dilutions of these samples 
were used to inoculate MDCK cells as described previously (135). HA-activity of the culture superna-
tants collected 5 days post inoculation was used as indicator of infection. The titers were calculated 
according to the Spearman-Karber method (108).
Flow cytometry of virus-specific CD8+ T cells
Preparation of single cell suspensions of lung cells and splenocytes
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Twelve and 28 days after influenza A/H3N2 virus infection, mice were bled and subsequently lungs 
of three to four mice per group were collected in gentleMACS tubes (Miltenyi Biotec, Bergish Glad-
bach, Germany) with IMDM medium supplemented with 5% FCS, 100μg/mL streptomycin and 100 
IU/mL penicillin and a single cell suspension was made following the manufacturers protocol. The 
lung suspension was then filtered with a 100μM cell strainer (BD Falcon, Erembodegem, Belgium) 
and subsequently treated with red blood cell lysis buffer (Roche, Mannheim, Germany). Single sple-
nocyte suspensions were prepared as described previously (77).
Tetramerstaining
After vaccination or infection with influenza A/H3N2, single cell suspensions of splenocytes and 
lung cells were washed and subsequently stained with fluorescently labeled monoclonal antibod-
ies (mAbs) CD3e-PeCy7, CD8b.2-FITC (both BD, Alphen a/d Rijn, the Netherlands), CD62L-APC-Cy7 
(BioLegend, San Diego, USA), CD127-Pacific Blue (eBioscience, San Diego, USA) and either the PE-
labeled H-2Db tetramer with the immunodominant NP366-374 epitope derived from influenza A vi-
rus X-31 (ASNENMETM; TmX-31) or influenza A/HK/2/68 (ASNENMDAM; TmH3N2) and the APC-labeled 
tetramer derived from influenza A/IND/5/05 NP366-374 (ASNENMEVM; TmH5N1) (137). Tetramers were 
purchased from Sanquin Research, Amsterdam, The Netherlands. To exclude dead cells in the analy-
sis, cells of vaccinated or H3N2-infected mice were also stained with LIVE/DEAD Aqua Fixable Dead 
Cell Stain (Invitrogen, Breda, the Netherlands). Following incubation with tetramers and mAbs for 
20 minutes, cells were washed twice and analyzed with a FACSCantoII and FACS Diva software (all 
BD). 
After H5N1-infection (BSL-III conditions), single cell suspensions of spleens were washed and sub-
sequently stained with mAbs against CD3e, CD8b.2 and with either the PE-labeled H-2Db tetramer 
TmX-31 or TmH3N2 and the APC-labeled tetramer TmH5N1. After incubation, cells were washed, fixed 
with Cytofix (BD) and subsequently acquired on a FACSCalibur and analyzed with Cellquest Pro 
software (both BD).
Peptides and intracellular interferon gamma (IFN-γ) staining
CD8+ T cell responses were measured by incubation of splenocytes or lung cells with peptides rep-
resenting two immunodominant epitopes of influenza A viruses in C57BL/6J mice (H2-b), PA224-233 
and NP366-374 (91, 109). Peptides were manufactured at Eurogentec (Seraing, Belgium). Splenocytes 
or lung cells were cultured for 6 h at 37°C in the presence of 5μM of either the NP366-374 ASNEN-
MDAM (NPH3N2), PA224-233 SCLENFRAYV (PAH3N2) peptides derived from influenza A/HK/2/68 (H3N2) 
virus or the NP366-374 ASNENMEVM (NPH5N1) or SSLENFRAYV (PAH5N1) peptides derived from influenza 
A/IND/5/05 virus in IMDM (Lonza, Breda, the Netherlands) with 5% FCS and Golgistop (BD). The 
PAH5N1 peptide is also a known epitope in the influenza A X-31 vaccine strain that was used. After 
incubation, cells were stored o/n at 4°C and the presence of intracellular IFN-γ in CD8+ T cells was 
subsequently analyzed as described previously (135). Peptide-specific responses were calculated 
by subtracting the percentage of CD8+ IFN-γ+ T cells after incubation with medium and Golgistop 
only from the percentage of CD8+ IFN-γ+ T cells after peptide-stimulation.
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Statistical analysis
Data for weight loss after infection, lung-virus loads, tetramerstaining, and peptide-pulsing were 
analysed statistically using the Mann Whitney Test. Survival was analysed using the Logrank test. 
Differences were considered significant at p<0.05.
RESULTS
Antibody and CD8+ T cell responses induced by vaccination with WIV
Twenty-eight days post administration of the WIV X-31 vaccine, mice of groups 2 and 5 developed 
HA–specific antibodies against influenza virus A/HK/2/68 (H3N2) as detected in the HI assay (geo-
metric mean titer (GMT) of 234) and VN assay (GMT of 19) (Figure 1A). Upon a second vaccination 
twenty-eight days later the GMTs increased to 915 and 144 respectively (Figure 1B). Influenza virus-
specific antibody responses were detected in none of the mock-vaccinated mice. The induction 
of virus-specific CTL responses by WIV vaccination was assessed by determining the frequency of 
CD8+ T lymphocytes in the spleens specific for the NP366-374 epitope (ASNENMETM) by tetramer 
staining using TmX-31. Eight days after the first vaccination, the mean percentage of CD8+TmX-31+ 
T lymphocytes was 4.7 (s.d. 2.2), which was significantly higher than in mock-vaccinated mice 
(p=0.02) (Figure 1C). Subsequently, the frequency of CD8+TmX-31+ T lymphocytes declined but re-
mained higher than in mock-vaccinated mice (0.25 and 0.05%, respectively p=0.04). The booster 
vaccination did not increase the frequency of NP366-374 specific CD8+ T cells. Twenty-eight and 56 
days after the second vaccination the percentages of CD8+TmX-31+ were no longer different from 
those determined in mock-vaccinated mice (p=0.13 and p=1.00, respectively). The frequencies of 
Figure 1. Antibody and CD8+ T cell re-
sponses after vaccination of mice with 
WIV X-31 (H3N2). Virus-specific serum an-
tibody levels were measured by HI-assay 
(A) and VN (B) assay. Splenic CD8+ T cell 
responses directed against the NP366-
374 epitope of influenza A X-31 (ASNEN-
METM) (C). White bars (with s.d.) repre-
sent mock-vaccinated mice (groups 1,3 
and 4) and grey bars (with s.d.) represent 
WIV X-31 vaccinated mice (groups 2 and 
5). *: p<0.05 compared to mice of group 1.
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CD8+TmX-31+ T lymphocytes in the spleens of control mice infected with influenza virus X-31, were 
8.9 (±3.0) and 1.0 (± 0.7) eight and twenty-eight days post infection, respectively. The proportion of 
cells that expressed CD62L or CD127 did not differ significantly between vaccinated and infected 
mice (data not shown). 
 
Outcome of infection with influenza virus A/HK/2/68 (H3N2)
Upon infection with influenza virus A/HK/2/68, mock-vaccinated mice developed mild to moderate 
clinical signs and lost body weight from day 3 to day 7 post infection (Figure 2A). From day 7 on-
wards, these mice recovered from infection. In contrast, mice vaccinated with the WIV X-31 vaccine 
(groups 2) did not develop any clinical signs upon infection and did not display loss of body weight, 
comparable to mock-infected mice (groups 1,4 and 5). The development of clinical signs correlated 
with virus titers in the lungs four days post infection (dpi). In the lungs of mock-vaccinated mice, 
the virus replicated to mean titers of 108.6 TCID50 per gram of tissue (Figure 2B). In contrast, infec-
tious virus could not be detected in the lungs of mice that were vaccinated with the WIV X-31 vac-
cine preparation and in lungs of mock-infected control mice.
CD8+ T cell responses after infection with influenza A/H3N2
Tetramerstaining
Twelve and 28 dpi with influenza virus A/HK/2/68 (H3N2), the frequency of CD8+ T cells specific for 
the NP366-374 epitope present in influenza virus A/HK/2/68 (H3N2) (ASNENMDAM) was assessed in 
the spleen and lungs by tetramerstaining. Twelve dpi, the mean percentage of CD8+ TmH3N2+ T cells 
in spleens and lungs of mock-vaccinated H3N2-infected mice of group 3 were 0.83 (s.d. 0.36) and 
4.00 (s.d. 1.00), respectively. In contrast, the mean frequency of CD8+ TmH3N2+ T lymphocytes was 
significantly lower in the WIV-vaccinated mice (0.22 ± 0.10% and 0.93 ± 0.54% in spleens (p=0.004) 
and lungs (p=0.02) respectively) and comparable to the frequencies found in naïve control mice 
(Figure 3A and B).
Twenty-eight dpi, the percentage of CD8+ TmH3N2+ T cells in the spleens and lungs had declined 
somewhat (Figure 3C and 3D). This percentage in the spleens and lungs was still lower in vacci-
nated mice H3N2-infected mice compared to unvaccinated/H3N2 infected mice.This difference was 
Figure 2. Outcome of infection with in-
fluenza virus A/HK/2/68 (H3N2). Mean 
weight loss of mock-infected (mice of 
groups 1, 4 and 5; white circles) or mice 
infected with influenza A/H3N2 virus 
(group 2; grey circles and group 3; black 
circles) ± s.e.m (A). Four dpi lung virus ti-
ters were determined of mice of groups 
1,2 and 3. Bars represent mean virus ti-
ters of four mice per group with standard 
deviations. The dotted line indicates the 
cut-off value for obtaining a positive re-
sult (B).
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statistically signficant for the spleens (p=0.01) and approached statistical significance for the lungs 
(p=0.05) at this time point post infection. 
Cross-reactivity and differentiation of CD8+ TmH3N2+ T cells
The cross-reactivity of CD8+ TmH3N2+ T cells with the epitope variant of the influenza A/H5N1 virus 
(ASNENMEVM) was analysed using TmH5N1. Only few CD8+ TmH3N2+ T cells induced after infection 
with influenza virus A/HK/2/68 (H3N2) cross-reacted with the H5N1-derived epitope. Furthermore, 
percentages of CD8+ TmH5N1 T cells did not differ between the respective groups after influenza A/
H3N2 infection (data not shown). 
The CD8+ TmH3N2+ T cells were also phenotyped according to their expression of CD62L and CD127. 
CD62Lhigh/CD127high cells were regarded as central memory (CM),CD62Llow/CD127high cells as effec-
tor memory (EM)  and CD62Llow/CD127low as effector (E) cells (138). In spleens and lungs of mock-
vaccinated, H3N2-infected mice (group 3) 12 and 28 dpi, most CD8+ TmH3N2+ T cells were of the 
EM phenotype (Figure 4). The percentage EM CD8+ TmH3N2+ T cells of these mice was significantly 
higher than that of X-31 vaccinated mice of group 2 (p<0.05) in both spleens (12 and 28 dpi) and 
lungs (only 12 dpi). Only twelve dpi, the percentage of E CD8+ TmH3N2+ T cells was higher in mice 
of group 3 compared to mice of group 2 in both lungs and spleens. On day 28 dpi this population 
was virtually absent in mice of all groups. Twelve dpi, an increase in the percentages of CM CD8+ 
TmH3N2+ T cells was observed in the spleens, but not in the lungs, of H3N2-infected mice com-
pared to mock-infected animals or those that were vaccinated and infected (p=0.002). At day 28 dpi 
these differences between groups were no longer detectable. 
Figure 3. Virusspecific CD8+ T cell re-
sponses after influenza A/HK/2/68 
(H3N2) infection. Percentages of CD8+ 
TmH3N2+ T cells were determined in 
spleens (A, C) and lungs (B,D) obtained 
12 (A,B) and 28 (C,D) days after infection 
with influenza A/HK/2/68 (H3N2). Bars 
represent mean percentages of CD8+ 
TmH3N2+ T cells ± s.d.. *: p<0.05 com-
pared to mice of group 2 and **: p<0.01 
compared to mice of group 2.
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Specificity of CD8+ T cell response (Intracellular IFN-γ staining)
To assess the cross-reactivity of the CD8+ T cell response with epitope variants present in the influ-
enza virus strain A/Indonesia/5/05 (H5N1),  splenocytes and lung cells obtained from mice twelve 
dpi with influenza virus A/HK/2/68 (H3N2) were stimulated with peptides NP366-374 and PA224-233 de-
rived from both viruses.  Upon infection with the H3N2 strain peptide-specific CD8+ T cells respons-
es were observed in spleens and lungs that also cross-reacted with the peptide from the hetero-
subtypic strain (Figure 5). The response to NPH5N1 peptide (H5N1) was significantly higher in mice 
that were X-31-vaccinated prior to infection with A/HK/2/68 (H3N2) than in mock-vaccinated mice. 
Otherwise vaccination reduced the magnitude of the CD8+ T cell response following infection with 
the H3N2 strain. 
Also in the lungs virus-specific CD8+ T cells were observed after infection of mock-vaccinated mice 
to the homologous NP366-374 peptide and the H3N2 and H5N1 PA224-233 peptide variants. These re-
sponses were significantly higher than those of mice that were vaccinated against the H3N2 strain. 
Twenty-eight dpi, peptide-specific CD8+ T cells were no longer detectable by intracellular IFN-γ 
staining in both lungs and spleens of any of the mice (data not shown).
Vaccination prevents heterosubtypic immunity against influenza A/H5N1
Twenty-eight dpi with influenza A/H3N2, mice of groups 2, 3, 4 and 5 were infected with a 90% 
lethal dose of influenza A/Indonesia/5/05 (H5N1). All H5N1-infected mice developed clinical signs 
including weight loss from two days post infection onward. Eleven out of 12 unvaccinated, H3N2-
infected mice (group 3) lost weight until day six or seven and then started to recover and gained 
weight. In contrast, all mice of groups 4 and 5 lost weight until they reached humane endpoints for 
Figure 4. Differentiation of CD8+ TmH3N2+ 
T cells. CD8+ TmH3N2+ T cells in spleens (A, 
C) and lungs (B,D) obtained 12 (A,B) and 28 
(C,D) dpi with influenza A/HK/2/68 (H3N2) 
were divided based on their expression of 
CD62L and CD127 by flow cytometry. White 
bars represent central memory cells (CD62L-
high CD127high), black bars effector memory 
cells (CD62Llow CD127high) and grey bars ef-
fector cells (CD62Llow and CD127low).
*: p<0.05 compared to mice of group 2 and 
**: p<0.01 compared to mice of group 2.
58
Chapter 4 -  WIV vaccination and heterosubtypic immunity
4
euthanasia according to animal welfare regulations (weight loss of more than 20% and severe clini-
cal signs). Of the X-31-vaccinated and H3N2 infected mice, eight out of twelve (67%) mice had to be 
euthanized. Mice of groups 2 and 3 that survived challenge and that were not taken out of the ex-
periment to assess lung virus titers or CD8+ T cell responses continued to gain weight and reached 
their original body weight 14 dpi. The difference in weight loss and survival between mock-vacci-
nated and WIV X-31-vaccinated H3N2-infected mice was statistically significant (both p<0.01) (Fig-
ure 6A and B). No significant differences were observed between virus titers in the lungs of mice 
of groups 2 and 3 four (data not shown) and seven dpi, but the average virus titer at 7 dpi was the 
lowest in mice of group 3, which survived the lethal challenge (p=0.32) (Figure 6C). No virus was 
detected in lungs of mice that survived the lethal challenge until14 dpi.
Virus-specific CD8+ T cell responses after H5N1-infection
Seven dpi with influenza virus A/Indonesia/5/05 (H5N1) infection, the presence of CD8+ T cells spe-
cific for the NPH5N1, NPH3N2 NPX-31 and PAH5N1 epitopes in the spleen was assessed by tetramerstain-
ing and/or intracellular IFN-γ staining after stimulation with peptides.
In naïve mice, virus-specific CD8+ T cell responses were virtually undetectable seven dpi with in-
fluenza virus A/IND/5/05 (H5N1) (Figure 6D). In contrast, a prior infection with influenza virus A/
HK/2/68 (H3N2) (group 3 mice) primed for a CD8+ T cell response for both the NP366-374 and PA224-233 
epitope derived from the H5N1 strain (PAH5N1). The magnitude of the response to both epitopes 
was comparable indicating that the responses were co-dominant. In contrast, the response in 
group 5 that were vaccinated with WIV X-31 before infection with the A/H5N1 virus was dominated 
by the NP366-374 –specific response. A similar result was observed in mice of group 2 that were WIV-
X-31 vaccinated and subsequently infected with influenza virus A/HK/2/68 before infection with 
influenza virus A/IND/5/05 (H5N1). In this group the response to PA224-233 was virtually absent and 
significantly lower than that observed in mice of group 3 (p<0.001).
Figure 5. CD8+ T cell responses to NP366-374 and PA224-233 as measured by intracellular IFN-γ staining. Responses 
of CD8+ T cells directed against peptides NPH3N2 (grey bars), NPH5N1 (white bars), PAH3N2 (black bars) and PAH5N1 
(hatched bars) were detected by intracellular IFN-γ staining 12 days after influenza A/HK/2/68 (H3N2) infection in 
spleens (A) and lungs (B). Bars represent mean values ± s.d.. *: p<0.05 compared to mice of group 2 and **: p<0.01 
compared to mice of group 2.
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The results obtained with intracellular IFN-γ staining were in agreement with those obtained with 
NP366-374 based tetramer staining (table 2), illustrating that the response to the NP366-374 epitope 
was cross-reactive in mice of group 2, 3 and 5. In addition, this method allowed the assessment of 
the cross-reactivity of the CD8+ T cells that were induced against this epitope. Prior infection with 
influenza virus A/HK/2/68 (H3N2) (containing NP366-374 epitope ASNENMDAM) did not predispose 
for the induction of CD8 + T cells cross-reactive with NPH5N1 (ASNENMEVM). In contrast, vaccination 
with WIV-X-31 (containing ASNENMETM), primed for the induction CD8+ T cell responses not only 
cross-reactive with the H5N1 variant of the epitope ASNENMEVM but also with the H3N2 variant 
ASNENMDAM (table 2).  
Figure 6. Outcome of influenza A/IND/5/05 (H5N1) virus infection. Mice were mock-infected (group1; white circles) 
or infected with influenza A/IND/5/05 (H5N1) (group 2; grey circles, group 3; black circles, group 4; black diamond 
squares and group 5; white squares), were weighed daily and the mean weight loss ± s.e.m. was calculated (A). Mori-
bund animals were euthanized according to pre-fixed criteria and were recorded as dead to calculate the cumulative 
survival after H5N1 challenge as shown in the Kaplan Meier curve (B). Lung virus titers were determined 7 dpi with 
influenza A/IND/5/05 (H5N1). Horizontal bars represent the average titers of each group of mice (C). CD8+ T cells to 
peptides NPH5N1 (grey bars) and PAH5N1 (black bars) in spleens of mice were measured 7 dpi by intracellular IFN-γ 
staining (D). The data represent the mean percentage of CD8+ IFN-γ+ T-cells ± s.d..*: p<0.05 compared to mice of 
group 2 and **: p<0.01 compared to mice of group 2.
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Table 2. Specificity and cross-reactivity of NP366-374 specific CD8 T cells in spleens of mice 7 days 
post infection with A/IND/5/05 (H5N1) as detected by tetramer-staining. 
Group CD8+ Single Tm+ T cells CD8+ Double Tm+ T cells
NPX-31+ NPH3N2+ NPH5N1 + NPX-31+
NPH5N1 +
NPH3N2+
NPH5N1 +
2 1.1 (1.0)* 0.7 (0.9) 0.8 (0.7) 1.2 (1.8) 0.8 (1.2)
3 n.d. 1.0 (0.9) 2.0 (2.7) n.d. 0.1 (0.1)
4 n.d. 0.1 (0.1) 0.0 (0.1) n.d. 0.0 (0.0)
5 2.9 (3.3) 0.6 (0.5) 0.9 (0.9) 3.6 (6.9) 4.1 (6.6)
* data are represented as percentage Tm+ cells within the CD8+ T cell population (standard deviation)
n.d. : no data collected
DISCUSSION
In the present study, it was demonstrated that vaccination of mice with an inactivated influenza 
A/H3N2 vaccine induced protective immunity to infection with a corresponding A/H3N2 virus. By 
preventing productive infection with influenza virus A/HK/2/68 (H3N2) the protective potential of 
heterosubtypic immunity afforded by infection with the A/H3N2 virus was severely reduced. As a 
result, WIV X-31/H3N2 infected vaccinated mice suffered more from clinical signs as weight loss 
and displayed higher mortality rates after infection with the highly pathogenic influenza virus A/
IND/5/05 (H5N1) than unvaccinated/H3N2 infected mice. In addition, WIV X-31 vaccination altered 
immunodominance patterns of CD8 T cell responses induced after infection with the A/H5N1 virus 
and the extent of viral shedding.
In a previous study we have shown that the use of an experimental subunit vaccine exclusively 
containing the hemagglutinin and neuraminidase of influenza virus X-31 prevented the induction 
of heterosubtypic immunity against an influenza A/H5N1 virus infection, otherwise induced by in-
fection with influenza virus A/HK/2/68 (H3N2) (135). Since the viral inner proteins were absent, this 
vaccine preparation failed to induce CD8+ T cell responses to e.g. the NP. 
In this study, we evaluated the use of whole inactivated virus vaccines for several reasons: first, WIV 
vaccines are more immunogenic than subunit vaccines and are widely used in humans as unadju-
vanted influenza vaccines. Secondly, since WIV vaccines contain inner viral proteins it was antici-
pated that they also induce CD8+ T cell responses to these conserved proteins (104), albeit inef-
ficiently, and therefore may afford some level of heterosubtypic immunity. Indeed, vaccination with 
WIV X-31 induced detectable virus-specific CD8+ T cell responses, probably through cross-priming 
(139), in addition to virus-specific antibody responses and protected mice from infection with the 
corresponding H3N2 influenza virus A/HK/2/68. However, the T cell responses to the NP366-374 epit-
ope were transient and only detected shortly after the first vaccination. In addition, they were mod-
est compared to the responses observed after infection with influenza virus X-31. Furthermore, vac-
cination severely impaired the CD8+ specific T cell response to NPH3N2, PAH3N2 and PAH5N1, but not 
the response to NPH5N1 after infection with influenza virus A/HK/2/68 (H3N2). Apparently there is 
cross-reactivity between the X-31 (ASNENMETM), the H3N2 (ASNENMDAM) and the H5N1 (ASNEN-
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MEVM) variant of the NP366-374 epitope, which was also reported by others (92). 
Vaccination with WIV largely prevented the formation of central and especially effector memory 
cells specific for NPH3N2, otherwise induced after infection with influenza virus A/HK/2/68 (H3N2).  
However, vaccination did prime for a secondary CD8+ T cell response specific for the heterologous 
NP366-374 epitope derived from influenza virus A/IND/5/05 (H5N1) (ASNENMETM vs ASNENMEVM). 
Apparently these two variants are antigenically similar and are highly cross-reactive and CD8+ T 
cell responses were induced of which the relative responses to the NP366-374 and PA224-233 epitopes 
resembled that of a typical secondary influenza virus specific CTL response in C57BL/6 mice (91). 
Nevertheless, WIV X-31 vaccination did not afford protection against the development of clinical 
signs and mortality caused by A/IND/5/05 infection and did not reduce virus replication in the lung. 
In contrast, a primary infection with influenza virus A/HK/2/68 (H3N2) afforded partial protec-
tion against infection with influenza virus A/IND/5/05 (H5N1). These mice started to regain body 
weight seven dpi onward and fully recovered.  This protection correlated with the induction of co-
dominant CD8+ T cell responses against the NPH5N1 and PAH5N1 epitopes. Although the difference 
with naïve mice of group 4 and WIV-vaccinated mice of group 5 was striking, it is uncertain if the 
response to especially the PA224-233 epitope was responsible for the protective effect of a prior A/
H3N2 infection. Firstly, it has been demonstrated that the PA224-233 epitope was presented by pro-
fessional antigen presenting cells like dendritic cells, but not by virus-infected epithelial cells (140), 
indicating that PA224-233 specific CD8+ T cells are unable to eliminate virus-infected cells from the 
lung efficiently. In addition, it was shown that vaccination with DCs loaded with the PA224-233 pep-
tide induced an epitope-specific CD8+ T cell response but failed to control a subsequent infection 
with influenza virus or even delayed virus clearance (140). Secondly, only a minority of NP366-374 spe-
cific CD8+ T cells induced after infection with influenza virus A/HK/2/68 (H3N2) was cross-reactive 
with the peptide variant derived from the H5N1 virus, which could explain the co-dominant PA224-
233 specific response. Although the infection with influenza virus A/IND/5/05 (H5N1) resulted in the 
selective expansion of cross-reactive NP366-374 specific cells, this response is much lower than ob-
served after a secondary infection with an infuenza virus carrying the identical epitope sequence 
(141). In the absence of a dominant response to NP366-374, the response to PA224-233 can become 
co-dominant (141).
Vaccination with WIV-X-31 (group 2) completely abrogated the response to the PA224-233 epitope 
observed after consecutive infections with influenza viruses A/HK/2/68 and A/IND/ 5/05, but not 
the response to the NP366-374 epitope. With regard to the response to the latter epitope, two contra-
dictory mechanisms could be at work simultaneously: first, vaccination could reduce the induction 
of CD8+ T cells specific for NPH3N2 (ASNENMDAM) cross reactive with NPH5N1 (ASNENMEVM) as was 
also observed after vaccination with a subunit vaccine (135). Second, WIV vaccination could prime 
for a secondary response to the NP366-374 as was seen for the mice of group 5.  
In addition, vaccination may prevent the induction of other arms of the adaptive immune response 
otherwise induced by infection like virus-specific CD4+ T cells, antibodies to the extracellular do-
main of the matrix protein (M2e) (43, 46, 47, 96, 123, 126, 127, 129, 142-144) and the induction of 
tertiary lymphoid structures (116). Although it has been suggested recently that also antibodies to 
the nucleoprotein contribute to heterosubtypic immunity (36), it is unlikely that they played a role 
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in the present study since all vaccinated mice developed NP-specific antibodies which did not cor-
relate with protection against H5N1 infection (data not shown).
Collectively, this study demonstrates that vaccination with WIV X-31 induces virus-specific CD8+ T 
cell responses, induces protective immunity against homologous infection with influenza A/H3N2 
and primes for secondary CD8+ T cell responses after infection with A/H5N1 influenza virus. 
However, despite its capacity to induce memory CD8+ T cell immunity, vaccination with WIV, like 
the use of subunit vaccines, did not afford protection against influenza A/H5N1 infection.
In addition, the use of WIV vaccines affected the induction of heterosubtypic immunity by infec-
tion, like the use of subunit vaccine (135). Thus, regardless of the nature of the inactivated vaccine 
that is used for the protection against seasonal influenza, the induction of heterosubtypic immu-
nity is affected. This may be an unwanted effect of seasonal influenza vaccination using inactivated 
vaccines and is at present a matter of debate as it was recently recommended in a number of coun-
tries including the USA to to vaccinate all healthy children 6-59 months of age against seasonal 
influenza (60, 61, 145, 146).  
The interference with the induction of heterosubtypic immunity correlated with changes in the 
immunodominance patterns of the virus-specific CD8+ T cell response. However it is unlikely that 
these changes were responsible for the lack of protection per se and most likely reflect differences 
in imprinting of CD8+ T cell responses by the absence or presence of priming of NP366-374 specific T 
cell memory responses. Detailed analysis of the outcome of immune responses upon consecutive 
infections with influenza viruses of different subtypes may provide better insight in the pros and 
cons of the use of inactivated vaccines in immunologically naïve subjects.       
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ABSTRACT
Infection with seasonal influenza viruses induces a certain extent of protective immunity against 
potentially pandemic viruses of novel subtypes, also known as heterosubtypic immunity. Here we 
demonstrate that infection with a recent influenza A/H3N2 strain induces robust protection in fer-
rets against infection with a highly pathogenic avian influenza virus of the H5N1 subtype. Prior 
H3N2 virus infection reduced H5N1 virus replication in the upper respiratory tract, clinical signs, 
mortality, and histopathological changes associated with virus replication in the brains. This protec-
tive immunity correlated with the induction of T cells that cross-reacted with H5N1 viral antigen. 
We also demonstrated that prior vaccination against influenza A/H3N2 reduces the induction of 
heterosubtypic immunity otherwise induced by infection with the influenza A/H3N2 virus. The im-
plications of these findings are discussed in the context of adopting vaccination strategies and vac-
cine development aiming at the induction of immunity to pandemic influenza.
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INTRODUCTION
Since highly pathogenic influenza A viruses of the H5N1 subtype continue to circulate among do-
mestic bird populations and cause fatal infections of humans occasionally, a pandemic outbreak 
with these viruses is still feared (21). To become pandemic, these viruses need to adapt to their new 
mammalian host and become transmissible from human to human. Apparently the influenza A/
H1N1(2009) viruses that originated in swine, possessed these properties and were responsible for 
the first influenza pandemic in the 21st century.
Probably the most effective measure to reduce the impact of influenza pandemics is the develop-
ment and use of vaccines. Several candidate vaccines have been developed against influenza A/
H5N1 viruses, which in some cases contain adjuvants to make these vaccines more efficacious and 
to achieve dose-sparing (147-150). Also against the influenza A/H1N1(2009) virus vaccines were de-
veloped. Although these vaccines were efficacious (151, 152), they arrived late and after the peak of 
the pandemic (153), which precluded profiting optimally from the protection these vaccines would 
have afforded. Therefore, there is interest in the development of more universal vaccines (121, 154), 
that could induce protective immunity to influenza A viruses of various subtypes, including influ-
enza A/H5N1. Full understanding of the heterosubtypic immunity that is induced by infection with 
influenza A viruses may help developing such vaccines. Indeed, prior infection with an influenza A 
virus can reduce morbidity and mortality caused by infection with an influenza A virus of another 
subtype, including influenza A/H5N1 as was demonstrated in various animal models (40, 78, 80, 
136, 155). Thus, individuals previously infected with seasonal influenza viruses may be less suscep-
tible to developing severe disease after infection with (pandemic) viruses of a novel subtype than 
immunogenically naïve subjects (54). This might, at least in part, also explain the disproportionate 
age distribution of severe cases of infection with influenza A/H5N1 (57) and A/H1N1(2009) viruses 
(55) with higher incidences in subjects of young age which had not yet developed robust hetero-
subtypic immunity after one or more infections with seasonal influenza viruses. Elucidating the ba-
sis of heterosubtypic immunity has been the topic of numerous studies (for review see (40)). 
It is generally accepted that arms of the immune system other than serum-antibodies to hemagglu-
tinin and neuraminidase contribute to heterosubtypic immunity, like CD4+ and CD8+ T cells spe-
cific for conserved viral proteins, mucosal antibodies and B cells (40, 43, 47, 123, 136).
So far, infection-induced heterosubtypic immunity to highly pathogenic influenza A/H5N1 viruses 
has been studied predominantly in mice (76, 80, 136). Since the pathogenesis of influenza virus 
infections of mice differs from that of humans and results obtained in mice are considered to be 
of limited predictive value for humans (156), we wished to study the induction of heterosubtypic 
immunity to H5N1 influenza viruses with seasonal influenza virus in ferrets, which resemble the 
human situation more closely. In addition, we wished to investigate if vaccination of ferrets against 
seasonal influenza A/H3N2 virus would interfere with the induction of heterosubtypic immunity to 
influenza A/H5N1 viruses otherwise induced by infection with influenza A/H3N2 virus as was dem-
onstrated recently in mice (135, 157).
To this end, ferrets were vaccinated with a subunit vaccine based on a recent A/H3N2 influenza 
virus vaccine strain or mock-vaccinated and subsequently inoculated with a matching influenza 
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A/H3N2 virus strain or not. Four weeks after inoculation with the influenza A/H3N2 strain, all fer-
rets were infected with the highly pathogenic H5N1 strain A/Indonesia/5/2005 to assess the pres-
ence of heterosubtypic immunity and the effect H3N2 vaccination had on the development of this 
immunity. It was shown that vaccination against A/H3N2 virus infection affected the induction of 
heterosubtypic immunity to H5N1 influenza virus. This may have implications for the universal rec-
ommendation to vaccinate all healthy children in some countries and highlights the need for the 
development of broadly protective vaccines.
 
MATERIALS AND METHODS
Influenza A viruses 
Influenza virus A/Indonesia/5/2005 (H5N1, clade 2.1, A/Ind/5/05) was propagated in confluent 
MDCK cells. After cytopathic changes were complete, culture supernatants were harvested and 
cleared by low speed centrifugation and stored at −80°C. Influenza virus A/Brisbane/010/2007 
(H3N2) was propagated in the allantoic cavity of 11-days old embryonated chicken eggs. Allantoic 
fluid was harvested two days post inoculation, cleared by low speed centrifugation and stored at 
-80°C. Virus titers were determined in MDCK cells as described previously (85). All experiments with 
the influenza A/H5N1 virus were performed under Bio Safety Level (BSL)-3 conditions.
Vaccine preparation 
Preparation and purity testing of egg-grown, influenza A virus subunit antigen (SU) derived from 
influenza A/Uruquay/716/2007 (NYMC X-175-C, H3N2) was performed essentially as described pre-
viously (106, 135). Influenza NYMC X-175-C is the H3N2-vaccine strain for influenza seasons 2008-
2009 and 2009-2010 and is closely related to the vaccine reference strain of these seasons, influen-
za A/Brisbane/010/07 (H3N2). The viral nucleoprotein and matrix protein could not be detected in 
the vaccine preparation by SDS-PAGE and coomassie brilliant blue staining, while small traces were 
detected using Western blot analysis and on a silver stained SDS-PAGE gel. 
Ferrets
Healthy young adult outbred female ferrets (Mustela putorius furo; between 6 and 12 months of 
age) were purchased from a commercial breeder. Ferrets were tested for the presence of serum 
antibodies against recent influenza A/H1N1 and A/H3N2 viruses and for the presence of antibodies 
against influenza virus A/Indonesia/5/2005 (H5N1) by hemagglutination inhibition assay. Ferrets 
were also tested for the presence of antibodies against Aleutian disease virus and when the ab-
sence of these antibodies was confirmed, ferrets were randomly assigned to one of four experi-
mental groups (see below). During the experiment, ferrets were housed in groups and received 
food and water ad-libitum. An independent animal ethics committee (DEC consult) approved the 
experimental protocol before the start of the experiments. 
Immunizations and infection of ferrets
Fourty ferrets were divided over four groups of 10 animals each. Ferrets of groups 2 and 3 were im-
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munized twice with 15 µg influenza subunit vaccine in combination with Titermax Gold adjuvant 
(Sigma-Aldrich, Saint Louis, USA) with an interval of four weeks, while ferrets of groups 1 and 4 were 
mock-vaccinated with phosphate buffered saline (PBS). The experimental groups are listed in table 
1. All animals were tested simultaneously in a single experiment. Vaccinations were performed in 
the quadriceps muscles of the left hind leg in a total volume of 0.25 ml under anaesthesia with ket-
amine. Four weeks after the second immunization, ferrets of groups one and two were inoculated 
intranasally with 1x106 TCID50 influenza virus A/Brisbane/010/2007 (H3N2) in a total volume of 0.5 
ml PBS, while ferrets of groups 3 and 4 were inoculated with PBS. Four weeks after inoculation with 
the influenza A/H3N2 virus, two ferrets of each group were euthanized and lungs, nasal cavity and 
trachea were taken out for histopathological evaluation, while the eight remaining ferrets of each 
group were inoculated intranasally with 5x106 TCID50 influenza virus A/Ind/5/05. All inoculations 
were performed under anaesthesia with ketamine/medetomidine (reversed with atipamezole). 
During infection experiments, ferrets were checked daily for the presence of clinical signs. Before 
and two, four and seven days post inoculation (dpi) with the influenza A/H3N2 virus and before 
and two, four, six and seven dpi with the H5N1 influenza virus, ferrets were weighed and nasal and 
pharyngeal swabs were collected while anesthesized with ketamine. Seven days after inoculation 
with influenza A/H5N1 virus or earlier when ferrets became moribund, animals were weighed and 
subsequently killed by exsanguination while under anesthesia with ketamine and medetomidine. 
Necropsies were performed according to standard procedures and samples of the olfactory bulb, 
the cerebrum, lungs (all lobes of the right lung and the accessory lobe), spleen and duodenum 
were collected for determination of virus titers and evaluation of histopathological changes.
Table 1. Experimental groups 
Group Vaccination Primary infection Challenge infection
1 mock A/H3N2 virus2 A/H5N1 virus3
2 H3N2 vaccine1 A/H3N2 virus A/H5N1 virus
3 H3N2 vaccine mock A/H5N1 virus
4 mock mock A/H5N1 virus
1 subunit vaccine derived from influenza A/Uruquay/716/2007 (NYMC X-175-C, H3N2) adjuvanted with Titermax 
Gold adjuvant
2  influenza virus A/Brisbane/010/07 (H3N2)
3 influenza virus A/Indonesia/5/05 (H5N1
Serology
Serum samples were collected before, twenty-eight days after the first and second vaccination and 
twenty-eight days after infection with influenza virus A/Brisbane/010/07 (H3N2). Sera were stored 
at –20°C until use. Sera were tested for the presence of antibodies against influenza virus X-175-C 
(H3N2), A/Brisbane/010/07 (H3N2) and A/Indonesia/5/05 (H5N1) using the hemagglutination inhi-
bition assay (HI-assay) performed with four hemagglutinating units of virus and 1% turkey erythro-
cytes and a micro virus neutralization assay (VN-assay) performed with 100 TCID50 of the respective 
virus as described previously (107, 158).
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Preparation of viral antigens for T cell proliferation assay
Influenza A viruses A/Brisbane/010/07 (H3N2) and A/Ind/5/2005 (H5N1) were propagated in MDCK 
cells and purified and concentrated by isopycnic density centrifugation. Subsequently virus was 
inactivated by dialysis against PBS containing 0.1% formaldehyde for 4 days under continuous stir-
ring at room temperature. After inactivation, antigen was dialysed against PBS. The purity of the 
antigens was tested by SDS-PAGE and inactivation was confirmed by failure to passage on MDCK 
cells. The protein concentration was determined using a BCA Protein Assay kit (Pierce).
T cell proliferation assay
Blood samples were collected from the jugular vein of ferrets 28 days after the second vaccination 
and 28 days after infection with influenza A/H3N2 virus and isolation of peripheral blood mono-
nuclear cells (PBMC) and the T cell proliferation assay was performed as described previously (159). 
In brief, cryopreserved PBMC were thawed, washed and labelled with 0.3µM carboxyfluorescein 
diacetate succinimidyl ester (CFSE) for 5 minutes in PBS (Invitrogen, Breda, the Netherlands). Af-
ter washing the cells were resuspended in RPMI 1640 (Cambrex, East Rutherford, USA) containing 
10% (v/v) fetal calf serum, penicillin (100 μg/ml), streptomycin (100 U/ml) and L-glutamine (2mM) 
and seeded (5x 105 cells per well) in a 96-well round-bottom plate in the presence or absence of 
50 ng of inactivated influenza A/Brisbane/010/07 or A/Indonesia/5/2005 antigen and incubated at 
37°C/5% CO2.  After two days supernatant of Concanavalin A-stimulated ferret lymph node cells 
was added (160). For each condition duplicate samples were tested. After four more days, cells were 
incubated with a monoclonal antibody directed to human CD8 (OKT-8)-eFluor 450 (eBioscience, 
San Diego, USA) and LIVE/DEAD Aqua Fixable Dead Cell Stain (Invitrogen, Breda, the Netherlands). 
Cells were subsequently fixed and permeabilized with Cytofix and Cytoperm (BD Pharmingen, 
Alphen a/d Rijn, the Netherlands) and incubated with a Alexa Fluor 647-labelled monoclonal an-
tibody specific for human CD3 (PC3/188A) (Santa Cruz Biotechnology, Santa Cruz, USA). Fluores-
cence of cells was assessed by flow cytometry using a FACSCanto-II and analysed with FACS Diva 
software (BD). The specific proliferation of CD3+CD8- cells for each antigen was calculated by sub-
tracting the mean number of CD3+CD8-CFSElow cells of the medium controls from the mean num-
ber of CD3+CD8-CFSElow cells stimulated with antigen derived from A/Brisbane/010/07 (H3N2) or 
A/Ind/5/05 (H5N1). The same calculation was performed for CD3+CD8+ cells.
Virus titers in tissue and nasal and pharyngeal swabs
Tissue samples of ferrets were collected and snap frozen on dry ice with ethanol and stored at –70°C 
until further processing. Tissue samples were weighed and subsequently homogenized with a Fast-
Prep-24 (MP Biomedicals, Eindhoven, The Netherlands) in Hank’s balanced salt solution containing 
0.5% lactalbumin, 10% glycerol, 200 U/ml penicillin, 200 μg/ml streptomycin, 100 U/ml polymyxin B 
sulfate, 250 μg/ml gentamycin, and 50 U/ml nystatin (ICN Pharmaceuticals, Zoetermeer, The Neth-
erlands) and centrifuged briefly. 
After collection of nasal and pharyngeal swabs, swabs were stored at -70°C in the same medium as 
used to homogenize lung samples. Quadruplicate 10-fold serial dilutions of swab and tissue sam-
ples were used to infect MDCK cells as described previously (85). HA activity of the culture super-
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natants collected 5 days post infection was used as indicator of infection. The titers were calculated 
according to the Spearman-Karber method and expressed as 10log TCID50 per gram for tissue or per 
milliliter (ml) for swabs (108). 
Histopathology and immunohistochemistry
Tissues from ferrets euthanized 28 days after inoculation with influenza A/Brisbane/010/07 (H3N2) 
and 7 days after inoculation with influenza A/Ind/5/05 (H5N1) were examined macroscopically for 
the presence of lesions and lungs (after inflation with 10% neutral buffered formalin), liver, brain, 
spleen and duodenum were fixed with 10% neutral buffered formalin. After fixation and embed-
ding in paraffin, tissues were sectioned at 4 μm and tissue sections were examined by staining with 
hematoxylin and eosin (HE). Using an immunoperoxidase method, serial lung tissue sections were 
also stained with a monoclonal antibody directed against the nucleoprotein of the influenza A virus 
for the detection of virus-infected cells in the respective tissues (110). 
Statistical analysis
The presence of statistical significant differences in virus titers in nasal and pharyngeal swabs be-
tween groups after inoculation with influenza A/Brisbane/010/07 (H3N2) was assessed using the 
Mann-Whitney U test, while differences in the number of CD3+CD8-CFSElow cells and differences 
in virus titers in nasal and pharyngeal swabs and weight loss after challenge with influenza A/H5N1 
virus were calculated using the Games-Howell test. Differences were considered significant when P 
values were less than an α of 0.05.
 
RESULTS
Antibody responses after vaccination
Twenty-eight days after the first vaccination with Titermax-adjuvanted X-175-C subunit prepara-
tion, 11 out of 20 ferrets of groups 2 and 3 had developed HA-specific antibodies against influenza 
A/Brisbane/010/07 (H3N2) as measured with the hemagglutination inhibition (HI) assay (geometric 
mean titer, GMT, 28), while no antibodies were detected in mock-vaccinated ferrets of groups 1 and 
4 (Figure 1A). Twenty-eight days after the second vaccination, virus-specific HI antibodies were de-
tected in all ferrets of groups 2 and 3 (GMT 192). In the virus-neutralization assay, antibodies against 
influenza A/Brisbane/010/07 (H3N2) were detected in 12 out of 20 ferrets of groups 2 and 3 (GMT 
15) 28 days after the first vaccination and in 16 out of 20 ferrets of groups 2 and 3 28 days after the 
second vaccination (GMT 52) (data not shown). Of all ferrets tested, only a small number of ferrets 
showed a discrepancy in the presence of antibodies as measured in the VN and HI assay (VN -, HI 
+), which most likely is caused by the low antibody levels in these ferrets. Four weeks after inocula-
tion with influenza A/Brisbane/010/07, antibodies against influenza A/Brisbane/010/07 (H3N2) vi-
rus were only detected in all vaccinated and/or infected animals. In addition, no antibodies against 
influenza A/Ind/5/05 were detected in any of the sera of the animals with the HI and VN assay (data 
not shown).
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Outcome of inoculation with influenza A/H3N2 virus
Following inoculation with influenza virus A/Brisbane/010/07 (H3N2), unvaccinated ferrets of 
groups 1 developed mild to moderate clinical signs including sneezing, decreased appetite and 
weight loss (mean percentage of weight loss 6% at day 4). The ferrets of group 2 displayed similar 
weight loss (mean percentage of weight loss 5% at day 4, Figure 1B), although their clinical signs 
were less severe than those observed in group 1. The observed differences in clinical signs corre-
lated with differences in virus titers in pharyngeal swabs collected 2 and 4 days after inoculation 
of ferrets of both groups. Mean virus titers in pharyngeal swabs collected 2 and 4 dpi from un-
vaccinated ferrets of group 1 were respectively 102.6  and 101.5  TCID50/ml, while significantly lower 
(p<0.01 for both time points) virus titers were detected in pharyngeal swabs collected 2 and 4 dpi 
from vaccinated ferrets of group 2 (101.1 and 100.6 TCID50/ml) (Figure 1D). Mean virus titers in the na-
sal swabs of unvaccinated ferrets of group 1 were on 2 dpi 103.4 and on 4 dpi 101.5 TCID50/ml, while 
somewhat lower mean virus titers were detected in nasal swabs collected from vaccinated ferrets 
of group 2 (respectively 102.8  and 100.7 TCID50/ml on 2 and 4 dpi) , although these differences were 
not statistically significant (respectively p=0.32 and p=0.14 on 2 and 4 dpi) (Fig 1C). No virus was 
detected in nasal and pharyngeal swabs collected from H3N2 inoculated ferrets at 7 dpi and in na-
sal and pharyngeal swabs collected from mock-infected ferrets of groups 3 and 4 (data not shown). 
In addition, at 28 dpi no histopathological differences were observed in the brains, nasal and lung 
tissue of ferrets of each group (data not shown).
Figure 1. Antibody responses after vaccina-
tion and outcome of infection with influenza 
A/H3N2 virus. Mean virus-specific antibody 
responses ± S.D. as measured with the hem-
agglutination inhibition assay 28 days after 
the first and 28 days after the second vac-
cination for unvaccinated animals (shaded 
bars) and vaccinated animals (open bars) (A). 
Mean weight loss of vaccinated (open circles) 
and unvaccinated animals (shaded circles) 
after inoculation with influenza A/H3N2 virus 
(B). Virus titers of nasal (C) and pharyngeal 
swabs (D) collected 2 and 4 dpi with influenza 
A/H3N2 virus. Shaded bars represent mean 
results ± S.D. for unvaccinated animals and 
open bars represent mean results ± S.D. for 
vaccinated animals. **, P<0.01 compared with 
unvaccinated animals. The grey area indicates 
the detection limit of the assay.
72
Chapter 5 -  Vaccination and heterosubtypic immunity in ferrets
5
Virus-specific T cell responses after inoculation with influenza A/H3N2 virus
T cell responses against both influenza A/Brisbane/010/07 (H3N2) and A/Indonesia/5/05 (H5N1) 
antigens were assessed using PBMC collected from ferrets of all groups 28 days after inoculation 
with influenza A/H3N2 virus or PBS. Influenza A/H3N2 antigen-specific proliferation of CD3+CD8- 
cells was observed in only 1 out of 10 mock-vaccinated and mock-infected ferrets of group 4, while 
influenza A/H3N2 antigen-specific proliferation was observed in all ferrets of groups 1 and 3 and 
in 9 out of 10 ferrets of group 2 (although only low numbers of CFSElow cells were observed in 4 
ferrets of group 3). In Figure 2A, the number of proliferating cells of each individual ferrets and the 
mean number of proliferating cells of each group are indicated. Differences in influenza A/H3N2 
antigen-specific proliferation of CD3+CD8- cells were statistically significant between ferrets of 
groups 1 and 2 compared to ferrets of group 4 (p-values of respectively 0.01 and 0.02), while dif-
ferences between groups 3 and 4 approached statistical significance (p=0.05). No significant differ-
ences were observed between other groups. Furthermore, similar antigen-specific proliferation of 
CD3+CD8- cells was observed at 28 days and 56 days after the second vaccination for mock-infect-
ed, vaccinated ferrets of group 3 (data not shown). In addition, influenza A/H5N1 antigen-specific 
proliferation of CD3+CD8- cells was observed in 9 out of 10 ferrets of groups 1 and 2, while H5N1 
antigen-specific proliferation was virtually absent in ferrets of group 3 and group 4.  The number 
of proliferating cells of each individual ferrets and the mean number of proliferating cells of each 
group are indicated in Figure 2B. However, only differences between groups 2 and 4 were statisti-
cally significant (p=0.02). 
Only very small numbers of viral antigen-specific proliferation of CD3+CD8+ cells was observed 
in ferrets of all groups, and no significant differences were observed between groups (data not 
shown).
 
Figure 2. T cell immune responses 28 days after infection with influenza A/H3N2 virus. Proliferation of CD3+CD8- 
cells upon stimulation with whole inactivated influenza A/Brisbane/010/07 (H3N2) antigen (A) and upon stimula-
tion with whole inactivated influenza A/Indonesia/5/2005 (H5N1) antigen (B). *, P<0.05 compared with unvaccinated 
mock-infected animals.
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Outcome of inoculation with H5N1 virus
Twenty-eight days after inoculation with the 
A/H3N2 virus, ferrets were inoculated with 
influenza virus A/Ind/5/05 (H5N1). Clinical 
signs were observed in ferrets from day 1 after 
inoculation onwards and included anorexia, 
weight loss, labored breathing, neurological 
disorders and diarrhea. In figure 3, observed 
clinical signs are listed per group. Severe clini-
cal signs including weight loss were observed 
in all mock-vaccinated and mock-infected fer-
rets of group 4 and the H3N2-vaccinated and 
mock-infected ferrets of group 3. In contrast, 
only mild to moderate clinical signs were ob-
served in the ferrets of group 1, that had ex-
perienced an H3N2 infection. These animals 
hardly lost body weight upon infection with 
influenza virus A/Ind/5/05 and developed less 
severe clinical signs. Prior vaccination against 
H3N2 infection partially prevented the protec-
tive effect of H3N2 infection and three out of 
eight animals of group 2 developed severe 
clinical signs and displayed >15% loss of body 
weight. In total 6 ferrets of groups 2, 3 and 4 
died or had to be euthanized according to ani-
mal welfare regulations before all ferrets were 
euthanized at 7 dpi. No significant differences 
in weight loss were observed at 2 dpi between 
groups, while at 4 dpi significant more weight 
loss was observed in ferrets of group 4 com-
pared to groups 1 and 2 (p-values of respec-
Figure 3. Weight loss after inoculation with influenza 
A/Indonesia/5/05 virus. After inoculation with influ-
enza A/H5N1, ferrets were weighed and the relative 
weight loss compared to the body weight at the day 
of inoculation was calculated. Indicated is the relative 
weight loss of all individual ferrets for unvaccinated, 
H3N2-primed animals of group 1 (A), vaccinated, 
H3N2-primed animals of group 2 (B), vaccinated, 
unprimed animals of group 3 (C), and unvaccinated 
and unprimed animals of group 4 (D). +: indicates fer-
rets that died or had to be euthanized due to the pres-
ence of severe clinical symptoms.
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tively p=0.001 and p=0.01). In addition, at days 6 and 7, significantly more weight loss was observed 
in ferrets of group 4 compared to group 1 (p-values of respectively 0.009 and 0.006). Differences in 
body weight loss on these days p.i. between groups 2 and 4 were not statistically significant (p-
values of respectively 0.07 and 0.08). The weight loss of all ferrets.
Virus replication in the upper respiratory tract after inoculation with influenza A/H5N1 virus
Nasal and pharyngeal swabs collected at 2, 4, 6 and 7 dpi with influenza virus A/Ind/5/05 were test-
ed for the presence of infectious virus. Except for two ferrets of group 1, virus was detected in all 
nasal swabs collected 2 and 4 dpi, with mean virus titers of 102.7,104.3, 105.1, 104.5  TCID50/ml at 2 dpi 
and 101.6,103.6 ,104.3, 104.7  TCID50/ml at 4 dpi for groups 1, 2, 3 and 4 respectively. The average virus 
titers in nasal swabs of mock-vaccinated H3N2-infected ferrets of group 1 were significantly lower 
(p=0.04) than those of mock-infected ferrets of group 4 at 2 dpi. At 4 dpi differences between virus 
titers of group 1 were significantly lower than those of groups 2, 3 and 4 (p-values below 0.01 for 
all comparisons). At 6 dpi, virus was undetectable in nasal swabs collected from ferrets of group 2 
and in 7 out of 8 of group 1. In contrast, virus was detected in all except one of the nasal swabs of 
ferrets of groups 3 and 4, which thus had significantly higher titers than those of groups 1 and 2 
(both p<0.01). No significant differences in virus titers were observed in nasal swabs collected at 
7 dpi. In figure 4A, the mean virus titers in nasal swabs collected from ferrets of each groups are 
indicated. Similar results were obtained for virus titers in the pharyngeal swabs. Virus was detected 
Figure 4. Virus titers in nasal and pharyngeal 
swabs collected after inoculation with influenza 
A/H5N1 virus. Nasal (A) and pharyngeal swabs 
(B) were collected 2, 4, 6 and 7 dpi with influenza 
A/H5N1 virus and virus titers were determined. 
Indicated are mean virus titers ± S.D. for unvac-
cinated, H3N2-infected ferrets of group 1 (white 
bars), vaccinated, H3N2-infected ferrets of group 
2 (dark shaded bars), vaccinated, mock-infected 
ferrets of group 3 (light shaded bars) and unvac-
cinated, mock-infected bars of group 4 (black 
bars). * indicates a difference of P<0.05 between 
groups and ** indicates a difference of P<0.01 
between groups. The grey bar indicates the detec-
tion limit of the assay.
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in all pharyngeal swabs collected from H5N1-infected ferrets, with mean virus titers of 103.8,104.7, 
105.2, 105.1  TCID50/ml at 2 dpi and 10
3.7,104.4 ,104.9, 105.5  TCID50/ml at 4 dpi from ferrets of groups 1, 
2, 3 and 4 respectively. Differences between virus titers in pharyngeal swabs collected at 2 dpi from 
ferrets of group 1 and 4 were statistically significant (p<0.01), while also differences between fer-
rets of groups 1 and 4 (p=0.01) and 2 and 4 (p=0.02) were statistically significant.  At 6 and 7 dpi, no 
virus was detected in ferrets of group 1 and in two respectively one of the ferrets of group 2, while 
virus was detected in all ferrets except one respectively two of groups 3 and 4. Thus, significantly 
lower virus titers were detected in groups 1 (p=0.004) and 2 (p=0.01) compared to group 4, while 
differences between these groups were not significant at 7 dpi.  In Figure 4B, the mean virus titers in 
pharyngeal swabs collected from ferrets of each groups are indicated. 
Table 2. A/Indonesia/5/05 (H5N1) virus detection in tissues by virus isolation and IHC 7 dpi
Group Treatment Brain Lung Duodenum
H3N2 
vaccina-
tion
H3N2 
infec-
tion
Virus 
isolation
IHC Virus 
isolation
IHC Virus 
isolation
IHC
1 - + 0/8* 0/8 0/8 0/8 0/8 0/8
2 + + 0/7 2/7 0/7 1/7 0/7 0/7
3 + - 3/7 7/7 3/7 4/7 2/7 0/7
4 - - 0/6 5/6 1/6 2/6 0/6 0/6
*: numbers of animals tested positive/total number of ferrets tested. The number of tested tissues 
is lower than 8 in some group due to mortality before day 7.
Pathology and immunohistochemistry after A/H5N1 infection
Macroscopically, only focally extensive pulmonary lesions were observed in a number of lungs of 
ferrets of groups 2, 3 and 4 while no lesions were observed in lungs of ferrets of group 1. Brains, 
lungs, spleens, liver and duodenum were tested for the presence of histopathological changes 
caused by infection with influenza A/H5N1 virus A/Ind/5/05. In brains of three out of eight ferrets 
of group 2, and all ferrets of group 3 and 4, moderate to severe lesions were observed in the brain 
(Figure 5A), which co-localized with the abundant expression of influenza virus antigen (Figure 5C). 
In contrast, in the brains of ferrets of group 1 and five ferrets of group 2 no or only a mild lesions 
were observed (Fig 5B) and influenza virus expression was absent or scarce (Figure 5D). In lungs of 
some ferrets of groups 2, 3 and 4, a mild to moderate broncho-interstitial pneumonia was observed 
(Figure 5E), which co-localized with expression of viral antigen (Figure 5G). These lesions were not 
observed in the lungs of ferrets of group 1 (Figure 5F), and no influenza virus antigen expression 
was detected (Figure 5H).
In livers of a number of ferrets of groups 2 and all ferrets of groups 3 and 4, there was a diffuse 
vacuolization of the hepatocellular cytoplasm, consistent with fat, which was not observed in livers 
of ferrets of group 1 and a number of ferrets of group 2 with heterosubtypic immunity against influ-
enza A/H5N1 virus. These changes were considered to be hepatic lipidosis resulting from anorexia. 
No lesions were observed in spleens and duodenums of ferrets of all groups. 
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Presence of virus in tissues 7 days after inoculation
From all ferrets on which necropsy was performed at 7 dpi, olfactory bulbs, brains, lungs, spleens 
and the duodenum were tested for the presence of infectious virus by virus isolation in MDCK cells. 
Virus was undetectable in spleens of all ferrets and in all tissues of ferrets of group 1. For all other 
groups, infectious virus was detected in tissues of one or more ferrets. In general, low virus titers 
were detected. In addition to the virus titrations, the presence of virus-infected cells in organs of 
ferrets collected at 7 dpi was tested by immunohistochemistry. For the lungs, spleens and duo-
denum, the results obtained with immunohistochemistry correlated with virus isolation on MDCK 
cells. However, by immunohistochemistry, virus was detected in brains of almost all ferrets of 
groups 2, 3 and 4, while virus was not detected in brains of animals of group 1 (Table 2).
 
DISCUSSION
In the present study, we have demonstrated that infection with a seasonal influenza A/H3N2 vi-
rus induced robust heterosubtypic immunity against influenza A/H5N1 virus infection in ferrets. 
Prior infection with influenza A/Brisbane/010/07 (H3N2) reduced replication of influenza virus A/
Ind/5/05 (H5N1) in the upper respiratory tract and the brains and prevented clinical signs and his-
Figure 5. Histopathological analysis of 
tissues of ferrets inoculated with influenza 
A/H5N1. Seven days after inoculation, 
histopathologic changes associated with 
the expression of influenza virus antigen 
are observed in brains and lungs of ferrets 
without heterosubtypic immunity in three 
ferrets of group 2, and in all ferrets of group 
3 and 4 (A, C, E, G). In the cerebrum, there 
is necrosis of neurons and infiltration with 
inflammatory cells (A) associated with 
expression of influenza virus antigen in 
neurons (C). In the lungs, cell debris and 
erythrocytes are present in the alveolar 
lumina and neutrophils present in the al-
veolar walls (E). This is associated with the 
expression of influenza virus antigen in 
type II pneumocytes (G). Neither histopath-
ological changes (B and F) nor influenza 
virus expression (D and H) were present in 
lungs and brains respectively of five ferrets 
of group 2 and all ferrets of group 1.
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topathological changes associated with their infection. The induction of heterosubtypic immunity 
by infection with influenza A viruses has been demonstrated already more than 40 years ago in 
animal models and there is evidence for the presence of heterosubtypic immunity in humans (40, 
54). In addition, it has been demonstrated recently that infection with a seasonal influenza virus 
afforded protection against the pandemic influenza A/H1N1(2009) virus in the ferret model (155, 
161). However, the immunological basis of heterosubtypic immunity has not been completely elu-
cidated yet, and mucosal immunity, B cells and both CD4+ and CD8+ T cells may contribute to this 
type of immunity (40). In concordance with our previous findings in the mouse model, we were un-
able to detect antibodies cross-reactive with the H5N1 strain after infection with influenza A/H3N2 
virus by HI and virus neutralization assay, indicating that serum antibodies did not play a major role 
in the protection against influenza A/H5N1 virus. In contrast, infection with an influenza A/H3N2 
virus induced strong T cell responses that cross-reacted with influenza A/H5N1 viral antigen. To our 
knowledge, this is the first time that the presence of cross-reactive T cell responses is demonstrat-
ed in the ferret model. The cross-reactive in vitro proliferative response of CD3+CD8- cells, most 
likely CD4+ T helper cells, obtained from A/H3N2 virus infected ferrets correlated to some extent 
with the presence of heterosubtypic immunity. However, the three ferrets that displayed weight 
loss after infection with influenza A/H5N1 also had T cell responses against the H5N1 viral antigen 
indicating that other arms of the immune system also contribute to the development of heterosub-
typic immunity. In addition, we were unable to assess CD8+ T cell responses because probably the 
use of inactivated viral antigens precluded proper antigen processing and presentation to CD8+ 
T cells. Thus, we cannot exclude or confirm that virus-specific CD8+ T lymphocytes contributed to 
the heterosubtypic immunity observed after infection with the A/H3N2 influenza virus.  Further-
more, the trace amounts of nucleoprotein and matrix protein present in the subunit vaccine of this 
study could have induced immunodominant CD8+ T cell responses that skewed subsequent CD8+ 
T cell responses after infection with the influenza A/H3N2 virus, as was observed previously in the 
mouse model using a whole inactivated influenza A/H3N2 vaccine (157). In contrast to our findings 
in the mouse model (135), none of the ferrets euthanized 28 dpi after influenza A/H3N2 inocula-
tion developed inducible bronchus associated lymphoid tissue (iBALT) or other histopathological 
changes. Probably, the infection of ferrets with influenza A/H3N2 virus was restricted to the upper 
respiratory tract, while infection of mice also involves the lower respiratory tract. In the present 
study, we also demonstrated that effective vaccination against infection with the seasonal influ-
enza virus A/Brisbane/010/07 (H3N2) hampered the induction of heterosubtypic immunity. The 
vaccinated ferrets suffered more from the subsequent infection with the highly pathogenic H5N1 
influenza virus A/Ind/5/05 than their unvaccinated counterparts. These findings in the ferret model 
are in concordance with those we have obtained in the mouse model recently (135, 145, 157). Since 
subunit preparations are poorly immunogenic in mice (135) and ferrets (161), we used an adjuvant 
(Titermax) to increase the immunogenicity of the A/H3N2 subunit vaccine. Although the use of ad-
juvanted subunit preparations induced potent antibody responses to the influenza A/H3N2 virus, it 
failed to induce heterosubtypic immunity and did not afford any protection against infection with 
the influenza A virus A/Ind/5/05 (H5N1) as expected. Thus, the use of a potent adjuvant did not 
induce T cell responses against the trace amounts of NP and M1 present in the subunit H3N2 prepa-
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ration, strong enough to protect against the influenza A/H5N1 protection. Likewise, adjuvants have 
been used to increase the immunogenicity of seasonal and pandemic influenza A/H1N1(2009) vac-
cines (162, 163). Furthermore, the vaccine used in this study contained only influenza A/H3N2 virus 
antigen, while the currently used seasonal vaccine also contains influenza A/H1N1 and influenza B 
virus antigen. Especially the addition of the influenza A/H1N1 virus antigen might have changed 
the results as it has been described in mice that immunization with a seasonal influenza A/H1N1 
vaccine induce cross-reactive antibodies against the neuraminidase of the influenza A/H5N1 virus 
(164). In the present study, the ferrets were inoculated with influenza virus A/Ind/5/05 (H5N1) by 
the intranasal route. Although unprotected ferrets animals developed severe clinical signs, most 
of them did not develop severe pneumonia, typically seen after intratracheal inoculation (165) 
that could account for the loss of body weight. In contrast, these animals developed a moderate 
to severe meningo-encephalitis sometimes with a fatal outcome before the end of the experiment 
on day seven post inoculation, which was chosen for ethical reasons and to allow a meaningful 
comparison of the experimental groups on the same timepoint p.i.. The occurrence of meningo-en-
cephalitis also explains the neurological signs that we and others have observed after intranasal in-
oculation of ferrets with highly pathogenic avian influenza viruses of the H5N1 subtype (166, 167). 
The occurrence of severe encephalitis in absence of severe pneumonia suggests that the brains of 
these ferrets were infected directly from the nasal cavity, as has been shown in influenza A/H5N1 
infection in mice (168) . The possible occurrence of this phenomenon will be explored further. Prior 
infection with a seasonal influenza virus of the H3N2 subtype prevented dissemination of the H5N1 
virus and the clinical signs associated with virus replication in the brain, severe weight loss and the 
development of moderate to severe meningo-encephalitis. This protective effect correlated with 
a reduction of H5N1 virus replication in the upper respiratory tract and was prevented by vaccina-
tion against the H3N2 virus infection in three out of eight ferrets (38%). This scenario resembles the 
observation in Canada, where subjects vaccinated against seasonal influenza in previous seasons 
more likely developed severe disease caused by infection with pandemic influenza A/H1N1(2009) 
influenza viruses (169, 170). However, the lack of heterosubtypic immunity in these patients was 
not confirmed. Annual vaccination against influenza is beneficial, especially for patients with un-
derlying disease and the elderly, which are at high-risk for developing complications caused by in-
fluenza virus infection. In some countries, annual vaccination is also recommended for all healthy 
children >6 months of age. Although annual vaccination can reduce the burden of disease caused 
by seasonal influenza, on the long term it may affect the development of heterosubtypic immunity 
in this age group. Our findings emphasize the need for vaccines that can induce more broadly pro-
tective immune responses. In this respect the induction of cross-reactive virus-specific CD8+ T cells 
to conserved viral proteins like the NP and M1 protein holds promise (83, 171). Also the induction 
of antibody responses to the M2 protein and the conserved stalk region of the HA molecule may be 
interesting avenues for the development of more universal vaccines (172, 173).
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ABSTRACT
To gain insight in the age at which children become infected with influenza viruses for the first time, 
we analyzed the seroprevalence of antibodies against influenza viruses in children 0-7 years of age 
in The Netherlands. Serum samples were collected during a cross-sectional population-based study 
in 2006 and 2007 and were tested for the presence of antibodies against influenza A/H1N1, A/H3N2 
and B viruses representative for previous influenza seasons using the hemagglutination inhibition 
assay. The seroprevalence of antibodies to influenza was higher in children 1-6 months of age than 
that of children 7-12 months of age, which likely reflects the presence of maternally derived anti-
bodies.
The proportion of study subjects >1 year of age with detectable antibodies against influenza vi-
ruses gradually increased with age until they reached the age of six when they all had antibodies 
to at least one influenza A virus. These findings may have implications for the development of vac-
cination strategies aiming at the protection of young children against seasonal and/or pandemic 
influenza virus infection.
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INTRODUCTION
Infection with influenza viruses is an important cause of illness in children with estimated annual 
attack rates in this age group ranging between 20 and 30% during epidemics (174, 175). Especially 
young children with underlying disease are at risk for severe disease after infection with an influ-
enza virus, but it has been demonstrated that also the hospitalization rates attributable to influenza 
virus infection of young children without underlying disease are similar to those observed among 
older adults (59, 176). Furthermore, the importance of influenza as a cause of severe disease was 
demonstrated during the 2003-2004 influenza season when a newly emerged drift variant caused 
an unusual high number of severe fatal cases of influenza amongst children (177). In addition, the 
pandemic caused by the influenza A/H1N1(2009) virus has highlighted the importance of influenza 
viruses as a cause of morbidity and mortality in infants (178, 179). 
Furthermore, since children have a high number of contacts relative to other age groups, and have 
a tendency to make contacts within their own age group, they may have the highest incidence of 
infection after the introduction of a newly emerging virus (180). In addition, they also may shed vi-
rus for a prolonged period of time and have higher virus loads in the nasopharynx (181, 182). There-
fore, children most probably play an important role in the transmission of virus and are considered 
efficient vectors for spreading the disease.
To prevent morbidity and mortality of children due to infection with influenza viruses, a number of 
countries, including the USA, have recommended vaccinating all healthy children 6-59 months of 
age against influenza (60, 61). In various studies, it has been demonstrated that annual vaccination 
against seasonal influenza is beneficial for children and reduces the transmission of virus (62-66, 
183).  However, the impact of vaccination will be influenced by the immune status of the vacci-
nated individuals. Since they will be more at risk to become infected and develop disease, naïve 
subjects most likely will benefit from vaccination more than children that already have experienced 
an infection with one or more influenza viruses. In addition, it can be anticipated that with increas-
ing age the chance of having experienced an influenza virus infection also increases. However, at 
present it is not fully clear at which age children become infected for the first time and develop 
influenza virus specific immunity and detailed sero-epidemiological studies of this age group are 
largely lacking (184, 185). Here we report the seroprevalence of antibodies against influenza A/
H1N1, A/H3N2 and B viruses in children from one month to seven years of age in The Netherlands. 
To this end, serum samples were used that were collected during a cross-sectional population-
based study designed to represent the population of the Netherlands (186). These serum samples 
were tested for the presence of antibodies against representative influenza A/H1N1, A/H3N2 and B 
viruses from multiple influenza seasons using the hemagglutination inhibition (HI) assay, which is 
the gold standard for the demonstration of antibodies against influenza viruses (187). In addition, 
we were able to discriminate between antibodies against various antigenically distinct influenza A/
H1N1 and influenza A/H3N2 viruses and antibodies to influenza B viruses from B/Victoria/2/87 and 
B/Yamagata/16/88 lineages. In children >1 year of age, there was a gradual, age-related increase in 
the seroprevalence of antibodies against all influenza viruses until in all children >6 years of age an-
tibodies against at least one influenza virus were detected. Results obtained in this study give more 
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insight in the rate of infection of children with influenza viruses during non-pandemic seasons and 
may aid policy making regarding the implementation of vaccination strategies in this vulnerable 
age group. 
MATERIALS AND METHODS
Collection of serum samples
Serum samples were collected during a nationwide cross-sectional population-based study which 
was performed in the Netherlands from February 2006 to June 2007 (PIENTER 2 Study) to evaluate 
the Dutch national immunization program (186). For this purpose, serum samples were collected 
from in total 6386 individuals (aged 0-79 years, men and women). For our study, 720 serum samples 
obtained from children 0-7 years of age were used. Fifty-six samples were obtained from children 
1-6 months of age and 98 serum samples were obtained from children 7-12 months of age. The 
number of samples obtained from children that were one, two, three, four, five, six and seven years 
of age was 57, 80, 93, 91, 72, 75 and 97, respectively.
Selection of representative influenza viruses
Representative influenza A/H3, A/H1 and B viruses were selected that circulated in The Netherlands 
in seasons 1999/2000 to 2006/2007 based on data collected by the National Influenza Center for 
the World Health Organization (WHO) in the Netherlands (188-195). For most seasons, vaccine 
strains were used, but when epidemiological strains could be identified that gave higher antibody 
titers with reference ferret serum these were included as well (Table 1). Furthermore, influenza B 
viruses of both B/Victoria/2/87-like and B/Yamagata/16/88-like lineages (Victoria- and Yamagata-
lineages) were used for each year, although in some seasons only influenza B viruses belonging to 
one lineage were detected in clinical specimens in the Netherlands. In addition, data collected by 
the Dutch National surveillance program was used to assess the severity of the influenza seasons 
and to evaluate relative dominance of each of the influenza virus types and subtypes.
Before use in the HI assay, vaccine strains were inoculated in the allantoic cavity of 11-days old em-
bryonated chicken eggs while epidemiological strains were propagated in confluent Madin-Darby 
Canine Kidney (MDCK) cells. Allantoic fluid was harvested after two days and culture supernatant 
was harvested after cytopathologic changes were complete and both were cleared by low speed 
centrifugation. Sera of children between one month and 12 months of age were tested for the pres-
ence of antibodies against all influenza viruses representative for the six preceding influenza sea-
sons to analyze the presence of maternal antibodies, while serum samples collected from children 
older than one year were tested for the presence of antibodies against all influenza viruses of sea-
sons that they might have been exposed to according to their age (Table 1). 
Serological testing
Serum samples were tested for the presence of antibodies against the hemagglutinin of the respec-
tive  influenza viruses by HI assay as described previously (107). In brief, serum samples were treat-
ed with cholera filtrate and heat inactivated at 56°C for one hour. Duplicate two-fold serial dilutions 
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of pre-treated serum samples were subsequently incubated with 4 HA units of an influenza virus or 
phosphate buffered saline (PBS) for 30 minutes at 37°C and subsequently 1% turkey erythrocytes 
was added. Hemagglutination patterns were read after incubation for one hour at 4°C. The highest 
dilution of serum that still gave complete inhibition of the hemagglutination was recorded as titer 
and when duplo results were different, geometric mean titers were calculated. 
Serum samples were considered negative when they failed completely to inhibit agglutination of 
erythrocytes (antibody titer < 10) by any of the selected viruses. Serum samples of ferrets collected 
before and after infection with each of the respective influenza viruses were used as negative and 
positive control in the HI assay. 
Statistical analysis
Pearson’s correlation coefficient was used to calculate correlations between antibody titers detect-
ed against multiple variants of influenza A/H3N2, A/H1N1 and B viruses. Furthermore, assuming 
binominal distribution, the two-sided exact 95% confidence interval (CI) was calculated for serop-
revalences of antibodies against influenza A/H3N2, A/H1N1 and B viruses using Stata/SE software 
version 11.0. Statistical analysis of differences between children one to six months of age and six to 
12 months was performed using the chi-square test. The Cochrane-Armitage Trend test was per-
formed to evaluate the presence of a age-related trend in the presence of antibodies against influ-
enza viruses using SAS software version 9.2. 
RESULTS
Influenza epidemics from 1999 to 2007 in the Netherlands
Using epidemiological and virological data, we were able to assess the relative severity of the in-
fluenza epidemics in the Netherlands from 1999 to 2007 and the causative viruses. During most 
seasons, influenza viruses caused moderate epidemics, except for the 2004/2005 season that was 
relatively severe and caused by influenza A/H3N2 viruses predominantly and the 2000/2001 season 
that was relatively mild and caused by influenza A/H1N1 viruses. Furthermore, most seasons were 
dominated by influenza A/H3N2 viruses, while during the 2002/2003 and 2005/2006 influenza sea-
sons, both influenza A/H3N2 and B viruses were co-dominant. During most seasons, the majority 
of isolated influenza B viruses belonged to the Yamagata-lineage. However, during the 2002/2003 
influenza seasons, in which influenza B viruses were co-dominant, only viruses from the Victoria-
lineage were isolated in The Netherlands. During most epidemics from 1999 to 2007, influenza A/
H1N1 viruses caused only low influenza activity, except during the 2000/2001 season (Table 1).
Age-dependent seroprevalence of antibodies against individual influenza virus strains
First, the prevalence of antibodies directed against individual influenza virus strains was assessed 
using serum samples of children one to seven years of age. Strains were used against which based 
on their age at the time point of sampling, the study subjects potentially could have developed an 
antibody response.  As shown in figure 1A, an age-dependent increase in the proportion of subjects 
with antibodies to selected A/H3N2 strains was observed. The highest prevalence of antibodies to 
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a single strain was observed against influenza viruses A/NL/118/01 and A/Wyoming/3/03 (100%) in 
subjects of seven years old. 
A similar pattern was observed for the prevalence of antibodies to individual influenza A viruses 
of the H1N1 subtype, although the overall seroprevalence was lower (Figure 1B). The highest sero-
prevalence to individual strains was observed to influenza viruses A/NL/128/04 (77%) in subjects 
seven years of age, which was similar to that against most other H1N1 strains.
The seroprevalence of antibodies to individual influenza B virus strains displayed a different pattern 
and was largely depending on the lineage of the influenza B virus that was used. In general, higher 
Figure 1. Seroprevalence of antibodies against individual 
influenza viruses. Serum samples of children 0-7 years of 
age were tested for the presence of antibodies against rep-
resentative influenza A/H3N2 (A), A/H1N1 (B) and B (C) virus 
strains. For each age group, representative influenza viruses 
were selected to which they may have been exposed accord-
ing to their age. Indicated are the strains that have been 
used to evaluate the presence of antibodies in the serum 
samples and the percentage of serum samples in which an-
tibodies were detected against each influenza virus antigen. 
Shaded area: not tested.
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seroprevalences of antibodies against influenza B viruses of the Yamagata-lineage were detected 
than those to viruses of the B/Victoria lineage (B/Malaysia/2506/04 and B/Shangdon/7/97) (Figure 
1C). 
     
Seroprevalence during first year of life
Serum samples of children one to twelve months of age were not only tested for the presence of 
antibodies to influenza viruses from the 2006/07 season, but also for those specific for older strains 
since it was anticipated that these sera also might contain maternally derived antibodies.
In 15% (CI 6-27%) of the children between one and six months of age, antibodies were detected 
against at least one of the influenza A/H1N1 viruses tested, while only 4% (CI 1-10%) of children 
between 7 and 12 months of age had antibodies against A/H1N1 viruses (Figure 2A and 2C). In 43% 
(CI 30-57%) and 36% (CI 23-50%) of the children one to six months of age, antibodies were detected 
against a least one influenza A/H3N2 or B virus respectively. In the serum samples obtained from 
children 7-12 months of age the proportion of subjects with antibodies to these viruses was 19% 
(CI 12-28%) and 5% (CI  2-12%), respectively (Figure 2A).  The significant differences in the preva-
lence of antibodies to A/H3N2 and B viruses between the two age groups could be largely attrib-
uted to a difference in the proportion of serum samples containing antibodies to strains from previ-
ous influenza seasons like A/Wyoming/3/03, A/Panama/07/99, A/Sydney/5/97 (all A/H3N2) and B/
Yamanashi/429/99 (Figures 2B and 2D). This indicates that the relatively high seroprevalence of an-
tibodies in children 1-6 months of age indeed can be attributed to maternally derived antibodies.  
Figure 2. Seroprevalence of antibod-
ies against influenza viruses in chil-
dren 1-12 months of age. Seropreva-
lences of antibodies against influenza 
A/H3N2, A/H1N1 and B viruses of the 
2000-2007 influenza season in chil-
dren one to six months of age (grey 
bars) and seven to 12 months of age 
(white bars) (A). Serum samples were 
tested for the presence of antibodies 
against multiple antigens as is indi-
cated for influenza A/H3N2 (B), influ-
enza A/H1N1 (C) and B (D) viruses. 
Bars indicate the percentage of the 
serum samples in which antibodies 
were detected and error bars indicate 
the 95% confidence intervals.
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Age-dependent seroprevalence of antibodies to any influenza A or B virus
The seroprevalence to individual influenza virus strains was used to calculate the proportion of sub-
jects with antibodies to at least one influenza A or B virus. Within the influenza A viruses the relative 
contribution of antibodies to influenza A/H3N2 and A/H1N1 viruses was discriminated and within 
the influenza B viruses, those to the Yamagata and Victoria-lineage. 
As shown in Figure 3, the seroprevalence of antibodies to influenza A viruses declined after 6 
months of age. Thereafter, with increasing age the proportion of subjects with antibodies to influ-
enza A viruses increased steadily. At the age of six virtually all subjects (99%; CI 93-100) had devel-
oped antibodies to an influenza A virus. For subjects >2 years of age, the proportion with antibodies 
to influenza A/H3N2 viruses was significantly higher than those with antibodies to A/H1N1 viruses. 
A similar pattern was observed for the development of antibodies to influenza B viruses. After 
six months the proportion of subjects with antibodies to an influenza B virus dropped to 5% (CI 
2-12%). With increasing age a gradual incline was observed of the proportion of children with anti-
bodies to influenza B virus. At age seven, 72% (CI 61-80%) of the subjects had developed antibod-
ies to at least one influenza B virus. The seroprevalence of antibodies to influenza B viruses of the 
Yamagata lineage was higher that that of the Victoria lineage. Using the Cochrane-Armitage trend 
test, the presence of a significant age-related trend in the increase of seroprevalence of antibodies 
to influenza A/H1N1, A/H3N2 and B viruses was demonstrated (p<0.01).
 
Figure 3. Seroprevalence of antibodies against 
influenza A and B viruses depends on age. Percent-
ages of serum samples of children in which anti-
bodies were detected against at least one of the 
representative influenza viruses were calculated 
for influenza A/H1N1 (light grey bars), influenza A/
H3N2 (white bars) and all influenza A viruses (dark 
grey bars) (A). The same procedures was used to 
calculate the seroprevalence of antibodies against 
at least one of the influenza B viruses from the 
Victoria-lineage (light grey bars), the Yamagata-
lineage (white bars) and all influenza B viruses 
(dark grey bars (B). Bars indicate the percentage 
of the serum samples in which antibodies were de-
tected and error bars indicate the 95% confidence 
intervals.
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Estimated attack rates
The differences in seroprevalence of antibodies to the respective influenza viruses at various ages 
were used to estimate attack rates. The proportion of children with antibodies to influenza A/H3N2 
viruses, only increased 1.5% between children 7-12 months of age and one year of age. The high-
est increase in the seroprevalence of antibodies against influenza A/H3N2 viruses was observed at 
age two and three. At these ages, the proportion of subjects with antibodies increased with 25% 
each year. The highest increase in seroprevalence of antibodies to influenza A/H1N1 viruses were 
observed at age three (18%) and at age six (26%).  During the first year of life, only a minority of the 
subjects acquired antibodies to influenza B viruses (5%). The highest increase in the seroprevalence 
in antibodies against influenza B viruses was observed at age three (20%) and five (19%). These in-
creases could be attributed largely to the development of antibodies directed to influenza B viruses 
of the Yamagata lineage. In general, the increase in the seroprevalence of antibodies against viruses 
from the Victoria-lineage was modest, with the exception of a 14% increase observed in subjects 
five years of age.
Correlation between antibody titers against multiple influenza virus strains
As serum samples were tested for antibodies against various influenza viruses, we determined 
the correlation between antibody titers against different strains within a (sub)type (Figure 4). In 
Figure 4.  Correlation of antibody titers against individual influenza A virus strains in four year old children. Correla-
tion between the antibody titers against multiple representative influenza A/H3N2 viruses, influenza A/H1N1 viruses 
and influenza B viruses. Dots indicate individual serum samples and Pearson correlation coefficient was calculated for 
all datapoints for which antibodies against at least one influenza virus was detected. For influenza B viruses, the letter 
behind the name of each strain indicates the lineage to which the virus belongs (V= Victoria-lineage, Y= Yamagata-
lineage).
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general, antibody titers to various influenza A/H1N1 viruses correlated well (R>0.8), and also those 
against strains of each of the lineages of influenza B viruses (R>0.8). In contrast, antibody titers 
against viruses from the two different influenza B lineages correlated poorly (R<0.1), although in 
some samples antibodies against viruses from both lineages were detected. The correlation of 
antibody titers against different influenza A/H3N2 viruses was dependent on the year of isolation 
and most likely on the antigenic match between the two strains that were studied. For example a 
good correlation was observed between titers against A/New York/55/04 and A/Hiroshima/52/05 
and between A/Panama/2007/99 and A/Wyoming/3/03, whereas titers between A/Wyoming/3/03 
or A/Panama/2007/99 and A/Hiroshima/52/05 correlated poorly. Figure 4 shows an example of the 
correlations between antibody titers that were observed with the serum samples obtained from 
children four years of age. 
DISCUSSION
In the present study, the seroprevalence of antibodies against influenza viruses in The Netherlands 
was investigated in children. Sera were collected from February 2006 to June 2007 in a cross-sec-
tional population-based study and were tested for the presence of antibodies against influenza 
virus strains representative for viruses that circulated during the life span of the children tested. 
Since the persistence of maternally derived antibodies is short-lived and probably less than six 
months (196), sera of children <12 months of age were also tested for antibodies against older in-
fluenza viruses that may have infected their mothers. Indeed the seroprevalence of antibodies to 
influenza viruses was relatively high in children between one and six months of age which could 
be attributed to the presence of maternally derived antibodies to older influenza virus strains. The 
seroprevalence was lower in children between six months and one year of age, but showed an age-
dependent increase until the age of seven, when all of the children had developed antibodies to 
at least one influenza A virus and 72% antibodies to at least one influenza B virus. The increase 
in the seroprevalence was not caused by differences in the geometric mean titer (GMT) against 
influenza viruses, since GMTs against the respective strains were independent of age. Also high an-
tibody titers were observed in serum samples collected from some children 7-12 months of age, 
reflecting recent infections with the corresponding viruses.  In children of all ages, the seropreva-
lence of antibodies to influenza A/H3N2 viruses was higher than the seroprevalence of antibodies 
against influenza A/H1N1 or B viruses. This is in accordance with epidemiological data from the 
Netherlands collected between 1999 and 2007. During influenza seasons in this period, influenza 
A/H3N2 viruses were detected predominantly in clinical specimens compared to influenza A/H1N1 
and influenza B viruses. In addition, we observed a relative strong increase in the seroprevalence 
of antibodies against influenza A/H1N1 viruses in children six years of age compared to children of 
other ages, which could be attributed to the dominant circulation of influenza A viruses of this sub-
type during the 2000/2001 influenza season. Furthermore, the presence of antibodies to influenza 
B viruses of the B/Yamagata lineage and the B/Victoria lineage could be discriminated. These two 
lineages are antigenically distinct and cross-react poorly (197, 198). In addition in young children 
that most likely had been infected with only one influenza B virus only antibodies were detected 
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against influenza B viruses of a single lineage. In older children antibodies were detected against 
influenza B viruses of both lineages, with is in accordance with the possibility that these children 
have been infected subsequently with both viruses during their life.  Overall, the sero-prevalence of 
antibodies to influenza B viruses of the B/Yamagata-lineage is higher than those specific for viruses 
of B/Victoria-lineage. This correlates with epidemiological data which indicate that in five out of 
eight seasons under investigation only viruses from the B/Yamagata-lineage were isolated and in 
two other seasons viruses of both lineages were co-dominant. Assuming that children that were 
infected with influenza viruses also developed antibodies against the corresponding virus, we cal-
culated the estimated attack rates based on the sero-conversion rates at the respective ages. Influ-
enza A/H3N2 viruses had the highest attack rates in children that were between two and four years 
old. However, it can not be excluded that the attack rate of older children was underestimated, 
since subsequent infection with viruses of the same subtype may have remained undetected due 
to the presence of antibodies induced by previous infections. The estimated attack rates based on 
the sero-conversion rates are comparable with the attack rates during inter-pandemic influenza 
seasons reported by others (174, 175). 
Strikingly, in children <2 years of age, the attack rates were relatively low compared to older chil-
dren. Since the length and severity of the influenza seasons between 2004 and 2006 was not differ-
ent from most other seasons and antibody titers in seropositive subjects was not age dependent, 
differences in exposure to influenza viruses may explain the observed differences in attack rates. To 
account for potential confounding differences in the length and severity of flu seasons experienced 
between each age group, birth and sample collection dates were used to calculate the duration of 
flu season time each subject would have experienced. Further, these values were weighted using 
influenza-like illness data (199) as a measure of epidemic severity during each weekly period. When 
these values were used to control for differences in circulating flu conditions throughout the lives 
of the subjects forming each year group, a similar pattern of increases in seroprevalence was still 
encountered (Figure 5). 
In addition, vaccination against seasonal influenza is currently only recommended in The Nether-
lands for children that are at high risk for developing complications after infection with influenza 
due to underlying disease, and therefore is considered a minor confounding factor in the present 
study. Our results regarding the relatively high seroprevalence in infants <7 months of age coincide 
with those reported for newborns (200, 201) and it is likely that transplacentally acquired mater-
nal antibodies can protect young infants to a certain extent (202, 203). The high seroprevalence in 
children <7 months of age is explained by the presence of antibodies to older influenza viruses to 
which their mothers may have been exposed. In addition, since vaccination against influenza is not 
recommended for (pregnant) mothers in The Netherlands, the proportion of vaccinated mothers is 
most likely very low. Indeed the titers to these older strains decline rapidly and are not detectable 
in children 7-12 months of age. The presence and duration of maternal antibodies against influenza 
has been demonstrated previously (201, 204, 205). It is unlikely that the children <7 months of age 
had experienced an infection with influenza viruses since the day of birth and day sample collec-
tion were in between two influenza seasons for 20 of these children, including 14 with antibodies 
to various older influenza virus strains. In addition, two children >7 months were sero-negative and 
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may not have been exposed to influenza viruses for the same reason. The presence of maternal 
antibodies against various influenza A and B viruses in infants <7 months of age seems in paradox 
with the high hospitalization rate in this age group (176). However, in a substantial proportion of 
these infants (30%) antibodies against any influenza virus were not detectable which may consti-
tute the subjects highly susceptible to infection with influenza virus.
As expected, the antibody titers against antigenically related influenza A and B viruses correlated 
well. In contrast, antibodies to influenza B viruses of the B/Yamagata and B/Victoria lineages did not 
cross-react. Furthermore, a poor correlation was observed when antibody titers against antigeni-
cally distinct A/H3N2 viruses were compared. Apparently, there is heterogeneity in the antibody 
repertoire of various subjects, which dictates the level of cross reactivity with different influenza 
viruses. Collectively, in this study we determined the seroprevalence of antibodies against various 
influenza viruses in children from 0-7 years of age during non-pandemic influenza seasons. We 
demonstrated that at seven years of age, all children developed antibodies against at least one of 
the influenza viruses tested. Furthermore, the highest attack rates calculated based on the serop-
revalence of antibodies to influenza A viruses was observed in children two and three years of age. 
These data provide information on the age at which children experience their first infections with 
influenza viruses and develop immunity to these viruses.  This type of information may aid decision 
making for the implementation of vaccination strategies that aim at achieving optimal protective 
immunity against seasonal and pandemic influenza. Ideally, in infants vaccines are used that not 
only induce antibodies to seasonal influenza viruses but also immunity to influenza A viruses of 
other subtypes (145, 146). 
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Figure 5. The difference in proportion of sero-
positive individuals for each age group com-
pared to the previous age group. Unadjusted 
(light grey) and adjusted (dark grey) propor-
tions controlled for estimated differences in the 
severity of flu incidence throughout the life of 
individuals in each group. For the adjustment, 
firstly the mean total weighted season time ex-
perienced by the individuals of each age group 
was calculated using information about date 
of birth, date of sample collection and relevant 
influenza-like illness data.  Next, the differences 
in this mean for each age group compared to 
the previous age group were calculated, along-
side an overall mean difference between age groups.  Finally, the adjustments were made by scaling the value for each 
age group by the factor by which it differed from the overall mean for the dataset, to account for age groups that had 
lived through a time of abnormally high or low flu incidence.  For age 0, only individuals greater than 220 days old 
were included to reduce the chance of detecting potential maternal immunity rather than genuine exposure and val-
ues for age 0 were plotted assuming a previous seroprevalence of 0%. Error bars indicate the 95% confidence intervals.
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ABSTRACT
Seasonal vaccination against influenza is recommended for all healthy children in a number of 
countries. However, we recently demonstrated that vaccination against seasonal influenza prevent-
ed the induction of virus-specific CD8+ T cell responses by infection with an influenza A/H3N2 virus 
and the induction of heterosubtypic immunity against influenza A/H5N1 in mice and ferrets. In the 
present study, we compared influenza A virus-specific cellular and humoral responses of unvac-
cinated healthy control children with children with cystic fibrosis (CF) that were vaccinated annu-
ally. No differences were observed between groups in the virus-specific CD4+ T cell response, while 
the antibody profile of the vaccinated children was more broadly cross-reactive. An age-related 
increase in the virus-specific CD8+ T cell response was observed in unvaccinated healthy control 
children that was absent in vaccinated CF children. Our results indicate that influenza vaccination 
is effective against seasonal influenza viruses but hampers the development of virus-specific CD8+ 
T cell responses. The consequences of these findings are discussed in the light of the development 
of protective immunity to seasonal and pandemic influenza viruses.
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INTRODUCTION 
The recent pandemic caused by influenza A/H1N1 virus of swine origin and the ongoing pandemic 
threat of highly pathogenic avian influenza A/H5N1 viruses highlight the importance of influenza 
as a cause of disease in humans. Also seasonal influenza viruses are an important cause of morbid-
ity and mortality annually, especially in groups of people that are at risk to develop complications 
after infection due to underlying disease. The World Health Organization (WHO) has recommended 
annual influenza vaccination in these subjects to prevent excess morbidity and mortality (12). In 
addition to this recommendation the public health authorities of a number of countries have rec-
ommended to vaccinate all healthy children older than 6 months of age against seasonal influenza 
(60, 206). Since universal vaccines that protect against various intra subtypic drift variants and mul-
tiple subtypes of influenza A viruses are currently unavailable, annual vaccination aims at the in-
duction of immunity to circulating seasonal influenza viruses (A/H3N2, A/H1N1 and B-viruses). Cur-
rently used inactivated influenza vaccines generally induce protective antibody responses against 
the influenza A and B virus antigens but inefficiently induce protective immunity to other influenza 
A virus subtypes (e.g. H5N1), so called heterosubtypic immunity.
In animal models, infection with influenza A virus reduces the morbidity and mortality after subse-
quent challenge infection with an influenza A virus of another subtype (40, 42, 54, 77, 155). There is 
also evidence for the presence of heterosubtypic immunity in humans (56, 207). For example, indi-
viduals that experienced an infection with an influenza A/H1N1 virus before 1957 less likely devel-
oped flu during the H2N2 pandemic of 1957 (54). Especially influenza virus-specific CD8+ Cytotoxic 
T lymphocytes (CTL) are thought to contribute to heterosubtypic immunity since the majority of 
these cells recognize conserved epitopes located in proteins like the nucleoprotein and the matrix 
protein (208, 209). Virus-infected cells present these epitopes in association with MHC Class I mol-
ecules and are eliminated upon recognition by specific CTL (51, 52, 210, 211). Furthermore, it has 
been demonstrated in humans that the presence of cross-reactive CTLs inversely correlated with 
the extent of viral shedding in the absence of antibodies specific for the virus used for experimental 
infection and also in young children it has been demonstrated that cellular immune responses cor-
related with protection against culture-confirmed influenza virus (50, 212). 
The use of inactivated influenza virus vaccines induces virus-specific CD8+ T cell responses inef-
ficiently (105, 157). Furthermore, it can be hypothesized that the use of these vaccines interfere 
with the induction of virus-specific CD8+ T cell responses otherwise induced by natural infections 
especially in children who are immunologically naïve to influenza viruses (145). We tested this hy-
pothesis in mice and ferrets recently and confirmed that the use of subunit and whole inactivated 
A/H3N2 vaccines prevented the induction of heterosubtypic immunity to a lethal challenge infec-
tion with influenza A/Indonesia/5/05 (H5N1) otherwise induced by infection with A/H3N2 influ-
enza virus (135, 157, Bodewes et al J Virol in press). The prevention of heterosubtypic immunity by 
H3N2 vaccination correlated with reduced virus-specific CD8+ T cell responses. Furthermore, epi-
demiological data obtained during the 2009 pandemic  suggests that previous vaccination against 
seasonal influenza increased the risk of infection with the antigenically distinct influenza A/H1N1 
pandemic virus in children and the risk of medically attended illness caused by this virus in adults 
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(169, 170, 213). However, the reason for this in humans is lacking and therefore we wished to com-
pare the number of influenza virus-specific CD8+ T cells in children that received annually influenza 
vaccination with that of un-vaccinated children. To this end, we collected peripheral blood mono-
nuclear cells (PBMC) and plasma samples from cystic fibrosis (CF) patients and otherwise healthy 
children undergoing correctional surgery. Since CF patients are at risk for complications caused by 
influenza virus infections, annual influenza vaccination is recommended from the time point of CF 
diagnosis onwards. In the Netherlands, influenza vaccination is not practiced in healthy young chil-
dren. PBMC of the study subjects were tested for the presence of virus-specific T cells by intracel-
lular IFN-γ staining and plasma samples were tested for the presence of virus-specific antibodies 
against various influenza A virus strains. The results obtained in the present study give insight in 
the development of virus-specific CD8+ T cell immunity in young children and the effect that an-
nual vaccination with inactivated influenza A virus antigens has on the induction of this type of 
immunity.
MATERIALS AND METHODS
Study subjects
Children with cystic fibrosis (CF) that received inactivated influenza virus vaccine annually and un-
vaccinated healthy children that visited the hospital to undergo correctional surgery were enrolled 
in this study. Inclusion criteria for CF children were: age between 2 and 9 years first recorded vac-
cination against seasonal influenza viruses before or at four years of age and subsequently annual 
vaccination, no clinical signs of acute disease at the moment of blood collection, not chronically 
treated with immunosuppressive medications, and no laboratory confirmed infection with influen-
za A/H1N1(2009) before or at the moment of blood collection. Inclusion criteria for healthy control 
children were: between 2 and 9 years of age, not vaccinated against seasonal influenza, not chroni-
cally treated with immunosuppressive medications and no clinical signs of disease at the moment 
of blood collection. Blood samples were collected during autumn of 2009 and winter of 2009/2010. 
Written informed consent was obtained from parent or care takers prior to enrolment. The study 
was approved by the institutional medical ethics committee (Medisch Ethische Toetsings Commis-
sie Erasmus MC (METC)). Protocol registration number MEC-2009-359; ABR-number 29399. 
Serology
Plasma samples of children were collected and stored at -20°C until further processing. The pres-
ence of antibodies against influenza A viruses was evaluated using the virus neutralization (VN)-
assay as described previously (87). Plasma samples were tested for the presence of antibod-
ies against influenza A vaccine viruses from influenza seasons 2000-2010 and the influenza A/
H1N1(2009) virus. To this end, influenza A/H3N2 viruses A/Panama/07/1999, A/Wyoming/3/2003, 
A/New York/55/2004, A/Hiroshima/52/2005, A/Wisconsin/67/2005, A/Brisbane/010/2007, influenza 
A/H1N1 viruses A/New Caledonia/20/1999, A/Solomon Islands/3/2006, A/Brisbane/059/2007 and 
the influenza A/H1N1(2009) virus A/Netherlands/602/2009 were inoculated in the allantoic cavity 
of 11-days old embryonated chicken eggs. Allantoic fluid was harvested after two days, cleared by 
98
Chapter 7 - Vaccination and  CD8+ T  cell immunity in children
7
low speed centrifugation and stored at -80°C before use in the VN-assay. Sera from ferrets infected 
with each influenza A virus were used as a positive control. The plasma samples were also tested for 
the presence of IgG antibodies specific for various bacterial and viral vaccine antigen used in the 
National Immunization program including mumps, measles, rubella, Tetanus Toxin and Diphteria 
toxin and a common viral pathogen (Varicella Zoster virus) as described previously (Van Gageldonk 
et al J Immunol Methods 2008).
Collection of PBMC and intracellular IFN-γ staining of stimulated PBMC
Blood samples (max. 5ml) were collected in EDTA tubes (Greiner Bio-One, Alphen a/d Rijn, The 
Netherlands) and subsequently PBMC were isolated by density gradient centrifugation using lym-
phoprep (Axis-Shield PoC AS, Oslo, Norway) and then cryopreserved at -135°C until use. Thawed 
PBMC were resuspended in RPMI 1640 medium (Cambrex, East Rutherford, NJ, USA) supplemented 
with 10% Fetal Bovine Serum, 2mM L-Glutamine, 100 IU/ml penicillin and 100 µg/ml streptomycin. 
PBMC were seeded in 96 wells U-bottomplates (8x105 cells/well) and infected with influenza A/
H3N2 virus Resvir-9 (a reassortant containing the nucleoprotein, hemagglutinin and neuraminidase 
of A/Nanchang/933/95 and all other genes of A/Puerto Rico/8/34) with a multiplicity of infection 
of three or left untreated. After 16 hours at 37°C, Brefeldin A (2µg/ml, Sigma-Aldrich, Zwijndrecht, 
The Netherlands) was added to the cells. As a positive control, cells from each individual were also 
incubated with 1µg/ml staphylococcus enterotoxin B (SEB; Sigma-Aldrich, Zwijndrecht, The Nether-
lands) during incubation with brefeldin A. After another six hours of incubation, cells were washed, 
stained with fluorescent labelled monoclonal antibodies (moabs) CD4-Pacific Blue (BD, Alphen a/d 
Rijn, The Netherlands) and CD8-PeCy7 (eBioscience, San Diego, USA). To exclude dead cells in the 
analysis, cells were also stained with LIVE/DEAD Aqua Fixable Dead Cell Stain (Invitrogen, Breda, The 
Netherlands). Subsequently cells were fixed with Facs Lysing Solution (BD) and stored at -80°C until 
further processing. Cells were permeabilized with Facs permeabilizing solution (BD) and stained 
with moabs CD3-PerCP, CD69-APC (both BD) and IFN-γ-FITC (eBioscience). Data were acquired us-
ing a FACSCanto-II and analysed with FACS Diva software (BD, stad?). For each well, the virus-spe-
cific CD8+ and CD4+ T cell response was determined by calculating the percentage of IFN-γ+ cells 
of the CD69+CD3+CD8+ cell population (IFN-γ+CD8+) or CD69+CD3+CD4+ (IFN-γ+CD4+) cells. For 
cells incubated with medium or with Resvir-9, the assay was performed in duplicate. Subsequently, 
the influenza A virus-specific and SEB-specific CD8+ and CD4+ T cell response of each individual 
was calculated by subtracting the mean percentage of IFN-γ+CD8+ or IFN-γ+CD4+ cells from cells 
incubated with medium only from the (mean) percentage of IFN-γ+CD8+ or IFN-γ+CD4+ cells incu-
bated with Resvir-9 or SEB.
Statistical analysis
Associations between the age of children and the T cell responses of all groups were calculated us-
ing the Pearson’s correlation coefficient (r) and the significance was calculated using ANOVA which 
was also used to assess the difference in slope between groups. Furthermore, assuming binominal 
distribution, the two-sided exact 95% confidence interval (CI) was calculated for seroprevalences of 
antibodies against influenza A/H3N2 and A/H1N1 viruses using Stata/SE software version 11.0. The 
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Mann Whitney test was used to compare T cell responses of groups. Differences were considered 
significant at p<0.05.
RESULTS
Study population
Between October 15, 2009 and February 5, 2010, blood samples were collected from 27 unvacci-
nated healthy control children and 14 children with CF vaccinated against influenza annually. The 
mean age of unvaccinated control children was 5.9 years and the median age of this group was 6.0 
years (range 2.0-8.8 years), while the mean age of the group of vaccinated children was 6.2 (median 
6.6; range 3.1-9.0 years). 
Antibody responses to influenza viruses and other selected antigens
Plasma samples were tested for the presence of antibodies against influenza A/H3N2 and influenza 
A/H1N1 viruses by VN-assay. In 24 out of 27 children (89%) of the unvaccinated control group, an-
Figure 1. Influenza A virus-specific 
humoral immunity. The proportion 
of children of the healthy unvacci-
nated control group (grey bars) and 
the vaccinated group of children 
with CF (white bars) with antibod-
ies against at least one of the influ-
enza viruses was calculated for all 
influenza viruses of each subtype (A) 
or for all indicated viruses individu-
ally (B). Bars represent the percent-
age with 95% confidence intervals. 
GMTs were calculated for all samples 
in which antibodies were detected 
against the indicated viruses (C). 
Bars represent GMT with standard 
deviations and the horizontal grey 
bar indicates the detection limit of 
the assay. The asterisk indicates a 
significant differences between the 
two groups (p<0.05).
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tibodies were detected against at least one influenza A/H3N2 virus and in 20 out of 27 children, 
antibodies were detected against one of the influenza A/H1N1 viruses, including the influenza A/
H1N1(2009) virus. In two children of the unvaccinated control group, no antibodies were detected 
against both influenza A/H3N2 and influenza A/H1N1 viruses.
In all vaccinated children, antibodies were detected against at least one influenza A/H3N2 virus 
and at least one influenza A/H1N1 virus. In 10 out of 14 (71%) plasma samples of these children 
antibodies were detected against the influenza A/H1N1(2009) virus against which they were also 
vaccinated (Fig 1A). The proportion of subjects with antibodies to the relatively old strains A/Pan-
ama/07/99 (H3N2) and A/New Caledonia/20/99 was significantly (p<0.05) greater in the group of 
vaccinated children with CF than in the unvaccinated control group (Fig 1B). These differences were 
not observed with more recent virus strains. 
Geometric mean titers (GMT) were calculated for seropositive plasma samples to compare the 
magnitude of the antibody response of both groups. A significant higher GMT was observed in chil-
dren of the unvaccinated control group for both influenza A/Panama/07/99 (H3N2) and A/Solomon 
Islands/3/2006 (H1N1) viruses (p=0.04 and p=0.01 respectively). No significant differences were ob-
served between groups for GMTs of all other viruses (Fig 1C). 
The IgG antibody responses to viral antigens mumps, measles, rubella and Varicella Zoster and the
bacterial antigens Tetanus Toxin and Diphteria toxin were similar between the two study groups 
(Fig 4 A-F).
Influenza A virus-specific T cell immunity
To assess the influenza A virus-specific CD8+ and CD4+ T cell immunity of each study subject, PBMC 
were stimulated with Resvir-9 and subsequently intracellular IFN-γ staining was performed. The 
Figure 2. Correlation between age and 
influenza virus-specific T cell responses. 
The percentage of virus-specific CD8+ 
IFN-γ+ T cells (A and B) and CD4+ IFN-γ+ 
T cells (C and D) was determined and 
plotted as a function of age of the indi-
vidual subjects. Each dot represents the 
result of an individual subject and the 
correlation between all subjects of one 
group was calculated and is indicated 
by the black line. Both data of unvac-
cinated control children (A and C) and 
vaccinated children with CF (B and D) 
is shown. The correlation between age 
and the percentage of CD8+ IFN-γ+ T 
cells was significantly different (p<0.05) 
between the two study groups.
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percentage of virus-specific IFN-γ+CD8+ T cells varied between 0.00 and 2.32 for unvaccinated con-
trol children while the percentage of IFN-γ+CD8+ T cells ranged between 0.06 and 1.56 for vacci-
nated children. An age-dependent increase of the virus-specific CD8+ T cell response was observed 
in the group of unvaccinated healthy control children (r2=0.16; p=0.040; Fig 2A), which was not 
observed in the group of vaccinated children (r2=0.012; p=0.714; Fig 2B). In addition, the age-de-
pendent increase of virus-specific CD8+ T cells of the unvaccinated control group was significantly 
different from that of the vaccinated group (p=0.047) and in children older than 5 years of age, also 
a significant higher percentage (p=0.038) of IFN-γ+CD8+ T cells was observed in the unvaccinated 
control group (mean 0.86, s.d. 0.67) compared to the vaccinated group (mean 0.368, s.d. 0.451).
No significant age-dependent increase was observed for influenza A virus-specific CD4+ T cell im-
munity in both the unvaccinated control groups (r2=0.027; p=0.433; Fig 2C) and the vaccinated 
group (r2=0.065; p=0.379; Fig 2D). Furthermore, influenza A virus-specific CD4+ T cell responses 
were similar in both groups; in unvaccinated control group the mean percentage of IFN-γ+CD4+ 
T cells was 0.187 (s.d. 0.169), while in the vaccinated control group the mean percentage of IFN-
γ+CD4+ T cells was 0.202 (s.d. 0.276) (p=1.00).
Figure 3. T cell responses to stimula-
tion with SEB. The percentage of CD4+ 
IFN-γ+ T cells (A,C) and CD8+ IFN-γ+ T 
cells (B,D) responding to SEB was de-
termined for each subject of the group 
of unvaccinated control children (A,C) 
and the vaccinated children with CF 
(B,D). The percentage of SEB-specific 
CD8+ IFN-γ+ T cells was also plot-
ted against the percentage influenza 
virus-specific CD8+ IFN-γ+ T cells for 
both the control children (E) and the 
vaccinated children with CF (F).
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SEB-specific T cell immunity 
In addition to the virus-specific T cell response, the response of CD4+ and CD8+ T cells to the su-
perantigen SEB was assessed for each subject. No age-related increase for both the SEB-specific 
CD4+ (r2=0.039; p=0.347; Fig 3A) and CD8+ (r2=0.024; p=0.463; Fig 3C) T cell response was observed 
in the unvaccinated control group and no significant differences were observed between the vac-
cinated children (mean 1.72, s.d. 1.47) and the unvaccinated control children (mean 1.37, s.d. 1.01) 
regarding the SEB-specific CD4+ T cell responses (p=0.558). 
In addition, no age-related increase of the SEB-specific CD4+ T cell response was observed in vac-
cinated children (r2=0.148, p=0.147; Fig 3B), while the correlation of age-related with the SEB-spe-
cific CD8+ T cell response approached statistical significance (r2=0.229, p=0.083; Fig 3D). This indi-
cates that at young age the percentage of SEB specific CD8+IFN-γ+ T cells was lower in vaccinated 
children compared to unvaccinated children, while in children older than five years of age no sig-
nificant differences were present between groups (p=0.134). Furthermore, no correlation was ob-
served between the SEB-specific CD8+ T cell response and the influenza A virus-specific CD8+ T cell 
response in the group of unvaccinated control children (r2=0.021, p=0.492; Fig 3E) and vaccinated 
children (r2=0.18, p=0.12; Fig 3F).
DISCUSSION
In the present study, we assessed influenza A virus-specific cellular and humoral immune responses 
in children with CF that had been vaccinated against seasonal influenza annually and in unvac-
cinated healthy control children. The virus-specific antibody profile was broader in vaccinated 
children with CF compared to unvaccinated control children. No differences were observed in the 
development of virus-specific CD4+ T cell responses. However, in healthy control children, an age-
related increase in the percentage of virus-specific CD8+ T cells was detected which was not ob-
served in children with CF, vaccinated annually. This is in concordance with our previous results in 
the mouse model in which we demonstrated that vaccination against seasonal influenza A virus 
prevented the development of influenza A virus specific CD8+ T cell immunity otherwise induced 
by infection (135, 157). 
The age-dependent increase in the frequency of virus-specific CD8+ T cells in the unvaccinated 
control group most likely reflexes the increase in the number of subjects that experienced an infec-
tion with an influenza virus early in life. Of interest, a similar pattern was observed for the develop-
ment of antibodies to influenza viruses in a large sero-epidemiological study performed in children 
age 0-7 years recently (Bodewes et al, Clinical Vaccine Immunology, in press). Indeed two healthy 
unvaccinated control subjects without detectable antibodies to any of the influenza A viruses also 
had very low frequencies of virus-specific CD8+ T cells which thus reflects lack of exposure to in-
fluenza A virus. In addition, maturation of the immune system may have contributed to increased 
responsiveness observed in older children. The latter was demonstrated using non-specific stimu-
lation of the lymphocytes resulting in an age-dependent increase in Th1-like cytokines (214-216). 
However, using SEB, we were not able to demonstrate an age-dependent increase in CD4 and CD8 
T cell responses to this super antigen. 
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In the group of CF patients vaccinated annually the age-dependent increase in virus-specific CD8+ 
T cell responses was absent. Our interpretation of these findings is that vaccination efficiently in-
duced virus-specific antibodies which protected against infection with seasonal influenza viruses 
to a great extent, and thereby prevented the induction of specific CD8+ T cell responses. Although, 
ideally cell-mediated and humoral immune responses of unvaccinated healthy children were com-
pared with those of vaccinated healthy control subjects, it is unlikely that patients with CF respond-
ed poorly because of intrinsic immunological defects for various reasons. First, the virus-specific 
CD4+ T cell response of this group was comparable with that of the unvaccinated healthy control 
group. This confirms that the use of inactivated vaccines induced CD4+ T cell responses but not 
virus-specific CD8+ T cell responses.  Second, the antibody titers in the seropositive subjects were 
comparable between the two groups.  The vaccinated children with CF responded rather better 
than the unvaccinated subjects especially to older strains of influenza A virus. This confirms that pa-
tients with CF can be vaccinated effectively against seasonal influenza and the complications these 
infections may cause in this vulnerable group of high-risk patients. In addition, it has been demon-
strated in adults that during years with only mild influenza activity also the CTL immunity declined 
(217).  Third, the CD8+ T cell response after stimulation with SEB was not affected in the group of 
CF patients and comparable to that of unvaccinated control subjects. 218 comparable to that of 
unvaccinated control subjects. Finally, the antibody responses to various viral and bacterial vaccine 
antigens used in the Dutch national immunization program were similar for the two study groups, 
indicating that there were no differences in the functionality of T and B cells between the groups. 
Furthermore, universal vaccination of healthy children is not practised in the Netherlands, so this 
study group was not available. In addition, since vaccination of children 6-59 months of age is only 
recommended and practised since 2007 in other countries, the long term effects of vaccination of 
healthy children can not be examined at present. Therefore, the results from the present study war-
rant follow-up studies with a larger cohort of vaccinated and unvaccinated children in the future 
especially since epidemiological data suggests that previous vaccination against seasonal influenza 
increased the risk of infection with pandemic influenza A/H1N1 virus in 2009 (207).
Thus, annual vaccination against influenza is effective but may have potential drawbacks that 
have been underappreciated previously and that are also a matter of debate (145, 146, 170). By no 
means, we suggest halting annual vaccination of children, especially those at high risk for compli-
cations such as the CF patients. A number of studies have demonstrated that annual vaccination 
reduces morbidity and mortality caused by seasonal influenza in children and is (cost-)effective (63-
65, 213). However, long-term annual vaccination using inactivated vaccines may hamper the induc-
tion of cross-reactive CD8+ T cell responses by natural infections and thus may affect the induction 
of heterosubtypic immunity. This may render young children that have not been previously infect-
ed with an influenza virus more susceptible to infection with a pandemic influenza virus of a novel 
subtype. Therefore, we argue for the development and use of vaccines that could induce broadly 
protective immune responses in children. For example, it has been demonstrated that live attenu-
ated influenza vaccines induce virus-specfic CD8+ T cell responses. The development of broadly 
protecive vaccines has been on the research agenda for some time and progress has been made 
(121, 173, 218). Especially young children, whether at high risk for influenza-associated complica-
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tions or not, may benefit the most from these vaccines. 
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Fig 4. IgG antibody responses to various 
viral and bacterial vaccine antigens. Mean 
IgG antibody response (± s.d.) to various 
viral and bacterial antigens including those 
of the Dutch national vaccination program 
of the healthy unvaccinated control group 
(grey bars) and the vaccinated group of 
children with CF (white bars) for Measles 
(A), Mumps (B), Rubella (C), Varicella Zoster 
(D), Diphtheriatoxin (E) and Tetanus toxin 
(F).
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ABSTRACT
A candidate influenza H5N1-vaccine based on cell-culture-derived whole inactivated virus and the 
novel adjuvant CoVaccine HT™ was evaluated in vitro and in vivo. To this end, mice were vaccinated 
with the whole inactivated influenza A/H5N1 virus vaccine with and without CoVaccine HT™ and vi-
rus-specific antibody and cellular immune responses were assessed. The addition of CoVaccine HT™ 
increased virus specific primary and secondary antibody responses against the homologous and 
an antigenically distinct heterologous influenza A/H5N1 strain. The superior antibody responses 
induced with the CoVaccine HT™-adjuvanted vaccine correlated with the magnitude of the virus-
specific CD4+ T helper cell responses. CoVaccine HT™ did not have an effect on the magnitude of 
the CD8+ T cell response. In vitro, CoVaccine HT™ upregulated the expression of co-stimulatory 
molecules both on mouse and human dendritic cells and induced the secretion of pro-inflammato-
ry cytokines TNF-α, IL-6, IL-1ß and IL-12p70 in mouse- and IL-6 in human dendritic cells. Inhibition 
experiments indicated that the effect of CoVaccine HT™ is mediated through TLR4 signaling. These 
data suggest that CoVaccine HT™ also will increase the immunogenicity of an influenza A/H5N1 
vaccine in humans.
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INTRODUCTION
Influenza viruses are a major cause of respiratory tract infections and responsible for excess mor-
bidity and mortality annually. In addition to seasonal influenza epidemics, influenza pandemics 
occur occasionally caused by the introduction of influenza A viruses of novel subtypes into the 
human population. At present, highly pathogenic avian influenza A viruses of the H5N1 subtype 
continue to cause outbreaks in domestic birds and are transmitted regularly from infected poul-
try to humans. Since 2003, more than 400 human cases have been reported of which >60% had a 
fatal outcome (219). It is feared that these viruses will adapt to their new host, become transmis-
sible from human-to-human and cause a new pandemic (17, 102). Furthermore, a previous unde-
scribed influenza A/H1N1 virus was isolated from humans in Mexico in april 2009, which did subse-
quently spread all over the world (13, 220, 221). As of july 6 2009, there have been 94512 laboratory 
confirmed cases of pandemic new influenza A/H1N1, resulting in 429 deaths (221). Therefore, the 
World Health Organization has issued a pandemic alert phase 6 for these viruses on june 11 2009. 
To mitigate the impact of a next influenza pandemic, there is a need for safe and effective vaccines 
(222-225). Key issues for pandemic influenza vaccine development are: the time required that vac-
cines become available after the start of a pandemic, optimal use of the existing production capac-
ity to produce sufficient vaccine doses for a world wide vaccination campaign and improvement of 
the efficacy of the vaccine not only against homologous virus strains but also against heterologous 
viruses derived from antigenically distinct clades. Some of these issues have been addressed and 
it has been shown that the use of adjuvants increases the immunogenicity of inactivated vaccines 
that are otherwise poorly immunogenic (226, 227), allows dose sparing, increasing the number of 
vaccine doses that can be made (226) and broadens the specificity of the antibody responses that 
are induced (149, 227). 
In the present study, we evaluated the immune potentiating effect of the novel adjuvant CoVaccine 
HT™ on the immune response in mice induced with a whole inactivated influenza A/H5N1 vaccine 
produced in Madin Darby Canine Kidney (MDCK) cells on a commercial scale.   CoVaccine HT™ con-
sists of a sucrose fatty acid sulphate ester  (SFASE) immobilized on the oil droplets of a submicron 
emulsion of squalane-in-water (228). It has been shown that CoVaccine HT™ increased the humoral 
and cellular immune responses to an experimental classical swine fever vaccine based on recom-
binant E2 glycoprotein in pigs and it enhanced humoral responses to a Gonadotropin-releasing 
hormone (GnRH) conjugate vaccine in horses and was well-tolerated in both species (228-230). Fur-
thermore, preliminary data on the immune potentiating properties of CoVaccine HT™ in mice and 
ferrets also shows improved immunogenicity to an inactivated cell culture derived whole influenza 
virus vaccine by the addition of CoVaccine HT™ (231).
Here we show that the addition of CoVaccine HT™ to the influenza A/H5N1 vaccine increased 
the magnitude of the virus specific antibody response in mice considerably. Even after a single 
immunization sizable antibody response were detected, which were boosted after a second im-
munization. Furthermore the antibody responses directed to the homologous vaccine strain A/
Vietnam/1194/04 (clade 1) cross-reacted to a certain extent with influenza virus A/Indonesia/5/05 
derived from an antigenically distinct clade of H5N1 viruses (clade 2.1) (232). The enhanced anti-
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body responses observed with the use of CoVaccine HT™ correlated with improved CD4+ T helper 
cells responses. CoVaccine HT™ did not potentiate CD8+ T cell responses.      
To elucidate the potential mechanism underlying the adjuvant effect of CoVaccine HT™, we test-
ed its effect on the maturation of mouse and human dendritic cells. CoVaccine HT™ induced the 
expression of co-stimulatory molecules CD80 and CD86 and the production of pro-inflammatory 
cytokines in murine bone marrow derived myeloid dendritic cells (BM-mDCs). A similar effect was 
observed with human monocyte-derived dendritic cells. Based on these findings we anticipate that 
CoVaccine HT™ also increases the immunogenicity of whole inactivated H5N1 vaccines in humans.  
MATERIALS AND METHODS
Vaccine and adjuvant
The vaccine strain NIBRG-14, based on strain A/Vietnam/1194/04, (H5N1, clade 1) was used to pre-
pare a whole inactivated influenza A virus vaccine. The vaccine was produced in MDCK cells and 
inactivated using beta-propiolactone on a commercial scale by Nobilon Schering-Plough, Boxmeer, 
The Netherlands. The hemagglutinin content was assessed by a single radial immunodiffusion as-
says according to standard methods (233). CoVaccine HT™ was produced and formulated according 
proprietary technology by Protherics Ltd., London, United Kingdom. 
Mice and immunizations
Female specified pathogen free 6-8 weeks old C57BL/6J mice were purchased from Charles River 
(Sulzfeld, Germany). Mice were housed in individual ventilated cages and were fed food and water 
ad libitum. Mice were divided in 5 groups (n=16-17 mice per group) and were immunized twice by 
the intramuscular route in the hind legs (50 µl per leg) with an interval of four weeks with either 
PBS (group 1), 5μg HA of whole inactivated influenza A virus vaccine (WIV NIBRG-14) only (group 2), 
CoVaccine HT™ (1 mg SFASE) only (group 3) or 5 μg HA of WIV NIBRG-14 in combination with CoVac-
cine HT™ (group 4).  Mice of group 5 were infected intranasally twice with an interval of four weeks 
with 2x 104 TCID50 in 50μl PBS of a reassortant virus containing the surface glycoproteins of influen-
za A/VN/1194/04 (H5N1) and the inner proteins of influenza A/PR/8/34, which is a commonly used 
vaccine backbone strain. This virus was produced by reverse genetics technology as described pre-
viously (234) and the basic cleavage site was removed from the HA by site-directed mutagenesis, 
corresponding the NIBRG-14 vaccine strain. Mice of this group were used as a positive control for 
the detection of CD8+ Tetramer+ T cells (group 5). Mice of each group were euthanized 8 days after 
the first vaccination (n=6 per group), 8 days after the second vaccination (n=6 per group) and 21 
days after the second vaccination (n=4-5 mice per group). After collection of blood samples for the 
determination of serum antibody responses and euthanasia by cervical dislocation, spleens and 
inguinal lymph nodes were resected. Infections and euthanasia were performed under anesthesia 
with isoflurane (3% in 02). An independent animal ethics committee approved the experimental 
protocol before the start of the experiments. 
Serology
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Serum samples were collected before and twenty-eight days after the first vaccination and twenty-
one days after the second vaccination. Sera were stored at –20°C until use. Sera were tested for the 
presence of anti-HA antibodies using a hemagglutination inhibition assay (HI-assay) with 1% turkey 
erythrocytes and for the presence of virus neutralizing antibodies using a micro virus neutralization 
assay (VN-assay) as described previously (87, 107). Sera were tested for the presence of antibodies 
reactive with influenza A/H5N1 viruses of two antigenically distinct clades, influenza A/VN/1194/04 
(H5N1) and influenza A/IND/5/05 (H5N1). For this purpose, reverse genetics viruses of both viruses 
were produced. The titers obtained with these viruses were comparable with those against the 
wild-type strains (data not shown). Positive control serum specific for influenza A/VN/1194/04 was 
obtained from hyperimmune serum from a rabbit and positive control serum specific for influenza 
A/IND/5/05 was obtained from a swan immunized twice with inactivated H5N1 influenza virus A/
Duck/Potsdam/1402/86 (Intervet, Boxmeer, The Netherlands) (89).
Intracellular cytokine staining of virus-specific CD4+ T cells
Virus-specific CD4+ T cells were detected by intracellular cytokine staining. After single cell suspen-
sions were obtained from spleens of mice and red blood cells were removed using erythrocyte lysis 
buffer (Roche, Almere, The Netherlands), cells were stained with trypan blue and living cells were 
counted. Five-hundred-thousand splenocytes were incubated for two hours with or without 1μg 
HA of WIV NIBRG-14 in Iscove’s Modified Dulbecco’s Medium (Lonza, Breda, The Netherlands) con-
taining 5% Fetal Calf Serum (FCS), and subsequently Golgistop (Monensin, BD, Alphen a/d Rijn, The 
Netherlands) was added. After an additional incubation for six hours in the presence of Golgistop, 
cells were o/n stored at +4°C and subsequently stained for flow cytometry with fluorescently la-
belled antibodies to detect intracellular IL-2, IFN-γ, IL-4 and IL-5. In brief, cells were washed with PBS 
containing 2% FCS (P2F) and Golgistop and stained with monoclonal antibodies directed to CD3e-
APC-Cy7 and CD4-PerCP (Both from BD, Alphen a/d Rijn, The Netherlands). To exclude dead cells in 
the analysis, cells were stained with LIVE/DEAD Aqua Fixable Dead Cell Stain (Invitrogen, Breda, The 
Netherlands). After staining, cells were fixed and permeabilized with Cytofix and Cytoperm (BD) 
and stained with monoclonal antibodies specific for IL-2 FITC, IL-5 PE, IL-4 APC and IFN-γ PE-Cy7 (all 
BD, Alphen a/d Rijn, The Netherlands). Samples were acquired with a FACSCanto and analyzed us-
ing FACS Diva software (BD). The mean percentage of cytokine-positive CD4+ T cells of duplicates 
was calculated.
Detection of virus-specific CD8+ CTL by tetramer staining 
After the removal of red blood cells from single cell suspensions of spleens and inguinal lymph 
nodes, cells were washed with P2F and stained for flow cytometry with antibodies to anti-CD3e 
PerCP, anti-CD8a APC, the PE labeled H-2Db tetramer with the NP366-374 epitope ASNENMETM 
(TMASNENMETM; Sanquin Research, Amsterdam, The Netherlands) and LIVE/DEAD Aqua Fixable Dead 
Cell Stain. Samples were acquired with a FACSCanto and analyzed using FACS Diva software (BD).
Collection of murine bone marrow derived myeloid dendritic cells
Bone marrow cells were collected from the femurs and tibiae of six PBS vaccinated C57bl/6J mice 
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and cultured for nine days in DC culture medium (DC-CM; RPMI 1640 containing GlutaMAX-I; Invit-
rogen, Breda, The Netherlands) supplemented with 5% (v/v) FCS (HyClone, Etten-Leur, The Nether-
lands), 50μM 2-mercaptoethanol (Sigma-Aldrich, Zwijndrecht, The Netherlands), 100 U/ml penicil-
lin, 100 U/ml streptomycin and 20 ng/ml recombinant mouse GM-CSF (a gift from K. Thielemans, 
Vrije Universiteit Brussel, Brussels, Belgium) essentially as described previously (235). On day 9, 1 x 
106 cells/ml were stimulated with PBS, three different concentrations of CoVaccine HT (50, 100 and 
200 μg SFASE/ml) or 1μg/ml lipopolysaccharide (LPS; positive control). After incubation for 16-18 
hours at 37°C, BM-mDCs were harvested and subsequently stained with CD80-FITC and CD86-PE or 
CD11c-APC, I-A-FITC and CD86-PE (all from BD, Alphen a/d Rijn, The Netherlands). Dead cells were 
excluded by staining with LIVE/DEAD Aqua Fixable Dead Cell Stain (Invitrogen, Breda, The Neth-
erlands). Samples were acquired on a FACSCanto and subsequently analyzed with Cellquest Pro 
Software (both BD). 
Collection of human monocyte derived dendritic cells 
PBMC from healthy blood donors, between 35 and 50 years of age, were isolated from heparinized 
blood (Sanquin Bloodbank, Rotterdam, The Netherlands) by density gradient centrifugation using 
Lymphoprep (Axis-Shield PoC, Oslo, Norway) and were cryopreserved at 
–135°C. Immature human DCs were obtained by isolation of CD14+ cells from thawed PBMC of 
three different donors by magnetic cell sorting, using human CD14 microbeads (Miltenyi Biotec 
GmbH, Bergisch Gladbach, Germany) according to the instructions of the manufacturer. Subse-
quently, cells were cultured in RPMI 1640 medium (Cambrex, East Rutherford, NJ, USA) containing 
10% FCS (Sigma-Aldrich, Zwijndrecht, The Netherlands), 1000 U/ml recombinant human GM-CSF 
and 200 U/ml recombinant human IL-4 (both BD Pharmingen, Alphen a/d Rijn, The Netherlands). 
After culturing for 7 days, cells were stimulated for 16-18 hours with PBS, CoVaccine HT (50 μg 
SFASE/ml) or LPS (1 μg/ml). After stimulation, cells were stained with CD80-FITC, CD83-APC and 
CD86-PE or HLA-DR-PerCP and CD11c-APC (all from BD, Alphen a/d Rijn, The Netherlands) and sub-
sequently acquired on a FACSCanto and analysed with Cellquest Pro Software (both BD).
Detection of cytokines in DC culture supernatants
Concentrations of TNF-α, IL-12p70, IL-6, IL-1ß and IL-10 in culture supernatants of murine and hu-
man dendritic cells were assessed by enzyme-linked immunosorbent assay (ELISA) in 96-well mi-
crotitre plates using Elisa-kits (eBioscience, San Diego, USA) according to the instructions of the 
manufacturer. Culture supernatants of dendritic cells incubated with LPS were used as a positive 
control for the release of cytokines while culture supernatants of dendritic cells incubated with PBS 
were used as negative controls. 
Effect of anti-Toll Like Receptor (TLR) antibodies on the secretion of IL-6 and IL-10 by human DCs
Immature human DCs (1x106 cells/ml) of three healthy blood donors were incubated with 20μg/ml 
of either anti-TLR4 MoAb (Clone HTA-125), anti-TLR2 MoAb (Clone TL2.1) (both eBiosciences, San 
Diego, USA), both monoclonal antibodies, PBS or mouse IgG1 isotype control for half an hour at 
room temperature. Subsequently CoVaccine HT™ (50 μg SFASE/ml) or LPS (1 μg/ml) was added and 
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cells were incubated for 16-18 hours at 37°C. After incubation, supernatants were harvested and 
stored at –70°C until concentrations of IL-6 and IL-10 were determined using Elisa-kits.
Statistical analysis
Differences in the antibody titer, and the percentages of CD4+ Cytokine+ T cells and CD8+ TMAS-
NENMETM+ T cells between mice of groups 2 and 4 were analyzed statistically using the Mann-
Whitney U test. The differences between mice of groups 2 and 4 regarding the percentages of CD4+ 
Cytokine+ T cells were calculated after subtracting the mean percentage of CD4+ Cytokine+ T cells 
stimulated with PBS from the mean percentage of WIV stimulated cells of each individual mouse.
RESULTS
Serology
To assess the immunogenicity of WIV NIBRG-14 and the adjuvant effect of CoVaccine HT™, pre- and 
post vaccination sera were tested for the presence of virus specific antibodies by HI and VN assay. 
Mice vaccinated with PBS or CoVaccine HT™ only did not develop detectable antibody titers against 
homologous and the heterologous influenza A/H5N1 virus (data not shown). After one vaccina-
tion, in 3 out of 11 mice vaccinated with WIV NIBRG-14 only low antibody titers against influenza A/
VN/1194/04 were detected in the HI assay (Geometric Mean Titer (GMT) = 8). Two of these animals 
also developed detectable VN antibodies (GMT =6). In contrast, all eleven mice vaccinated with WIV 
NIBRG-14 and CoVaccine HT™ developed detectable HI and VN antibody titers, with GMTs of 42 and 
Figure 1.  Geometric mean serum 
antibody titers of mice 28 days after 
the first vaccination and 21 days af-
ter the second vaccination with 5μg 
HA of WIV NIBRG-14 with (grey bars) 
and without (black bars) CoVac-
cine HT. Sera were tested for the 
presence of antibodies against in-
fluenza A/VN/1194/04 (H5N1) and 
influenza A/IND/5/05 (H5N1) with 
the HI assay and the VN assay. Indi-
cated above the bars is the number 
of mice that developed detectable 
antibody titers (e.g. 1/11 = 1 out of 
11 mice).
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36 respectively. The differences in the HI and VN antibody titers between mice vaccinated with WIV 
NIBRG-14 only and WIV NIBRG-14 in combination with CoVaccine HT™ were statistically significant 
(p<0.001 for both assays). Antibodies against influenza A/IND/5/05 were detected in 1 out of 11 
mice vaccinated with WIV NIBRG-14 only in the HI-assay and not in the VN-assay, while 4 out of 
11 mice vaccinated with CoVaccine HT™ adjuvanted WIV NIBRG-14 had detectable HI antibodies 
against influenza A/IND/5/05.
Three weeks after the second vaccination, antibody titers were boosted and antibodies against in-
fluenza A/VN/1194/04 were detected in the HI and VN assay in four out of five mice vaccinated with 
WIV NIBRG-14 only (GMTs of 35 in both assays). All mice vaccinated with CoVaccine HT™-adjuvanted 
WIV NIBRG-14 developed virus specific antibodies detected in HI and VN assays with GMTs of 112 
and 160 respectively. The VN antibody titers induced with CoVaccine HT™ adjuvanted vaccine prep-
aration were significantly higher than those induced with the WIV NIBRG-14 only (p=0.04). For the 
HI antibody titers this difference approached statistical significance (p=0.07).  Twenty-one days af-
ter the booster vaccination, also antibodies were detected in the HI and VN assay that cross-reacted 
with influenza virus A/IND/5/05. The proportion of mice with these cross-reactive antibodies was 
higher in the group vaccinated with CoVaccine HT™-adjuvanted vaccine than in mice vaccinated 
with WIV NIBRG-14 only (Fig 1).
Intracellular cytokine staining of virus-specific CD4+ T cells
Splenocytes of mice euthanized 21 days after the second vaccination were incubated with or with-
Figure 2. Intracellular cytokine ex-
pression of CD4+ T cells after vacci-
nation with PBS, 5μg HA of WIV NI-
BRG-14 with and without CoVaccine 
HT™. Splenocytes of mice obtained 
21 days after the second vaccina-
tion were incubated with medium 
with (grey bars) and without (black 
bars) NIBRG-14. Production of IL-2 
(A), IFN-γ (B), IL-4 (C) and IL-5 (D) by 
CD4 T cells was monitored using in-
tracellular cytokine staining.
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out WIV NIBRG-14 and the production of IFN-γ, IL-2, IL-5 and IL-4 by virus specific CD4+ T cells was 
determined using intracellular cytokine staining.  Virtually no cytokine+ cells were found in mice 
vaccinated with PBS, while vaccination with WIV NIBRG-14 resulted in the production of cytokines 
IL-2, IFN-Y and IL-5 by CD4+ T cells after re-stimulation in vitro. The use of CoVaccine HT™ in the vac-
cine increased the percentages of virus specific cytokine+ CD4+ T cells to some extent (p-values of 
0.08, 0.25, 0.9 and 0.30 for the difference in percentage of CD4+ Cytokine+ T cells between groups 2 
and 4 for IL-2, IFN-γ, IL-4 and IL-5 respectively) (Fig.2). 
Detection of virus-specific CTL by tetramerstaining 
Inguinal lymph nodes and spleens were collected from vaccinated or infected mice 8 days after the 
first and 8 and 21 days after the second vaccination and the percentage of CD8+ TMASNENMETM+ 
T cells was determined. In the spleen, CD8+ TMASNENMETM+ T cells were detected only in mice 
vaccinated with WIV NIBRG-14 with (group 4) and without CoVaccine HT™ (group 2) and in infected 
mice (group 5). In mice of groups 2 and 4 and in infected mice (group 5), CD8+ TMASNENMETM+ 
T cells were observed 21 days after the second immunization, but the percentage of CD8+ TMAS-
NENMETM+ T cells was lower in mice of group 2 compared to mice of group 5 (p<0.03) (Fig 3). The 
addition of CoVaccine HT™ did not significantly alter the CD8+ T cell responses compared to the use 
of WIV NIBRG-14 alone (p=0.2). Only very low percentages of CD8+ TMASNENMETM+ T cells were 
observed in the inguinal lymph nodes of both vaccinated and unvaccinated mice (data not shown).
Effect of CoVaccine HT™ on murine bone marrow derived myeloid DCs
BM-mDCs of 6 mice were incubated for 16-18 hours with PBS, three different concentrations of 
CoVaccine HT™ (50, 100, 200 μg SFASE/ml) or LPS. After incubation, the cell surface expression of 
MHC-II (I-A), CD11c, CD80 and CD86 was analyzed using flow cytometry. DCs incubated with PBS 
had low expression of MHC-II (data not shown), moderate expression of CD11c (data not shown) 
and low expression of CD80 and CD86. Incubation with LPS or CoVaccine HT™ induced a marked in-
crease of CD80, CD86 and MHC-II expression on BM-mDCs compared to BM-mDCs incubated with 
PBS (Fig. 4A), while CD11c expression was not increased (data not shown). The expression of CD80 
or CD86 was not dependent on the concentration of CoVaccine HT™ that was used. 
Figure 3. CD8+ T cell responses to the im-
munodominant influenza A epitope on the 
nucleoprotein (NP366-374) of C57bl/6 mice 
as detected by tetramerstaining 8 days after 
the first, 8 days after the second and 21 days 
after the second vaccination with either PBS 
(hatched bars), WIV NIBRG-14 with (grey 
bars) and without (black bars) CoVaccine 
HT™. Infected mice were used as a positive 
control for the tetramerstaining (white bars).
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Furthermore, culture supernatants of BM-mDCs incubated with PBS, CoVaccine HT™ (50 μg SFASE/
ml) or LPS were collected and the concentration of IL-6, IL-10, TNF-α, IL-1ß and IL-12p70 was deter-
mined using ELISA. CoVaccine HT™ induced an increase of the secretion of IL-6, TNF-α, IL-1ß and 
IL-12p70, but not of IL-10 (Table 1). 
Effect of CoVaccine HT™ on human monocyte derived DCs
Human dendritic cells of three donors were incubated for 16-18 hours with PBS, CoVaccine HT™ (25, 
50, 100 and 200μg SFASE/ml) or LPS. After incubation, the expression of MHC-II, CD11c, CD80, CD83 
and CD86 on the surface of the cells was analyzed. After incubation with 50μg SFASE/ml of CoVac-
cine HT™, a marked increase of CD86 expression and a moderate increase of CD83 expression were 
observed on human DCs of all donors compared to incubation with PBS, while expression of CD80, 
MHC class II and CD11c was not increased. The use of higher concentrations of CoVaccine HT™ did 
not further increase the expression of CD83 and CD86. LPS, which was used as a positive control, 
induced a marked increase in the expression of CD80 and CD86 (Fig 4B).
Culture supernatants of human DCs incubated with PBS, CoVaccine HT™ (50 μg SFASE/ml) or LPS 
were also collected and the concentration of IL-6, IL-10, TNF-α, IL-1ß and IL-12p70 was determined 
using ELISA. CoVaccine HT™ increased the secretion of IL-6 and decreased the secretion of IL-10. The 
secretion of TNF-α, IL-1ß and IL-12p70 was essentially unaffected (Table 1). 
Effect of blocking anti-TLR antibodies on the CoVaccine HT™-induced cytokine secretion by hu-
mans DCs
To assess the possible involvement of TLR signaling in the adjuvant acitivity of CoVaccine HT™, an-
tibodies directed to TLR4 and TLR2 (both IgG2a) were used that can block the interaction of these 
TLRs with their respective ligands (236). As shown in figure 5A, treatment of human DCs with TLR4 
specific antibodies abrogated the CoVaccine HT™-induced IL-6 secretion almost completely by 
these cells, whereas TLR2 specific antibodies did not affect the secretion of IL-6 into the culture su-
pernatant. Similarly, the treatment of the DCs with TLR4 specific antibodies reversed the reduction 
of IL-10 secretion induced by CoVaccine HT™ in two out of three donors (figure 5B), whereas the 
Figure 4. Effect of CoVaccine HT™ 
on the phenotype of murine and hu-
man DCs. DCs were incubated with 
either PBS (grey area), CoVaccine 
HT™ (-) and LPS (---) and CD80 and 
CD86 expression of was monitored 
on murine DCs (A) and CD80, CD83 
and CD86 expression on human 
DCs (B). A representative example 
of at least three experiments with 
three human subjects or six mice is 
shown.
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use of TLR2 specific antibodies did not. The induction of IL-6 secretion by LPS, which was used as a 
positive control, was downregulated when the the human DCs were treated with a combination of 
the TLR4 and TLR2 specific antibodies, but not when these antibodies were used individually. Treat-
ment of DCs with isotype-matched control antibodies did not affect the CoVaccine HT™ induced 
changes in cytokine secretion (data not shown).  
Table 1. Effect of CoVaccine HT™  on the secretion of cytokines by murine and human DCs
Murine BM-mDCs Human DCs
Cytokine PBS CoVaccine HT™ LPS PBS CoVaccine HT™ LPS
TNF-α 176 (39) 8317 (2614) 1775 (1190) <4 7 (7) 779 (193)
IL-6 16 (11) 16003 (3822) 13739 (4368) 12 (13) 139 (81) 360 (63)
IL-10 <30 <30 <30 20 (6) <2 486 (162)
IL-12p70 20 (5) 1859 (376) 2081 (1750) <4 <4 11 (5)
IL-1ß <8 207 (67) 135 (16) <4 6 (2) 18 (13)
Effect of CoVaccine HT™ on the secretion of cytokines by murine bone-marrow derived DCs and human monocyte-
derived DCs. The secretion of cytokines was determined by ELISA using the culture supernatants of DCs incubated 
with PBS, CoVaccine HT™ or LPS. Results were acquired of at least three mice or human subjects. Indicated are mean 
cytokine concentrations (pg/ml) and in between brackets the standard deviations. 
DISCUSSION
In the present study, state of the art cell-culture vaccine production technology and the novel ad-
juvant CoVaccine HT™ were combined to formulate a whole inactivated virus vaccine preparation 
against A/H5N1 influenza viruses.  The use of CoVaccine HT™ increased the immunogenicity of 
the WIV vaccine prepared with the vaccine strain NIBRG-14 considerably and improved response 
rates and GMT antibody titers not only against the homologous strain A/Vietnam/1194/04, but also 
against the antigenically distinct strain A/Indonesia/5/05 derived from clade 2.1. [18]. The superior 
antibody responses induced with the aid of CoVaccine HT™ correlated with improved CD4+ T help-
er cell responses, which in turn, correlated with the stimulating effect of CoVaccine HT™ on profes-
sional antigen presenting cells in vitro. CoVaccine HT™ stimulated the expression of co-stimulatory 
molecules of mouse and human dendritic cells and the production of pro-inflammatory cytokines 
by these cells.
Early attempts to prepare H5N1 vaccines were based on the production method and formulation 
of seasonal influenza vaccines (237). However, these vaccines were poorly immunogenic and high 
doses of antigen were required for the induction of appreciable antibody responses (237, 238). The 
use of adjuvants MF59 and AS03, but not aluminium hydroxide, improved the immunogenicity of 
H5N1 vaccines prepared in embryonated chicken eggs and allowed dose-sparing (147-150, 239). 
For the induction of antibody titers that are considered protective (240, 241), usually two adminis-
trations of adjuvanted vaccine is required (147, 149). Of course a single immunization for the induc-
tion of protective antibody levels would be more ideal since the time that people are susceptible 
to infection can be limited which could save lives in case a pandemic occurs. Here we show that a 
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single dose of 5 µg HA of whole inactivated NIBRG-14 adjuvanted with CoVaccine HT™ induced a HI 
antibody response in all vaccinated mice with GMT against the homologous strain of >40, sufficient 
to meet the EMEA criteria for licensing (pre-pandemic) influenza vaccines (240). A second vacci-
nation with the same dose increased the HI and VN antibody levels. The addition of the adjuvant 
CoVaccine HT™ not only increased the magnitude of the antibody response but also the breadth of 
the response, since in most vaccinated mice antibodies were detected against the influenza virus 
A/Indonesia/5/05 obtained from the antigenically distinct clade of A/H5N1 viruses (clade 2.1).  This 
is of importance since it cannot be predicted which viruses ultimately may cause the next pan-
demic and broadly reactive antibodies may confer protection against a variety of different viruses.
In order to elucidate the mechanisms underlying the potent adjuvant effect of CoVaccine HT™, we 
also assessed the virus specific T cell responses. The virus-specific CD4+ T cell response induced 
after vaccination with WIV NIBRG-14 was analysed by intracellular cytokine staining using antibod-
ies against IL-2, IFN-Y, IL-4 and IL-5. Mainly IL-5, IFN-γ and IL-2 producing CD4+ T lymphocytes were 
detected, suggesting that both T helper 1 and T helper 2 cell responses were induced. Furthermore, 
the virus-specific CD4+ T cell responses observed in mice vaccinated with WIV and CoVaccine 
HT™seemed stronger than those observed in mice vaccinated with WIV only, although this differ-
ence was not statistically significant.
Vaccination with WIV NIBRG-14 induced a modest virus-specific CD8+ T cell response as assessed 
by tetramer staining using H-2Db tetramers containing the NP366-374 epitope from the vaccine back-
bone strain A/PR/8/34, which was still detectable 21 days after the second vaccination. Also others 
have demonstrated that with WIV vaccine preparation virus-specific CD8+ T cell responses can be 
induced (104, 242), most likely through cross-priming (139). However, compared to infection, vac-
cination with WIV induced virus-specific CD8+ T cell responses inefficiently and the addition of Co-
Vaccine HT™ to WIV NIBRG-14 did not increase the response of virus specific the CD8+ T cells. 
The potentating effect of CoVaccine HT™ on the induction of T helper cell responses could be ex-
plained by its effect on dendritic cells in vitro. CoVaccine HT™ induced the upregulation of CD80 
and CD86 expression on murine dendritic cells and CD83 and CD86 expression on human dendritic 
Figure 5. Effect of blocking anti-TLR antibodies on the CoVaccine HT™-induced cytokine secretion by humans DCs. 
Human DCs were either incubated with PBS, anti-TLR2 or anti-TLR4 and subsequently incubated o/n with (grey bars) 
or without (black bars) CoVaccine HT™. The concentration of IL-6 (A) and IL-10 (B) was determined in supernatants. 
Indicated are mean cytokine concentrations of three human subjects with standard deviations.
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cells in vitro and an increase in the release of pro-inflammatory cytokine TNF-α, IL-6, IL-10, IL-12p70 
and IL-1ß by murine DCs and IL-6 by human DCs. The secretion of IL-10 was reduced in hDCs in-
cubated with CoVaccine HT™. As IL-10 is known as a major anti-inflammatory cytokine (243, 244), 
CoVaccine HT™ may prevent an anti-inflammatory response induced by the secretion of IL-10 by 
human DCs. Results of experiments with MoAbs which block the signal transduction through either 
TLR2 and TLR4 showed that the effect of CoVaccine HT™ on the increased secretion of IL-6 and the 
reduced secretion of IL-10 by human DCs was blocked by the addition of MoAbs TLR4 and not TLR2. 
This indicates that the effect of CoVaccine HT™ was mediated by binding to the TLR4. Interestingly, 
no reduced expression of CD80 and CD86 was observed by the incubation with MoAbs against 
TLR2 and TLR4. This indicates that the effect of CoVaccine HT on human DCs can not completely 
attributed to binding to TLR4. The observed release of pro-inflammatory cytokines by both murine 
and human DCs indicate activation of DCs via a MyD88 or Trif dependent pathway, which is charac-
terized by expression of maturation markers and production of cytokines (245).  The upregulation 
of the co-stimulatory molecules on professional antigen presenting cells implies that this played a 
role in the induction of the strong T helper cell responses that were observed after vaccination with 
CoVaccine HT™ adjuvanted WIV NIBRG-14. 
Furthermore, intramuscular vaccination of mice with CoVaccine HT™ resulted in the enlargement 
of the inguinal lymph nodes eight days after vaccination. The macroscopic enlargements was as-
sociated with an increase in the numbers of various cell types, including CD4+ T cells, CD8+ T cells, 
DCs and B-cells as determined by flow cytometry (data not shown). This indicates that CoVaccine 
HT™ can provoke a pro-inflammatory response in vivo as well. Clinical dose-finding trials need to be 
performed to obtain information about the safety and optimal doses of CoVaccine HT™ for future 
use in humans.
In conclusion, the data presented here show that the use of the adjuvant CoVaccine HT™ increases 
the virus-specific antibody response against a whole inactivated influenza A/H5N1 antigen pre-
pared in cell culture. The addition of CoVaccine HT™ to the vaccine slightly improved the CD4+ T 
cell-, but not the CD8+ T cell response and up regulated the expression of co-stimulatory molecules 
and the production of pro-inflammatory cytokines by dendritic cells. Since the effect on dendritic 
cells, which may be at the basis of the adjuvant effect of CoVaccine HT™ on T helper cell and an-
tibody responses, was also observed with human dendritic cells, it is anticipated that the use of 
CoVaccine HT™ may also enhance the antibody response to vaccination with a whole inactivated 
influenza A/H5N1 virus vaccine in humans. 
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ABSTRACT
Highly pathogenic avian influenza A viruses of the H5N1 subtype continue to circulate in poul-
try and zoonotic transmissions are reported frequently. Since a pandemic caused by these highly 
pathogenic viruses is still feared, there is interest in the development of influenza A/H5N1 virus 
vaccines that can protect humans against infection, preferably after a single vaccination with a low 
dose of antigen. Here we describe the induction of humoral and cellular immune responses in fer-
rets after vaccination with a cell-culture derived whole inactivated influenza A virus vaccine in com-
bination with the novel adjuvant CoVaccine HT™. The addition of CoVaccine HT™ to the influenza A 
virus vaccine increased antibody responses to homologous and heterologous influenza A/H5N1 vi-
ruses and increased virus-specific cell-mediated immune responses. Ferrets vaccinated once with a 
whole-virus equivalent of 3.8 μg HA and CoVaccine HT™ were protected against homologous chal-
lenge infection with influenza virus A/VN/1194/04. Furthermore, ferrets vaccinated once with the 
same vaccine/adjuvant combination were partially protected against infection with a heterologous 
virus derived from clade 2.1 of H5N1 influenza viruses. Thus,  the use of the novel adjuvant CoVac-
cine HT™ with cell culture derived inactivated influenza A/H5N1 antigen is a promising and dose 
sparing vaccine approach warranting further clinical evaluation.
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INTRODUCTION
Since the first human case of infection with a highly pathogenic avian influenza A virus of the H5N1 
subtype in 1997 (17, 18, 103) hundreds of zoonotic transmissions have been reported with a high 
case-fatality rate (17, 246). Since these viruses continue to circulate among domestic birds and hu-
man cases are regularly reported, it is feared that they will adapt to their new host or exchange 
gene segments with other influenza A viruses, become transmissible from human-to-human and 
cause a new pandemic. Recently, a novel influenza A virus of the H1N1 subtype emerged. This virus, 
which originated from pigs, was transmitted between humans efficiently, resulting in the first influ-
enza pandemic of the 21st century (247, 248). Although millions of people have been inoculated 
with the (H1N1) 2009 virus, compared to infections with the H5N1 viruses, the case-fatality rate was 
relatively low (249, 250). However, the unexpected pandemic caused by influenza A/H1N1(2009) 
viruses, has further highlighted the importance of rapid availability of safe and effective pandemic 
influenza vaccines. Other key issues for the development of pandemic influenza A virus vaccines 
include optimal use of the existing (limited) production capacity of viral antigen and effectiveness 
against viruses that are antigenically distinct. Ideally, a single administration of a low dose of anti-
gen would be sufficient to induce protective immunity against the homologous strain and heter-
ologous antigenic variant strains. However, since the population at large will be immunologically 
naïve to a newly introduced virus, high doses of antigen are required to induce protective immu-
nity in un-primed subjects (149, 226). The use of safe and effective adjuvants in pandemic influenza 
vaccines is considered as a dose-sparing strategy. Clinical trials evaluating candidate inactivated 
influenza A/H5N1 vaccines showed that the use of adjuvants can increase their immunogenicity 
and broaden the specificity of the induced antibody responses (147-150, 226, 239, 251). These re-
search efforts have resulted in the licensing of adjuvanted vaccines against seasonal and pandemic 
influenza (252). The protective efficacy of immune responses induced with candidate influenza A/
H5N1 vaccines was demonstrated in ferrets after two immunizations (68, 253-255) or after a single 
immunization. The latter was achieved with a low dose of antigen in combination with the adjuvant 
ISCOMATRIX (256).  
Recently, a novel adjuvant has been developed that consists of a sucrose fatty acid sulphate ester 
(SFASE) immobilized on the oil droplets of a submicron emulsion of squalane-in-water (228). It has 
been demonstrated that the addition of this novel adjuvant, called CoVaccine HT™, to multiple an-
tigens increased the immune response to these antigens in pigs and horses and was well tolerated 
in both-species (228-230). Furthermore, it was shown that the use of CoVaccine HT™ increased the 
virus-specific antibody responses in mice and ferrets after vaccination with a cell culture-derived 
whole inactivated influenza A/H5N1 virus vaccine (231, 257). One of the mode of actions of CoVac-
cine HT™ is the activation of antigen presenting cells like dendritic cells, most likely through TLR-4 
signaling (257).
In the present study,  we evaluated the protective potential of CoVaccine HT™-adjuvanted cell-cul-
ture derived whole inactivated influenza A/H5N1 (WIV) vaccine in the ferret model, which is consid-
ered the most suitable animal model for the evaluation of candidate influenza vaccines (166, 258, 
259). To this end, ferrets were vaccinated once or twice with various antigen doses with or without 
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the adjuvant to test if dose-sparing could be achieved. The use of CoVaccine HT™ increased virus 
specific antibody responses and T cell responses. A single administration of 3.8µg hemagglutinin 
of WIV NIBRG-14 vaccine-preparation in combination with CoVaccine HT™ conferred protection 
against challenge infection with the homologous highly pathogenic A/H5N1 strain A/VN/1194/04 
and partial protection against infection with a heterologous, antigenically distinct strain, A/
IND/5/05. Therefore, it was concluded that the use of CoVaccine HT™ in inactivated influenza vac-
cines induced protective virus specific humoral and cell mediated immune responses and could be 
suitable as adjuvant in (pre)pandemic A/H5N1 vaccines. Further clinical testing of these candidate 
vaccines seems warranted.
MATERIALS AND METHODS
Vaccine and adjuvant formulations
The vaccine strain NIBRG-14 (H5N1), based on strain A/Vietnam/1194/04 (H5N1, clade 1) was used 
to prepare a whole inactivated influenza A virus (WIV NIBRG-14) vaccine. The vaccine was produced 
in Madin-Darby Canine Kidney (MDCK; European Collection of Cell Cultures, London, UK) cells and 
inactivated using beta-propiolactone on a commercial scale by Nobilon Schering-Plough (Boxmeer, 
The Netherlands). The hemagglutinin content was assessed by a single radial immunodiffusion as-
say according to standard methods (233). CoVaccine HT™ is a proprietary adjuvant of Protherics 
Medicines Development Ltd., a BTG Company London, United Kingdom. The optimal dose of Co-
Vaccine HTTM in ferrets was determined by Nobilon Schering-Plough, Boxmeer, The Netherlands 
before the start of this experiment (data not shown).
Influenza A viruses
Virus stocks of influenza viruses A/Vietnam/1194/2004 (H5N1, clade 1) and A/Indonesia/5/2005 
(H5N1, clade 2.1) were prepared by propagation in confluent MDCK cells. After cytopathologic 
changes were complete, culture supernatants were cleared by low speed centrifugation and stored 
at −70°C. Infectious virus titers were determined in MDCK cells as described previously (85). All ex-
periments with these viruses were performed under Bio Safety Level (BSL)-3 conditions.
Ferrets
Healthy young adult outbred female ferrets (Mustela putorius furo; between 6 and 12 months old) 
were purchased from a commercial breeder. Ferrets were screened for the presence of antibodies 
against circulating influenza A/H1N1 and A/H3N2 viruses and the influenza A/H1N1(2009) virus by 
hemagglutination inhibition assay. Ferrets that were tested negative for these viruses were used in 
this experiment. An independent animal ethics committee (DEC consult) approved the experimen-
tal protocol before the start of the experiments. 
Immunizations and inoculations
Thirty-six sero-negative ferrets were divided into six groups of 6 ferrets and vaccinated with either 
one dose of 3.8 μg HA-content of WIV NIBRG-14 in combination with CoVaccine HT™ (2 mg SFASE; 
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group S3.8+), one dose of 15μg HA-content of WIV NIBRG-14 in combination with CoVaccine HT™ 
(2 mg SFASE; group S15+), two doses of 3.8 μg HA-content of WIV NIBRG-14 in combination with 
CoVaccine HT™ (2 mg SFASE; group T3.8+), two doses of 3.8 μg HA-content of the WIV NIBRG-14 
only (group T3.8-), two doses of phosphate buffered saline (group PBS ), or two doses of CoVaccine 
HT™ (2 mg SFASE; Cve). Groups are listed in table 1. Vaccinations were performed under anesthe-
sia with ketamine in the quadriceps muscles of the left hindleg in a total volume of 0.5 ml. Fer-
rets that received two immunizations were vaccinated with an interval of four weeks, while ferrets 
that received only one immunization were vaccinated with PBS at the moment of the first vacci-
nation of ferrets receiving two vaccinations. During vaccination experiments, ferrets were housed 
in groups and received food and water ad-libitum. Four weeks after the (last) immunization, the 
animals were anesthesized with ketamine/medetomidine (reversed with atipamezole), weighed 
and subsequently inoculated intratracheally with 1x105 TCID50 influenza A/VN/1194/04 (H5N1) vi-
rus in a total volume of 3 ml PBS. After inoculation, ferrets were monitored three times daily for the 
development of clinical signs. Before inoculation and two and four days after inoculation, throat 
swabs of each ferret were collected while the ferrets were anesthesized with ketamine. Four days 
after inoculation, animals were weighed and subsequently killed by exsanguination while under 
anesthesia with ketamine and medetomidine. In previous experiments, it has been demonstrated 
that inoculated ferrets start to lose weight as early as one day after infection and continue to lose 
weight as disease progresses (166, 167). It was anticipated that also during the course of our experi-
ments the maximum weight loss was at day 4 post inoculation and therefore the difference in body 
weight between the day of inoculation and 4 days post inoculation was considered to be a good 
clinical indicator for protection against the development of disease.
Necropsies were performed according to standard procedures. After finishing this experiment, the 
experiment was repeated following exactly the same procedure (n=6 animals per group) except 
that ferrets were challenged with 1x105 TCID50 of influenza A/IND/5/05 (H5N1) virus. Because no 
differences were observed between mock-vaccinated ferrets and ferrets vaccinated with CoVaccine 
HT only (group Cve) in the first experiment, the latter group was omitted in the second experiment 
to reduce the number of animals. One ferret of the group that was vaccinated twice with 3.8 µg HA 
of WIV NIBRG-14 (T3.8-) died between the second vaccination and inoculation with influenza virus 
A/IND/5/05 due to reasons unrelated to the experiment.
Table 1. Overview of vaccination regimens in this study
Group Number of
immunizations
WIV NIBRG-14 
(µg HA-content)
CoVaccine HT™ 
(2mg SFASE)
S3.8+ 1 3.8 +
S15+ 1 15 +
T3.8+ 2 3.8 +
T3.8- 2 3.8 -
PBS 2 - -
CVe 2 - +
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Serology
Serum samples were collected before, twenty-eight days after the first and twenty-eight days after 
the second vaccination. Sera were stored at –20°C until use. Sera were tested for the presence of 
anti-HA antibodies using a hemagglutination inhibition assay (HI-assay) with 1% turkey erythro-
cytes and for the presence of virus neutralizing antibodies using a micro virus neutralization as-
say (VN-assay) as described previously (87, 107). Sera were tested for the presence of antibodies 
reactive with influenza A/H5N1 viruses A/VN/1194/04 and A/IND/5/05. For this purpose, reverse 
genetics viruses of both viruses were produced. The titers obtained with these viruses were com-
parable with those against the wild-type strains (data not shown). A hyperimmune rabbit serum to 
influenza strain A/Tern/South Africa/1/63  and serum obtained from a swan immunized twice with 
inactivated H5N1 influenza virus A/Duck/Potsdam/1402/86 (Intervet, Boxmeer, The Netherlands) 
(89) were used as positive control sera specific for influenza viruses A/VN/1194/04 and A/IND/5/05, 
respectively .
T cell proliferation assay
Blood samples were collected from the jugular vein of ferrets before, twenty-eight days after the first 
vaccination and twenty-eight days after the second vaccination in EDTA-tubes (Greiner Bio-One, Al-
phen a/d Rijn, The Netherlands). Peripheral blood mononuclear cells were isolated by density gradi-
ent centrifugation using lymphoprep (Axis-Shield PoC AS, Oslo, Norway) and then cryopreserved 
at -135°C until use. Thawed PBMC were washed twice with PBS, labeled with 0.3µM carboxyfluo-
rescein diacetate succinimidyl ester (CFSE) in PBS (Invitrogen, Breda, The Netherlands) for five min-
utes at 37°C, washed twice and subsequently cells were resuspended in RPMI 1640 (Cambrex, East 
Rutherford, USA) containing 10% (v/v) fetal calf serum, penicillin (100 μg/ml), streptomycin (100 U/
ml), L-glutamine (2mM). Cells were seeded (105 cells per well) in a 96-well round-bottom plate in 
the presence or absence of WIV NIBRG-14 (200ng HA content) or phytohaemagglutinin (PHA) (1 µg/
ml) and incubated at 37°C/5% CO2 for six days. For each condition duplicate samples were tested. 
Two days after stimulation, 100μl supernatant of Concanavalin A-stimulated ferret lymph node cells 
was added, which was prepared essentially as described previously (160). After the remaining four 
days of incubation, cells were transferred to a 96-wells V-bottom plate, washed and subsequently 
stained with a monoclonal antibody directed to human CD8 (OKT-8)-Pacific Blue (eBioscience, San 
Diego, USA). To exclude dead cells in the analysis, cells were also stained with LIVE/DEAD Aqua Fix-
able Dead Cell Stain (Invitrogen, Breda, The Netherlands). Cells were subsequently fixed and perme-
abilized with Cytofix and Cytoperm (BD Pharmingen, Alphen a/d Rijn, The Netherlands) and stained 
with a Alexa Fluor 647-labelled monoclonal antibody specific for human CD3 (PC3/188A) (Santa 
Cruz Biotechnology, Santa Cruz, USA). It has been demonstrated that these CD3 and CD8-specific 
monoclonal antibodies are cross-reactive with ferret CD3 and CD8 (260, 261). Data were acquired 
using a FACSCanto-II and analysed with FACS Diva software (BD). The proliferation of PBMC from 
at least 9 ferrets of each group was assessed in this assay, except for group Cve, since this group 
only contained six ferrets. The proliferation of CD3+CD8- cells was calculated by subtracting the 
mean number of CD3+CD8-CFSElow cells of the medium only controls from the mean number of 
CD3+CD8-CFSElow cells stimulated with WIV NIBRG-14. The same calculation was performed for 
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CD3+CD8+ cells.
Virus titers of lungs and throat swabs
Samples of all lobes of the right lung and the accessory lobe of inoculated ferrets were collected 
and snap frozen on dry ice with ethanol and stored at –70°C until further processing. Lung samples 
were weighed and subsequently homogenized with a FastPrep-24 (MP Biomedicals, Eindhoven, 
The Netherlands) in Hank’s balanced salt solution containing 0.5% lactalbumin, 10% glycerol, 200 
U/ml penicillin, 200 μg/ml streptomycin, 100 U/ml polymyxin B sulfate, 250 μg/ml gentamycin, and 
50 U/ml nystatin (ICN Pharmaceuticals, Zoetermeer, The Netherlands) and centrifuged briefly. 
After collection of throat swabs, swabs were stored at -70°C in the same medium as used to homog-
enize lung samples. Quadruplicate 10-fold serial dilutions of both throat and lung samples were 
used to infect MDCK cells as described previously (85). HA activity of the culture supernatants col-
lected 5 days post infection was used as indicator of infection. The titers were calculated according 
to the Spearman-Karber method and expressed as log TCID50 per gram for lung tissue or per mil-
liliter (ml) for swabs (108). 
Histopathology and immunohistochemistry
Four days after inoculation with influenza A/VN/1194/04 and A/IND/5/05 virus, ferrets were eutha-
nized and lungs were observed macroscopically and weighed before samples from the right lungs 
were collected to determine the virus titers. Subsequently left lung lobes were inflated with 10% 
neutral buffered formalin. After fixation and embedding in paraffin, lungs were sectioned at 4 μm 
and tissue sections were examined by staining with hematoxylin and eosin (HE). Using an immu-
noperoxidase method, serial lung tissue sections were also stained with a monoclonal antibody 
directed against the nucleoprotein of the influenza A virus (110). 
Statistical analysis
The presence of overall statistical significant differences between groups regarding weight loss, 
the number of CFSElow cells, percentage of affected areas in the lungs, viral load in the lungs and 
throat swab specimens was calculated using the Kruskal-Wallis test. Before individual When calcu-
lated P values were less than an α of 0.05, data of each group was individually compared with data 
from the PBS group using the Games-Howell test. Differences were considered significant when P 
values were less than an α of 0.05. The number of CFSElow cells were converted to 10log values be-
fore statistical analysis was performed. 
RESULTS
Antibody responses after vaccination 
To assess antibody responses after vaccination with various NIBRG-14 antigen/CoVaccine HT™ com-
binations, pre- and post-vaccination ferret sera were tested for the presence of antibodies against 
influenza viruses A/VN/1194/04 and A/IND/5/05 by HI and VN-assay. Like in mock-vaccinated ferrets 
(group PBS) and ferrets receiving CoVaccine HT™ only (group Cve), virus-specific antibodies were 
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not detectable by HI or VN assay in ferrets that received two vaccinations with 3.8µg un-adjuvanted 
WIV NIBRG-14 (group T3.8-) (Table 2). In contrast, a single immunization with as little as 3.8 µg HA of 
WIV NIBRG-14 adjuvanted with CoVaccine HT™ (group S3.8+) induced HI and VN antibodies against 
the homologous virus in seven and eight out of twelve animals respectively. The geometric mean 
antibody titers were low (24 and 9, respectively) and only in a small number of ferrets, antibod-
ies against the heterologous virus A/IND/5/05 were detected. Increasing the antigen dose did not 
improve the serological outcome of vaccination. Five out of 12 ferrets receiving a single dose of 15 
µg WIV NIBRG-14 with CoVaccine HT™ (group S15+), developed antibodies against influenza virus 
A/VN/1194/04. The serum of one of these animals displayed cross-reactivity with the heterologous 
influenza virus A/IND/5/05.
All twelve ferrets that received two immunizations of 3.8µg HA of NIBRG-14 with CoVaccine HT™ 
(group T3.8+) developed antibodies against influenza virus A/VN/1194/04 as detected by HI-  (GMT 
86) and the VN assay (GMT 65) 28 days after the second immunization. The serum antibodies of 
these twelve animals cross-reacted with the heterologous influenza virus A/IND/5/05 as detected 
by the VN assay (GMT 38). By HI assay, cross-reactive antibodies were detected in six out of the 
twelve serum samples (GMT 30).
Table 2.  Antibody responses four weeks after the second immunization 
Group Antibody titers against A/VN/1194/04 Antibody titers against A/IND/5/05
HI GMT 
(sd)
Re-
spond-
ers
VN
GMT (sd)
Re-
spond-
ers
HI GMT 
(sd)
Re-
spond-
ers
VN GMT  
(sd)
Re-
spond-
ers
S3.8+ 24 (22) 7/12 9 (4) 8/12 <10 1/12 <10 2/12
S15+ 13 (12) 5/12 9 (6) 5/12 <10 1/12 <10 1/12
T3.8+ 86 (21) 12/12 65 (23) 12/12 30 (30) 6/12 38 (21) 12/12
T3.8- <10 0/11 <10 0/11 <10 0/11 <10 0/11
PBS <10 0/12 <10 0/12 <10 0/12 <10 0/12
Cve <10 0/6 <10 0/6 <10 0/6 <10 0/6
Vaccine-induced T cell responses
To assess the induction of T cell immunity after vaccination, PBMC of the ferrets collected before 
the first vaccination, 28 days after the first and 28 days after the second vaccination were labeled 
with CFSE and subsequently stimulated with WIV NIBRG-14 antigen, PHA or were left untreated 
(medium control). The number of CSFE low cells was determined in the CD3+CD8- and CD3+CD8+ 
cell population as shown in figure 1A.
Viral antigen specific proliferation was virtually undetectable with PBMC collected before the im-
munization of the ferrets. PBMC obtained from mock-vaccinated ferrets or from those vaccinated 
with CoVaccine HT™ only responded to stimulation with NIBRG-14 antigen very poorly. In contrast, 
PBMC obtained from ferrets vaccinated with NIBRG-14 proliferated upon in vitro re-stimulation 
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with viral antigen, whereas CSFElow cells were virtually absent in un-stimulated PBMC obtained 
from any of the ferrets (medium controls). The latter numbers were substracted from the number 
of antigen or PHA-stimulated PBMC to asses the number of cells that proliferated upon stimula-
tion. Increased numbers of CFSElow CD3+CD8- cells and CFSElow CD3+CD8+ cells were observed 
in PBMC of ferrets after stimulation with PHA compared to the stimulation with medium only. Fur-
thermore, the numbers of CFSElow CD3+CD8- and CFSElow CD3+CD8+ cells after PHA stimulation 
did not differ between ferrets from groups S3.8+, S15+, T3.8+, T3.8- and Cve in mock-vaccinated 
ferrets (data not shown). 
Antigen-specific proliferation of CD3+CD8- cells was observed in PBMC collected from ferrets 
of groups S3.8+, S15+, T3.8+ and T3.8-. The in vitro proliferative response of ferrets from groups 
S3.8+, S15+ and T3.8+ was significantly stronger than that of mock-vaccinated animals (p-values 
below 0.01) for all three groups compared to mock-vaccinated group, while differences between 
ferrets vaccinated twice with WIV NIBRG-14 without CoVaccine HT™ and mock-vaccinated ani-
mals approached statistical significance (p=0.08). In addition, the in vitro proliferative response 
of CD3+CD8- cells obtained from ferrets that received two immunizations of 3.8 µg HA of WIV NI-
BRG-14 with CoVaccine HT™ compared to ferrets that received 3.8 µg HA of WIV NIBRG-14 twice 
without CoVaccine HT™ also approached statistical significance (p=0.06) (Fig 1B). With PBMC ob-
tained from ferrets of groups S15+ and T3.8+, a virus-specific proliferative response of CD3+CD8+ 
cells was observed (Fig 1C), that was significantly stronger than that of mock-vaccinated ferrets (p-
values of respectively 0.03 and 0.01). Furthermore, proliferative responses of CD3+CD8+ cells ob-
tained from ferrets that received two immunizations of 3.8 µg HA of WIV NIBRG-14 with CoVaccine 
HT™ was significantly stronger than that of ferrets that received 3.8 µg HA of WIV NIBRG-14 twice 
without CoVaccine HT™ (p=0.03). Like CD3+CD8+ cells obtained from mock-vaccinated ferrets, also 
those from animals vaccinated with CoVaccine HT™ only responded to NIBRG-14 antigen poorly. 
Clinical signs after inoculation with influenza viruses A/VN/1194/04 and A/IND/5/05
From day 3 post inoculation with influenza viruses A/VN/1194/04 and A/IND/5/05 onwards, severe 
clinical signs were observed in mock-vaccinated ferrets and those vaccinated with CoVaccine HT™ 
only (group Cve)  or with WIV NIBRG-14 only (group T3.8-), and included breathing difficulties, leth-
argy, decreased appetite and weight loss.
In contrast, only mild clinical signs were observed after inoculation with influenza virus A/
VN/1194/04 in ferrets immunized once with 3.8 μg NIBRG-14 and CoVaccine HT™ (S3.8+), once 
with 15 µg NIBRG-14 and CoVaccine HT™ (S15+) or twice with 3.8 μg NIBRG-14 and CoVaccine HT™ 
(T3.8+). In these groups moderate clinical signs were observed after inoculation with influenza vi-
rus A/IND/5/05 (H5N1). One ferret vaccinated with CoVaccine HT™ died in the night between day 
three and four post inoculation with influenza virus A/VN/1194/04 and one mock-vaccinated ferret 
succumbed two days post inoculation with influenza virus A/IND/5/05. No mortality was observed 
in other groups. The relative loss in body weight four days post inoculation was calculated for each 
ferret. The mean weight loss of each group was used as a quantative clinical indicator of disease 
upon inoculation with influenza viruses A/VN/1194/04 and A/IND/5/05. Following inoculation with 
influenza virus A/VN/1194/04 (Fig 2A), all ferrets lost body weight, except one animal vaccinated 
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twice with 3.8 µg NIBRG-14 and CoVaccine HT™. The highest mean weight loss was observed in 
ferrets of groups S15+ (12%), T3.8- (11%), PBS (11%) and Cve (13%), while ferrets of groups S3.8+ 
and T3.8+ lost 3% and 2% of their body weight respectively, significantly less than mock-vaccinated 
ferrets (p-values respectively 0.02 and 0.04). After inoculation with influenza virus A/IND/5/05 (Fig 
2B), all ferrets lost body weight. The mean weight loss of ferrets in groups PBS (mock-vaccinated), 
T3.8- , S3.8+, S15+, T3.8+ was 13%, 14%,  9%, 10% and 8%, respectively. No statistically significant 
differences were observed between groups. 
Virus titers in pharyngeal swabs
To assess the extent of virus replication in the upper respiratory tract after inoculation with both in-
fluenza A/H5N1 viruses, pharyngeal swabs were collected before and on day 2 and 4 after inocula-
tion and tested for the presence of virus. No virus was detected in any of the swabs collected before 
inoculation (data not shown). On day 2 and 4 post inoculation with influenza virus A/VN/1194/04, 
virus was not detected in pharyngeal swabs obtained from ferrets of groups 3.8+, S15+ and T3.8+, 
while those obtained from ferrets of T3.8-, PBS and Cve all tested positive at day 2 with mean virus 
titers of 104.4, 103.7 and 103.4 TCID50/ml respectively (Fig 3A). Four days post inoculation these swabs 
Figure 1. T cell immune responses after vaccination of fer-
rets. The proliferation of CD3+CD8- and CD3+CD8+ cells 
was measured by a CFSE dilution assay. As an example 
the results obtained with PBMC of two ferrets are shown 
(A), one mock-vaccinated ferret and one ferret vaccinated 
twice with 3.8µg HA of WIV and CoVaccine HT™ (T3.8+). 
The scale of the y-axis differs between graphs. PBMC of 
the non-immune ferret respond to PHA only, while PBMC 
of the immune ferret responded to stimulation with WIV 
NIBRG-14 and with PHA. The number of CD3+CD8- cells 
responding to WIV NIBRG-14 was calculated by subtract-
ing the mean number of CD3+CD8-CFSElow cells incubated with medium from the mean number of CD3+CD8-CF-
SElow cells incubated with WIV NIBRG-14 (B). The same procedure was used to calculate the number of responding 
CD3+CD8+ cells (C). The number of ferrets of each group tested in this assay differed between the respective groups, 
group Cve (n=6), group T3.8- (n=9), groups T3.8+ and PBS (n=10) and groups S3.8+ and S15+ (n=12). Significant dif-
ferences compared to the mock-vaccinated group are indicated by one (p<0.05) or two asterisks (p<0.01).
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also tested positive with mean virus titers of 104.0, 104.9, and 105.1 TCID50/ml, respectively. Following 
inoculation with influenza virus A/IND/5/05, similar results were obtained. Two and four days post 
inoculation, no virus was detected in pharyngeal swabs collected from ferrets of groups S3.8+ and 
T3.8+, while virus was detected in only one ferret of group S15+ on day 2 and 4 post inoculation. All 
swabs obtained from ferrets of groups T3.8- and PBS tested positive with mean virus titers of 103.9 
and 104.3 TCID50/ml two days post inoculation and 104.1 and 105.5 TCID50/ml four days post inocula-
tion, respectively (Fig 3B).
Virus detection in the lungs
Lungs of ferrets euthanized four days after inoculation and the lungs of the mock-vaccinated fer-
ret that died two days after inoculation were tested for the presence of infectious virus. After in-
oculation with influenza virus A/VN/1194/04, virus was detected in lungs of all ferrets of the T3.8-, 
PBS and Cve groups with mean titers of 105.5, 106.7, 106.5 TCID50/gram lung respectively (Fig 3C). The 
mean virus titer in lungs of ferrets vaccinated twice with 3.8 μg of WIV NIBRG-14 only were (10-fold) 
lower than mock-vaccinated ferrets, although differences were not significant (p=0.17). In contrast, 
after inoculation with influenza virus A/VN/1194/04, no virus was detected in lungs of ferrets vac-
cinated once or twice with 3.8 μg WIV NIBRG-14 and CoVaccine HT™ (S3.8+ and T3.8+), while in 
only two out of six ferrets vaccinated with 15 μg WIV NIBRG-14 and CoVaccine HT™ (S15+) low titers 
were detected in the lungs, which was significantly lower than mock-vaccinated animals (p<0.01 
for all three groups). After inoculation with influenza virus A/IND/5/05, lungs of all ferrets tested 
positive by virus isolation, except for one ferret of group T3.8+. The virus titers in lungs of ferrets of 
group T3.8- were not significantly different from those in lungs of mock-vaccinated ferrets (p=0.99) 
(titers of 107.4 and 107.0 TCID50/gram lung respectively). In contrast, the mean lung virus titers of 
ferrets of groups S3.8+ (104.7 TCID50/gram), S15+ (105.4 TCID50/gram) and T3.8+ (103.8 TCID50/gram) 
were significantly lower (p<0.01, p<0.01 and p=0.03 respectively) than those of mock-vaccinated 
ferrets and ferrets of group S3.8- (Fig 3D). 
Figure 2. Weight loss after inoculation with influenza A/VN/1194/04 and A/IND/5/05 viruses. The loss of body weight 
four days p.i. was determined for each ferret relative to the body weight at the day of inoculation (%). For each group, 
the mean weight loss ± s.d. after inoculation with influenza A/VN/1194/04 (A) and A/IND/5/05 (B) was calculated. Bars 
represent mean weight loss of each group with standard deviations. Significant differences compared to the mock-
vaccinated group are indicated by an asterisk (p<0.05).
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Four days after inoculation with influenza viruses A/VN/1194/04 or A/IND/5/05, ferrets were eutha-
nized and lungs were examined macroscopically and weighed before assessing virus replication 
and histopathological changes. Macroscopically, dark red and firm consolidated areas were present 
in lungs of inoculated animals. The percentage of affected lung tissue was estimated and varied 
significantly between different groups of animals. In lungs obtained from ferrets of groups S3.8+, 
S15+ and T3.8+  affected areas were significantly smaller than in lungs of mock-vaccinated animals 
(p-values for all groups <0.01) (Fig 4A and 4B). The extent of consolidation was more pronounced in 
lungs of ferrets from group S15+ than in those from group S3.8+, especially after inoculation with 
influenza virus A/IND/5/05, although no significant differences were present between these two 
groups (p=0.09).
After inoculation with influenza A/VN/1194/04 virus, the mean relative lung weight was highest in 
groups T3.8- (1.6% of body weight ± 0.4), PBS (1.8% ± 0.2), Cve (1.7% ± 0.2), while that of groups 
S3.8+ (1.0 ± 0.2), S15+ (1.0 ± 0.2) and T3.8+  (1.0 ± 0.1) was significant lower than that of mock-vacci-
Figure 3. Virus titers of pharyngeal swabs and lungs after inoculation with influenza A/VN/1194/04 and A/IND/5/05 
virus. Virus titers were determined in pharyngeal swabs obtained 2 (grey bars) and 4 days (black bars) after inocula-
tion with influenza A/VN/1194/04 (A) and influenza A/IND/5/05 (B). Virus titers are expressed as TCID50 per milliliter 
(log10). The plus sign indicates that no virus was detected in pharyngeal swabs obtained from ferrets of groups S3.8+, 
S15+ and T3.8+ after inoculation with influenza A/VN/1194/04 virus and from ferrets of groups S3.8+ and T3.8+ after 
inoculation with influenza A/IND/5/05 virus resulting in a mean virus titer below the cut-off value. Lung virus titers 
were determined four days after inoculation with influenza A/VN/1194/04 (C) and influenza A/IND/5/05 (D) virus. Vi-
rus titers are expressed as the TCID50 per gram lung (log10). The dotted line indicates the cut-off value for obtaining 
a positive result. Significant differences compared to the mock-vaccinated group are indicated by one (p<0.05) or two 
asterisks (p<0.01).
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nated ferrets (p-values for all groups <0.01) (Fig 4C) Similar results were observed after inoculation 
with influenza virus A/IND/5/05. Again, the highest relative lung weight was observed in groups 
T3.8- (2.0 ± 0.3) and PBS (1.7 ± 0.2). The mean relative lung weight of groups S3.8+ (1.1 ± 0.1), S15+ 
(1.3 ± 0.1) and T3.8+ (1.1 ± 0.1) was significant lower (p-values <0.01, 0.03 and 0.01 respectively) 
than that of mock-vaccinated ferrets (Fig 4D).    
Histopathologic findings in lungs after inoculation
Upon inoculation with either influenza virus A/VN/1194/04 or A/IND/5/05, ferrets of groups T3.8-, 
PBS and Cve developed a moderate to severe broncho-interstitial pneumonia. Multifocally in the 
alveoli, the lumina contained many macrophages and neutrophils mixed with variable numbers 
of erythrocytes, edema fluid and fibrin; the alveolar septa also contained many macrophages and 
neutrophils and showed moderate hypertrophy and hyperplasia of type II pneumocytes (Fig 5A 
and B). Multifocally in the bronchioles and bronchi, the walls had loss of epithelium and the lumina 
contained cell debris. In addition, the walls of bronchioles, and bronchi contained multifocal many 
macrophages and neutrophils. A few macrophages, lymphocytes, plasmacytes, and occasional 
Figure 4. Gross pathological changes after inoculation with influenza A/H5N1 viruses. The percentage lung tissue 
displaying consolidation at necropsy of the ferrets was estimated for all ferrets of each group after inoculation with 
influenza virus A/VN/1194/04 (A) and A/IND/5/05 (B). Lungs of all ferrets of each group were also weighed after nec-
ropsy and the weight of the lungs was related to the body weight of the ferrets four days after inoculation which is 
shown as a percentage for ferrets inoculated with influenza virus A/VN/1194/04 (C) and A/IND/5/05 (D). Bars represent 
relative lung weight of each group with standard deviations (BW =body weight). Significant differences compared to 
the mock-vaccinated group are indicated by one (p<0.05) or two asterisks (p<0.01).
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neutrophils were present in perivascular and peribronchiolar tissue (Fig 5C). 
In contrast, upon inoculation with either of the two above viruses, ferrets of groups S3.8+, S15+ and 
T3.8+ developed only a mild to moderate broncho-interstitial pneumonia. Compared to the above 
lesion, fewer and smaller areas of lung parenchyma were affected, there were fewer inflammatory 
cells in alveoli and bronchioles, and there was less severe edema (Fig 5D). However, there was more 
prominent peribronchiolar and perivascular, and also peribronchial infiltration with many lympho-
cytes and plasmacytes and occasional macrophages and neutrophils. Also, bronchus-associated 
lymphoid tissue was present in the lungs of these ferrets Fig 5E and F). Upon infection with either 
of the two viruses, ferrets in the S15+ group had more severe broncho-interstitial pneumonia than 
ferrets in S3.8+ and T3.8+ groups. This increased severity was characterized by both a greater ex-
tent of necrosis and inflammation, and by a higher number of inflammatory cells. 
Detection of virus-infected cells by immunohistochemistry
By immunohistochemistry, influenza virus antigen expression of cells in the lung tissue was as-
sessed. After inoculation with influenza A/VN/1194/04 virus, numerous virus-infected cells were
present in the lungs of mock-vaccinated ferrets or ferrets vaccinated with 3.8µg HA WIV NIBRG-14 
only or CoVaccine HT™ only (Fig 6A and B). The infected cells were predominantly observed in af-
fected areas of the lungs. Inoculated cells were only found sporadically in the lungs of ferrets of 
groups S3.8+, S15+ and T3.8+ (Fig 6C and D).  After inoculation with influenza A/IND/5/05 virus, 
virus-inoculated cells were present widespread in lungs of ferrets of groups PBS and Cve (Fig 6E and 
Figure 5. Examples of histopathologic findings in lungs after inoculation with influenza A/VN/1194/04 and A/
IND/5/05. Histopathologic changes in the lungs of ferrets of groups T3.8-, Cve and PBS inoculated with either influenza 
virus A/VN/1194/04 or influenza A/IND/5/05 included multiple large areas of severe alveolitis with proteinaceous fluid 
(edema) (A) and the presence of an inflammatory infiltrate consisting mainly of neutrophils and macrophages, cel-
lular debris and erythrocytes (B). In the bronchioles, there was multifocal loss of epithelial cells and cellular debris (C). 
In lungs of ferrets of groups S3.8+, S15+ and T3.8-, only a mild to moderate alveolitis was observed with inflammatory 
infiltrate mainly in the alveolar septa (D). Perivascular (E) and peribronchiolar (F), infiltrates were present consisting 
mainly of lymphocytes and plasma cells and some macrophages and neutrophils. Pictures were made from lungs of 
ferrets inoculated with influenza A/VN/119/04. H&E staining, magnification 20x.
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F), while the number of virus-inoculated cells was considerably lower in the  lungs of ferrets from 
groups S3.8+, S15+ and T3.8+ (Fig 6G and H). Influenza virus antigen expression was predominantly 
observed in alveolar and bronchiolar epithelial cells.
DISCUSSION
In the present study we have demonstrated that the addition of the novel adjuvant CoVaccine HT™ 
to an inactivated influenza H5N1 vaccine produced by state-of-the-art cell-culture technology 
makes a promising pandemic influenza vaccine candidate. This vaccine afforded protection against 
infection with the homologous and an antigenically distinct strain of A(H5N1) virus, even after a 
single administration of a low antigen dose. The protection of ferrets was associated with the in-
duction of humoral and cell-mediated immune responses in vaccinated animals.
CoVaccine HT™ potentiated the antibody response to the vaccine strain considerably. After two im-
munizations of 3.8 µg HA of the NIBRG-14 preparation without the adjuvant, virus-specific antibod-
ies were undetectable whereas the addition of CoVaccine HT™ resulted in detectable antibody re-
sponses in all ferrets. Even after a single immunization with the adjuvanted vaccine, approximately 
Figure 6. Detection of virus-infected cells 
by immunohistochemistry. Cells that are 
positive for the presence of viral antigen 
show a deep red staining in the nucleus. 
Four days after inoculation with influenza 
A/VN/1194/04 (A+B) virus and influenza A/
IND/5/05 (E+F), multiple virus-inoculated 
cells were present in both alveoli and bron-
chioles of lungs of ferrets of groups T3.8-, 
PBS, Cve. Inoculated cells were only found 
sporadically in the lungs of ferrets of groups 
S3.8+, S15+ and T3.8+ (C+D).  After inocu-
lation with influenza A/IND/5/05 virus, the 
number of inoculated cells was reduced in 
the  lungs of ferrets from groups S3.8+, S15+ 
and T3.8+ (G+H), most inoculated cells were 
present in areas with inflammatory infiltrate 
(see insert).
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50% of the animals developed detectable antibody levels against the homologous vaccine strain. 
In some ferrets, but especially those vaccinated twice with the CoVaccine HT™-adjuvanted vaccine, 
antibodies reactive with the heterologous strain A/IND/5/05 were detectable. This is of importance 
since multiple antigenically distinct A/H5N1 viruses are circulating and it is impossible to predict 
which clade of these viruses eventually may cause a pandemic. In this light, the induction of broad-
ly reactive antibodies is advantageous and may correlate with protection against infection with 
heterologous influenza A/H5N1 viruses.
In addition, the induction of T cell responses after vaccination was evaluated. Recently reagents 
have become available to evaluate T cell responses in ferrets but assays for the detection of virus-
specific T-cells have not been described sofar to our knowledge (260 -262). Using monoclonal an-
tibodies cross-reactive with ferret CD3 and CD8 (260, 261) we developed a T cell proliferation assay 
that allowed discriminating proliferation of CD8+ and CD8- virus-specific T cells. Using this assay, it 
was shown that the use of CoVaccine HT™ significantly improved the virus-specific T cell response 
after vaccination of ferrets. Even after a single immunization with the adjuvanted vaccine substan-
tial T cell responses were observed. Strong CD8-, presumably CD4+, T cell response, were detected 
that could be at the basis for the improved immunogenicity of the vaccine in term of antibody 
responses. After vaccination with the CoVaccine HT™-adjuvanted vaccines, a virus-specific CD8+ T 
cell response was observed, which could be the result of cross-priming in vivo (139). Previously we 
were unable to detect virus-specific CD8+ T cell responses in mice after vaccination with CoVaccine 
HT™-adjuvanted vaccine (257). However, in the mouse model CD8+ T cell responses were assessed 
ex vivo using tetramers detecting the responses to a single epitope only. It is likely that the prolif-
eration and amplification of virus specific T cells in vitro increased the sensitivity of the detection 
of these cells in the current study. In the mouse model it was demonstrated that, at least partially, 
the adjuvant effect of CoVaccine HT™ was mediated through TLR-4 signaling (257).  At present it is 
unclear whether this mode of action of the adjuvant also played a role in the improved immunoge-
nicity of the vaccine in the ferret model. 
The ultimate goal of vaccination of course is to protect against the development of severe disease 
upon exposure to the pathogen. Since the breadth of protective immunity is considered an im-
portant property of vaccines, vaccinated ferrets were inoculated with two antigenically distinct in-
fluenza A/H5N1 viruses, the homologous clade 1 virus A/VN/1194/04 and the heterologous clade 
2.1 virus A/IND/5/05. With the vaccines containing CoVaccine HT™, a dramatic reduction of clini-
cal signs, gross pathological and histopathological changes and virus replication in the upper and 
lower respiratory tract after inoculation with influenza virus A/VN/1194/04 was achieved. In con-
trast, two immunizations with unadjuvanted NIBRG-14 vaccine failed to induce protective immu-
nity. Even after a single administration of a vaccine containing CoVaccine HT™ and as little as 3.8 
µg HA, ferrets were fully protected against the homologous virus A/VN/1194/04. Vaccination was 
somewhat less effective against the development of clinical signs after infection with the heterolo-
gous virus A/IND/5/05, although still a significant reduction of virus replication in the upper and 
lower respiratory tract was achieved, even after a single administration of a low dose of antigen 
and CoVaccine HT™. In previous studies, it was demonstrated that with two immunizations with a 
low vaccine dose in combination with the adjuvant AS03, protection could be achieved against the 
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virus A/IND/5/05, but this vaccine also failed to induce sterilizing immunity in ferrets against this 
heterologous challenge virus (68). This indicates that it is inherently difficult to induce sterilizing 
immunity against viruses that are antigenitically distinct. Our findings are in concordance with the 
results obtained in other studies that show that immunogenicity of otherwise poorly immunogenic 
inactivated H5N1 vaccines can be increased dramatically with the use of adjuvants, like MF59 and 
AS03 (237, 238, 252).  It is of interest to note that the use of a higher vaccine dose (15 µg of HA) did 
not result in the induction of higher antibody titers or increased protection against infection. In 
contrast, a single administration of the adjuvanted vaccine containing 15 µg seemed less effective 
in preventing virus replication, weight loss and the development of (histo)pathological changes 
after inoculation with influenza viruses A/VN/1194/04 or A/IND/5/05 than the use of the vaccine 
containing only 3.8 µg of HA. The mechanism of this phenomenon is poorly understood, but it sug-
gests that the ratio between the amount of viral antigen and adjuvant can affect the outcome of 
vaccination and the protective efficacy of the vaccine. 
In general, the protection against infection with both challenge viruses correlated with the induc-
tion of virus specific HI and VN antibodies. However, a number of animals vaccinated once with 
adjuvanted-vaccine were protected against infection in the absence of detectable virus-specific an-
tibodies. This discrepancy also has been observed in other studies that evaluated candidate H5N1 
vaccines (68, 70, 256, 263).  It is possible that lower, undetectable levels of virus specific antibodies 
are already protective, or that priming of B cells for a secondary antibody response contributes to 
protective immunity. Alternatively, the induction of virus specific T cell immunity could have con-
tributed to protection against infection.  However, in the present study, the induction of virus spe-
cific T cells correlated only partially with the protection against infection and the magnitude of the 
antibody response did not correlate with the CD3+CD8- cell response. 
The CoVaccine HT™-adjuvanted vaccines were well tolerated by the ferrets. Only some mild local 
reactions were observed at the site of vaccination, consisting of local erythema for one day. Data 
collected from temperature loggers that were placed in the abdominal cavity before the start of the 
experiment with ferrets that were challenged with influenza A/VN/1194/04 indicated that the Co-
Vaccine HT™ adjuvanted NIBRG-14 vaccine caused a rise of body temperature for 1-2 days. It should 
be noted however, that these side effects are not uncommon after administration of adjuvanted 
influenza vaccines (149, 163).
Collectively, we conclude that CoVaccine HT™ is a promising adjuvant for the use in (pandemic) in-
fluenza vaccines. In the present study we have shown that its use in ferrets increased the immuno-
genicity of a cell-culture produced inactivated H5N1 vaccine. It increased both virus-specific T cell 
and antibody responses, resulting in protection against infection with the homologous and an an-
tigenically distinct virus, even after a single administration of as little as 3.8 µg of HA antigen. These 
favorable properties justify the further clinical development of this influenza vaccine candidate.
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ABSTRACT
Most patients infected with highly pathogenic avian influenza A/H5N1 virus suffer from severe 
pneumonia resulting in acute respiratory distress syndrome, with extra-respiratory disease as an 
uncommon complication. The ferret is a traditional animal model for influenza in humans. Intrana-
sal inoculation of ferrets with influenza A/H5N1 virus causes lesions in both respiratory tract and ex-
tra-respiratory organs, primarily brain. However, the route of spread to extra-respiratory organs and 
the relative contribution of extra-respiratory disease to pathogenicity are largely unknown. In the 
present study, we characterized lesions in respiratory tract and central nervous system (CNS) of fer-
rets (n = 8) inoculated intranasally with influenza A/Indonesia/5/2005 (H5N1) virus. By 7 days after 
inoculation, only 3 of 8 ferrets had a mild or moderate broncho-interstitial pneumonia. In contrast, 
all 8 ferrets had moderate or severe CNS lesions, characterized by meningo-encephalitis, choroiditis 
and ependymitis, and centred on tissues adjoining the cerebrospinal fluid. These findings indicate 
that influenza A/H5N1 virus spread directly from nasal cavity to brain, and that CNS lesions con-
tributed more than pulmonary lesions to the pathogenicity of influenza A/H5N1 virus infection in 
ferrets. In comparison, intratracheal inoculation of ferrets with the same virus reproducibly caused 
severe broncho-interstitial pneumonia. The implications are that the method of virus inoculation 
needs to be considered carefully when designing ferret experiments as a model for influenza A/
H5N1 in humans. 
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INTRODUCTION
Since the first human cases of infection with highly pathogenic avian influenza A/H5N1 virus were 
recognized in 1997, infection has been confirmed in more than 500 people, about 60% of whom 
have died (21). Typically, infected individuals develop a severe pneumonia, which often is fatal (24, 
264). Different experimental animal species also develop severe pneumonia after inoculation with 
highly pathogenic avian influenza A/H5N1 virus (166, 167, 265-267). In addition to the respiratory 
tract, influenza A/H5N1 virus has been detected in different extra-respiratory organs, particularly 
the central nervous system (CNS), both in a few human cases and in multiple experimental animal 
species (24, 110, 166, 266, 268, 269).
The ferret (Mustela putorius furo) is considered a good animal model for influenza virus infection 
in humans and frequently is used to study the pathogenesis of influenza (156, 270-272). In most 
pathogenesis studies with influenza A/H5N1 viruses in ferrets, intranasal inoculation is performed 
(166, 167, 273). After intranasal inoculation, it is assumed that the virus spreads from the nose to the 
lower respiratory tract and, if pathogenic, causes pneumonia. From there, virus might spread sys-
temically and cause extra-respiratory disease, including encephalitis. However, the route of spread 
to the CNS and the relative contribution of CNS disease to the pathogenicity of influenza A/H5N1 
virus infection for ferrets are largely unknown. Therefore, we wished to determine the character and 
severity of lesions caused by influenza A/H5N1 virus in the respiratory tract and CNS after intranasal 
inoculation. To this end, ferrets were inoculated intranasally with highly pathogenic avian influenza 
A/Indonesia/5/2005 (H5N1) virus and multiple tissues were collected for macroscopic, microscopic, 
and immunohistochemical evaluation after euthanasia at 7 days post inoculation (dpi), and results 
were compared with those of ferrets inoculated intratracheally with the same virus.
MATERIALS AND METHODS
 Virus preparation
Influenza virus A/Indonesia/5/2005 (H5N1, clade 2.1) was propagated in confluent Madin-Darby ca-
nine kidney (MDCK) cells. After cytopathic changes were complete, culture supernatants were har-
vested and cleared by low speed centrifugation and stored at –80°C. The virus titer was determined 
in MDCK cells as described previously (85).
Experimental protocol
Healthy outbred female ferrets between 6 and 12 months of age were purchased from a commer-
cial breeder. They tested negative for the presence of antibodies against recent influenza A/H1N1 
and A/H3N2 viruses, influenza A/Indonesia/5/05 virus, and Aleutian disease virus. During the ex-
periment, ferrets were housed together and received food and water ad libitum. Eight ferrets were 
inoculated intranasally with 5 x 106 median tissue culture infectious dose (TCID50) influenza virus A/
Indonesia/5/2005 in a total volume of 0.5 ml phosphate-buffered saline under anesthesia with ket-
amine and medetomidine, and reversed with atipamezole. After inoculation, ferrets were checked 
daily for the presence of clinical signs. Before and 2, 4, 6, and 7 dpi with influenza A/H5N1 virus, fer-
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rets were weighed under anesthesia with ketamine. At 7 dpi, or earlier in case ferrets became mor-
ibund, animals were weighed and subsequently killed by exsanguination under anesthesia with 
ketamine and medetomidine. Experimental procedures were approved by an independent animal 
ethics committee, and were performed under biosafety level 3 conditions.
Pathological examination and immunohistochemistry
Necropsies were performed according to standard procedures. Samples of olfactory bulb, cere-
brum, cerebellum, brain stem, lungs (all lobes of the right lung and the accessory lobe; after infla-
tion with 10% neutral-buffered formalin), spleen, liver and duodenum were fixed in 10% neutral-
buffered formalin, embedded in paraffin, and sectioned at 4 μm. Tissue sections were stained with 
hematoxylin and eosin (HE) for histological evaluation or with an immunoperoxidase method using 
a monoclonal antibody directed against the nucleoprotein of the influenza A virus for detection of 
virus-infected cells (110). An IgG2a isotype control for each tissue and a positive control tissue were 
included in each staining procedure. 
Figure 1. Comparison of histological lesions and viral antigen expression in lungs of ferrets inoculated intranasally (A 
to C) or intratracheally (D to F) with influenza A/Indonesia/5/05 (H5N1) virus. A, B: Absence of lesions in the lung of an 
intranasally inoculated ferret (original magnifications, X200 and X1000). C: Absence of cells expressing virus antigen 
in alveoli of an intranasally inoculated ferret (original magnification, X1000). Inset: Rare type 2 pneumocyte express-
ing virus antigen. D: Broncho-interstitial pneumonia, with inflammatory exudate in bronchiolar and alveolar lumina, 
in the lung of an intratracheally inoculated ferret (original magnification, X200). E: Neutrophils, macrophages, cel-
lular debris and erythrocytes in the alveolus of an intratracheally inoculated ferret (original magnification, X1000. F: 
Epithelial cells, mainly type 2 pneumocytes, expressing virus antigen in alveoli of an intratracheally inoculated ferret 
(original magnification, X1000). 
K, L: Influenza viral antigen in neurons and glial cells of the cerebrum (original magnifications, X400 and X1000). M: 
Infiltration of inflammatory cells, vacuolation and neuronal necrosis in the olfactory bulb (original magnification, 
X400). N, O: Influenza viral antigen in glial cells and neuronal cells of the olfactory bulb (original magnifications, X400 
and X1000).
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Figure 2. Histological lesions and viral antigen expression in the central nervous system of ferrets inoculated intrana-
sally with influenza A/Indonesia/5/05 (H5N1) virus. A: Leptomeninges of the cerebrum infiltrated with many inflam-
matory cells, mainly macrophages (original magnification, X400). B, C: Influenza viral antigen in mesothelial cells of 
the leptomeninges (original magnifications, X400 and X1000). D: Infiltration of mainly macrophages in the connec-
tive tissue of the choroid plexus, and segmental dissociation of the epithelial layer (original magnification, X400). E, 
F: Influenza viral antigen in epithelial cells of the choroid plexus (original magnifications, X400 and X1000). G: Seg-
mental loss of the epithelial layer of the ependyma, and infiltration of mainly macrophages (original magnification, 
X400). H, I: Influenza viral antigen in epithelial cells of the ependyma (original magnifications, X400 and X1000). J: 
Infiltration of inflammatory cells, vacuolation and neuronal necrosis in the cerebrum (original magnification, X400). 
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RESULTS
Clinical signs
From 1 dpi onwards, ferrets developed clinical signs including anorexia, diarrhea, neurological 
signs and lethargy. All ferrets lost between 13% and 24% of their original body weight by 7 dpi. Two 
ferrets were found dead at 5 and 7 dpi. One ferret was euthanized at 6 dpi due to the presence of 
severe clinical signs, in accordance with animal welfare regulations.
Macroscopic and microscopic observations
At necropsy, three of eight ferrets had multifocal dark red areas of consolidation in the lungs. The 
estimated percentage of lung tissue involved per ferret was 8 ± 14 (mean ± s.d.) and the lung 
weight as a percentage of body weight was 0.9 ± 0.48 (mean ± s.d.) (Table 1). No macroscopic le-
sions were seen in other organs except for diffuse hepatic pallor in all eight ferrets.
Upon histological examination, three of eight ferrets had a mild or moderate, multifocal, broncho-
interstitial pneumonia (Figures 1A and B; Table 2). In the affected areas, alveolar lumina were filled 
with cellular debris, edema fluid, eyrthrocytes, fibrin and inflammatory cells (many macrophages 
and some neutrophils); alveolar walls showed epithelial necrosis, moderate hypertrophy and hy-
perplasia of type 2 pneumocytes, and infiltration with moderate numbers of macrophages and 
neutrophils. Bronchiolar lumina contained cellular debris, macrophages and neutrophils; bron-
chiolar walls had loss of epithelium and infiltration with moderate numbers of macrophages and 
neutrophils. Bronchial lumina contained a few inflammatory cells and fibrin, while bronchial walls 
contained a few inflammatory cells.
Table 1. Comparison of macroscopic lung lesions between ferrets inoculated intranasally (this 
study) or intratracheally (159) with influenza A/Indonesia/5/05 (H5N1) virus
Route of 
inoculation
Inoculation dose 
(TCID50)
Number of 
animals with 
macroscopic 
lung lesions/total 
number
Area of affected 
lung tissue
(%, mean ± s.d.)
Relative lung 
weight
(mean ± s.d.)
Intranasal 5 x 106 3/8 8 ± 14 0.9 ± 0.5
Intratracheal 1 x 105 6/6 59 ± 21 1.7 ± 0.2
 
All eight ferrets had a moderate or severe, diffuse, non-suppurative leptomeningitis in cerebrum, 
cerebellum, brain stem, and olfactory bulb (Figure 2A). It was characterized by an infiltrate in the 
subarachnoidal space ranging from 4 to 20 cells in thickness and consisting of many large mono-
nuclear cells (macrophages), a few lymphocytes and rare neutrophils. Multifocally, there was disso-
ciation of the superficial mesothelial cells of the arachnoid membrane and endothelial hypertrophy 
of the meningeal blood vessels.
Five of seven ferrets had a moderate or severe, necrotizing choroiditis (Figure 2D). The connective 
tissue of affected choroid plexi had necrosis of cells and infiltration with many macrophages, while 
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cellular debris, inflammatory cells, fibrin and erythrocytes were present on the epithelial surface.
Six of seven ferrets had a moderate or severe, necrotizing ependymitis. This was characterized by 
segmental loss of the ependymal cell lining and infiltration by many macrophages, although at 
some locations higher proportions of lymphocytes or neutrophils were present (Figure 2G).
All eight ferrets had a multifocal necrotizing encephalitis, which was moderate in cerebrum and 
olfactory bulb and mild in the brain stem. Affected areas were characterized by infiltration with 
neutrophils, necrosis of neurons, gliosis, and vacuolization of neuropil (Figure  2J and M). Affected 
areas in the cerebrum were superficial and localized adjacent to the inflammatory lesions present 
in leptomeninges, ependyma, and olfactory bulb. Affected areas in the olfactory bulb were present 
throughout the tissue.
All eight ferrets had mild diffuse hepatic lipidosis, consistent with anorexia. None of the eight fer-
rets had microscopic lesions in spleen or duodenum.
Table 2. Presence of histological lesions and viral antigen expression in tissues of ferrets inoculated 
intranasally with influenza A/Indonesia/5/05 (H5N1) virus (n = 8)
Tissue No. of ferrets positive
Histological lesion Virus antigen expression
Leptomeninges
Choroid plexus*
Ependyma*
Olfactory bulb
Cerebrum
Cerebellum
Brain stem
Lung
Spleen
Liver
Duodenum
8
5
6
6
8
8
0
3
3
0
0
3
4
5
6
5
0
1
3
0
0
0
*Tissue missing from one ferret. 
Expression of viral antigen
Virus antigen expression was detected in the CNS of all eight ferrets and respiratory tract of three 
of eight ferrets (Table 2). In the CNS, moderate or abundant virus antigen expression was detected 
in mesothelial cells of cerebral leptomeninges (Figures 2B and C), epithelial cells of choroid plexus 
(Figures 2E and F) and ependyma (Figures 2H and I), and neurons and glial cells of cerebrum (Fig-
ures 2K and L), brain stem, and olfactory bulb (Figure 2N and O). Interestingly, virus-positive cells in 
cerebrum and brain stem were located superficially, adjacent to meninges, ependyma and olfacto-
ry bulb, while virus-positive cells in the olfactory bulb were located in the central part of this tissue.
In the respiratory tract, scant virus antigen expression was detected in the lungs, mainly in type 2 
pneumocytes (Figure 1C). None of the eight ferrets showed virus antigen expression in spleen, liver, 
or duodenum.
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DISCUSSION
 
Our study shows that all ferrets inoculated intranasally with this influenza A/H5N1 virus developed 
widespread and often fatal CNS disease, characterized by non-suppurative meningo-encephalitis, 
choroiditis, and ependymitis. Surprisingly for a highly pathogenic respiratory virus inoculated into 
the respiratory tract, broncho-interstitial pneumonia developed only in a minor proportion of fer-
rets, and was milder than the CNS disease.
Comparison of our results with those from other influenza A/H5N1 virus infections in experimental 
animals indicates the importance of route of inoculation for primary disease presentation and char-
acter of CNS lesions. First, route of inoculation is important for primary disease presentation. Intra-
nasal inoculation in our ferrets resulted in primary disease of the CNS rather than of the respiratory 
tract. These results are consistent with previous studies (274, 275), where intranasal inoculation of 
influenza A/Vietnam/1203/04 (H5N1) in ferrets resulted in death from severe neurologic disease, 
but caused only mild lung lesions. The authors suggested that these results were likely due to the 
low virus inoculation dose—101 or 102 median egg infectious dose (EID50) per ferret—used in those 
studies, and indicated that higher doses—106 or 107 EID50— led to more severe pulmonary lesions 
(166, 276, 277). However, in our study, we used a relatively high dose—5 x106 TCID50—without in-
ducing severe pulmonary lesions. A possible explanation is that intranasal inoculation results in 
virus deposition in the lower respiratory tract of some ferrets but not others. In contrast, when we 
inoculated a similar dose of the same virus intratracheally rather than intranasally (159), all ferrets 
developed severe broncho-interstitial pneumonia associated with influenza virus infection (Fig-
ure 1D, E and F; Table 1) and had to be euthanized at 4 dpi due to severe respiratory distress. CNS 
disease was not evaluated pathologically, but was not considered significant based on absence of 
neurologic signs.
Second, route of inoculation is important for the character of CNS lesions. In our intranasally in-
oculated ferrets, CNS lesions were centered on tissues adjacent to cerebrospinal fluid in the sub-
arachnoidal space and ventricular system—leptomeninges, choroid plexi, and ependyma—and 
were characterized by prominent infiltration of mononuclear cells; there was lesser involvement of 
adjacent brain parenchyma. Other studies also point out the infiltration of mononuclear cells in the 
meninges of intranasally inoculated ferrets (275, 276). In contrast, intratracheal inoculation of influ-
enza A/H5N1 virus in cats resulted in randomly distributed foci of necrosis and inflammation in the 
brain parenchyma, with minor involvement of leptomeninges, choroid plexi, and ependyma (267).
A possible explanation for the above disparities in pathological changes between routes of inocula-
tion is a different route of virus entry into the CNS. As suggested previously, intranasal inoculation 
of influenza A/H5N1 virus in ferrets may lead to direct spread of virus from the nasal cavity, via 
olfactory nerves through the ethmoidal plate, to the olfactory bulb (166). This route of entry has 
been shown for influenza A/H5N1 virus in mice (168, 265) and for canine distemper virus in ferrets 
(278). Because the barrier between olfactory bulb and cerebrospinal fluid is weak (279), virus would 
have easy and rapid access to tissues around the subarachnoidal space and ventricular system. This 
route of entry would explain the prominent involvement of the olfactory bulb, leptomeninges, cho-
roid plexi, and ependyma in our intranasally inoculated ferrets. In contrast, there was evidence of 
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blood-borne spread of influenza A/H5N1 virus in intratracheally inoculated cats (267), which might 
explain the random distribution of lesions in the brain parenchyma and the lesser involvement of 
tissues around the subarachnoidal space and ventricular system in those animals.
In conclusion, we here show that choice of route of inoculation is critical in designing ferret models 
to study the pathogenesis of influenza A/H5N1 virus infection in humans. Based on our results with 
different routes of inoculation of influenza virus A/Indonesia/5/2005 (H5N1) in ferrets, intranasal in-
oculation would be the route of choice to study influenza A/H5N1-virus-induced CNS disease, while 
intratracheal inoculation may be more appropriate to study influenza A/H5N1-virus-induced lower 
respiratory tract disease.
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The recent pandemic caused by the influenza A/H1N1(2009) virus has highlighted the importance 
of influenza viruses as a cause of disease in humans. However, seasonal influenza viruses also cause 
morbidity and mortality and the WHO has estimated that between 250.000 and 500.000 people 
die due to infection with influenza viruses annually (12). Mainly very young children, the elderly, or 
immunocompromised people die due to infection with seasonal influenza virus, while during the 
recent influenza A/H1N1(2009) pandemic also relatively high numbers of young healthy people died 
due to influenza virus infection (55). In addition, the relatively high mortality rates among young 
healthy people due to infection with highly pathogenic influenza A/H5N1 viruses indicate that in-
fluenza virus infection is not just an infection of the elderly or immunocompromised and that the 
development of safe and effective vaccines is important to prepare for a future pandemic.
The focus of this thesis is the development of immunity against influenza A/H5N1 viruses. In the first 
part, the induction of heterosubtypic immunity by infection with a seasonal influenza virus and the 
effect of vaccination against seasonal influenza on the development of this type of immunity against 
influenza was investigated. In addition, the seroprevalence of antibodies against influenza viruses in 
the Netherlands during non-pandemic years was analyzed and influenza virus-specific humoral and 
cellular immune responses between non-vaccinated healthy children and children with cystic fibro-
sis that were vaccinated annually against influenza viruses were compared.  The focus of the second 
part is the development of a novel influenza A/H5N1 virus vaccine based on a low dose of whole 
inactivated influenza A/H5N1 virus antigen in combination with the novel adjuvant CoVaccine HT™. 
Heterosubtypic immunity against influenza A/H5N1
As indicated, pandemics are caused by the introduction of influenza A viruses into the human popu-
lation with HA and NA that are antigenetically distinct from the currently circulating human seasonal 
influenza A viruses. Therefore antibodies directed to the seasonal influenza viruses are unable to rec-
ognize and neutralize the new strains allowing them to replicate to higher titers causing high trans-
mission and attack rates. Under these circumstances the presence of heterosubtypic immunity may 
tip the balance in favour of the host and afford some level of protection against these new pandemic 
strains. In chapter 2 of this thesis, it was demonstrated in the mouse model that previous infection 
with an influenza A/H3N2 virus also induces heterosubtypic immunity against a highly pathogenic 
influenza A/H5N1 virus. The observed reduction of clinical signs including weight loss and mortality 
correlated with differences in viral load in the lungs. Furthermore, it was demonstrated that survival 
of lethal challenge with the influenza A/H5N1 virus correlates with the presence of a strong response 
of CD8+ T cells against both the immunodominant NP366-374 and PA224-233 epitopes of the influ-
enza A/H5N1, while no cross-reactive antibodies were observed and serum transfer did not provide 
protection against challenge infection. In addition, previous infection with a respiratory syncytial 
virus (RSV) did not induce protective immunity against influenza indicating that an influenza A virus-
specific component of the immune system is responsible for the observed differences in protection. 
Essentially the same results were obtained in the ferret model using a recent seasonal influenza A/
H3N2 virus and the same highly pathogenic influenza A/H5N1 virus (chapter 5). Ferrets that were 
primed by infection with an influenza A/H3N2 virus, developed less severe clinical signs including 
weight loss following challenge infection than unprimed animals. The reduction of clinical signs 
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correlated with a reduction in viral load in nose and pharyngeal swabs collected at various time 
points after inoculation and with histopathological changes in the lungs and brain observed 7 days 
after inoculation. Also in this animal model, no cross-reactive antibodies were observed prior to 
inoculation with challenge with influenza A/H5N1. Results obtained in both animal models further 
confirm data from other studies in which it was demonstrated that previous infection with seasonal 
influenza A viruses can induce immunity against future pandemic influenza A viruses. However, the 
exact mechanism of the observed infection-induced heterosubtypic immunity is currently matter of 
debate, but it is generally accepted that various arms of the immune system other than serum-anti-
bodies to hemagglutinin and neuraminidase contribute to heterosubtypic immunity, like CD4+ and 
CD8+ T cells specific for conserved viral proteins, mucosal antibodies and B cells (40, 43, 47, 123, 136).
Vaccination against seasonal flu and interference with the induction of heterosubtypic immunity 
against pandemic strains
Since seasonal influenza A viruses of the H3N2 and H1N1 subtypes and influenza B viruses cause epi-
demics annually associated with excess morbidity and mortality mainly among the elderly, immuno-
compromised and other high-risk groups, influenza vaccination is recommended for these high-risk 
groups. Furthermore, due to the higher risk of complications and hospitalizations secondary to influ-
enza in children (58, 59), annual vaccination of all healthy children 6 to 59 months of age was recom-
mended in various countries including the United States since 2007 (60). Also in Europe, vaccination 
of children is currently considered and a number of countries already recommend vaccination of 
healthy children (61). In general, influenza vaccines most frequently used are inactivated vaccines, 
including subunit preparations that consist of the envelope proteins of the influenza viruses, the 
HA and NA. However, there is a potential downside of annual vaccination against seasonal flu as 
vaccination may prevent the induction of heterosubtypic immunity otherwise induced by infection. 
This interference with the induction of heterosubtypic immunity may not be of any consequence 
under normal circumstances, but in light of the pandemic threat caused by the influenza A/H5N1 
viruses, the presence or absence of heterosubtypic immunity might affect the clinical outcome of 
infection with the new pandemic strain. Since young infants are immunologically naïve to influ-
enza viruses (184), especially in this age group annual vaccination against seasonal influenza may 
prevent the induction of heterosubtypic immunity and render this age group more susceptible to 
pandemic strains compared to subjects that have experienced prior infections with seasonal strains. 
Currently used inactivated influenza vaccines provide protection against the homologous seasonal 
strains, but fail to induce cross-protective immune responses to strains of alternative subtypes. This 
poor cross-protective potential correlates with the inefficient induction of virus-specific CD8+ T cell 
responses induced by these vaccines (104, 105). In chapter 3 of this thesis we tested this hypothesis 
and investigated the effect of vaccination against a seasonal influenza virus A/H3N2 strain on the 
induction of heterosubtypic immunity against potentially pandemic highly pathogenic influenza A/
H5N1 viruses in a mouse model. Strikingly, mice that were protected from infection with the seasonal 
A/H3N2 strain developed severe disease and had a fatal outcome of the A/H5N1 infection whereas 
those that were not vaccinated against a prior infection with the A/H3N2 strain became less ill and 
did not succumb to infection.  The lack of clinical protection in the H3N2-vaccinated mice against 
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infection with A/H5N1 virus correlated with the lack of control of virus replication in the lungs nor-
mally seen in mice that experienced a prior infection with the influenza A/H3N2 virus.  The disease 
was similar to that observed in fully naïve mice infected with the A/H5N1 strain and characterized as 
a severe necrotizing broncho-interstitial pneumonia.  Essentially the same results were obtained in 
chapter 4, where a whole inactivated influenza A/H3N2 virus vaccine containing all components of 
the influenza A virus including the relatively conserved inner proteins was used. It was demonstrated 
that mice immunized with this vaccine developed a response of CD8+ T cells towards an epitope 
located on the nucleoprotein (NP366-374), however this response was relatively small compared to 
the response observed after infection. In addition, it was shown that the use of WIV vaccine for the 
protection against A/H3N2 infection affected the induction of heterosubtypic immunity otherwise 
afforded by A/H3N2 influenza virus infection. The reduction of protective immunity correlated with 
changes in the immunodominance patterns of the CD8+ T cell responses directed to the epitopes 
located in the acid polymerase (PA224-233) and the nucleoprotein (NP366-374). 
Since results obtained in the mouse model for influenza A virus infection are not easily translated to 
humans, the results were reproduced in ferrets that are more closely related to humans regarding 
the pathogenesis of influenza virus infections. To this end, in chapter 5 of this thesis the effect of vac-
cination on the induction of heterosubtypic immunity against influenza A/H5N1 was tested in this 
animal species. Also in ferrets, vaccination against seasonal influenza virus hampered the induction 
of heterosubtypic immunity in a proportion of the animals.
It has been suggested that vaccination with a seasonal influenza vaccine in children does not in-
duce sterilizing immunity and only reduces clinical signs and virus replication in the upper respira-
tory tract (280, 281) which is in contrast to our results in the mouse model as sterilizing immunity 
was observed after H3N2 infection in vaccinated animals. However, in our experiments with ferrets 
we observed that vaccination did not induce sterilizing immunity as reduced virus replication was 
observed in all vaccinated ferrets. Strikingly, a proportion of the vaccinated ferrets did not develop 
heterosubtypic immunity after infection with influenza A/H3N2 indicating that also reduction of 
virus replication can prevent the induction of heterosubtypic immunity.
Furthermore, the findings in our animal models coincided with a number of recent observational 
studies performed in adults in Canada and in children in Hong Kong (169, 170, 207), in which it 
was demonstrated that prior vaccination against seasonal influenza increased the risk of medically 
attended, laboratory-confirmed influenza A/H1N1(2009) illness. However, results inconsistent with 
this study have been published as well (282). 
Besides the absence of heterosubtypic immunity another possible explanation for these findings 
are the presence of high titers of low-avidity, non-protective antibodies and complement activation 
induced by pulmonary immune complexes in vaccinated subjects (283). In addition, it has been 
demonstrated that vaccination against seasonal influenza during the previous influenza season 
had a negative impact on the development of antibodies after vaccination against influenza A/
H1N1(2009) virus, although the underlying mechanism is unknown (284). 
Seroprevalence of antibodies against influenza in children
Since it was demonstrated in chapters 2, 4 and 5 that experimental infection of laboratory animals 
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with influenza A virus could provide at least partial protection against challenge with an influenza A 
virus of an unrelated subtype, it is of importance to know at which age children would be infected 
with influenza viruses for the first time. As detailed information about the seroprevalence of influ-
enza viruses in children was lacking, serum samples collected during a nationwide cross-sectional 
population-based study in the Netherlands were tested for the presence of antibodies against vari-
ous influenza viruses that circulated in recent years in chapter 6. In a relatively high proportion of 
the serum samples collected from children between one and six months of age antibodies were de-
tected, especially against older influenza virus strains, which could be attributed to the presence of 
maternally derived antibodies to these strains. Lower seroprevalences of antibodies were observed 
in children 7-12 months age, while it was observed that the proportion of study subjects >1 year of 
age with detectable antibodies against influenza viruses gradually increased with age until at age 
six all children had developed antibodies against at least one influenza A virus. In concordance with 
epidemiological data collected in the Netherlands, the highest seroprevalences were at each age 
detected against influenza A/H3N2 viruses. Besides the seroprevalence of antibodies against influ-
enza A viruses, also the presence of antibodies against influenza B viruses from both the Yamagata 
and Victoria lineage was evaluated. Also for these viruses an increase in the seroprevalence of an-
tibodies was observed from one to seven years of age, with the highest seroprevalence detected 
against viruses from the Yamagata lineage. In addition, using the increase in the seroprevalence of 
antibodies for each year, we were able to calculate attack rates. The attack rate observed in this study 
are similar to observed attack rates in young children in other studies in other countries (174, 175). 
Interestingly, the observed attack rates were lower than those demonstrated for other respiratory 
viruses in children (285-288). A possible explanation for this might be that viruses like RSV and hu-
man metapneumovirus induce only transient immunity (289, 290), indicating that every year people 
will become again susceptible to these viruses and can transmit the virus to new hosts, while only a 
small part of the population will be susceptible for influenza viruses as these viruses induce antibod-
ies that are able to prevent infection for a prolonged period of time. 
Strikingly, as it was demonstrated that previous infection with an influenza A virus can provide im-
munity against influenza A viruses of another subtype, findings of this seroprevalence study indicate 
that a proportion of the children below 6 six years of age has not been infected with an influenza A 
virus previously and might therefore not possess heterosubtypic immunity. Especially this age group 
might be at risk to develop severe disease upon infection with a highly pathogenic influenza A/H5N1 
virus or another future pandemic influenza virus.
Effect of annual vaccination on the virus-specific CD8+ T cell immunity in children
Since the extrapolation of data obtained in animal studies to the human situation is a matter of de-
bate since it was demonstrated in mice that the presence of CD8+ T cell immunity correlated with the 
presence of heterosubtypic immunity, the studies in mice and ferrets were extended to humans by 
comparing the virus-specific antibody responses and CD4+ and CD8+ T cell responses in vaccinated 
children with cystic fibrosis (CF) and unvaccinated healthy control children undergoing correctional 
surgery in chapter 7.  A somewhat broadened antibody response was observed in vaccinated chil-
dren compared to unvaccinated children, while no differences were observed in the virus-specific 
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CD4+ T cell response. In contrast, an age-related increase of the virus-specific CD8+ T cell response 
was observed in unvaccinated children that was not present in vaccinated children with CF. These 
findings confirm observations in the mouse model in which it was demonstrated that 28 days after 
infection with influenza A/H3N2 virus vaccinated mice had lower virus-specific CD8+ T cell responses 
than unvaccinated infected animals. In addition, as it has been demonstrated in mice that the pres-
ence of virus-specific CD8+ T cells is an important correlate of heterosubtypic immunity against in-
fluenza A viruses, these results might indicate that vaccinated children will not have heterosubtypic 
immunity against future pandemic viruses. These findings are important in the light of the pandemic 
threat caused by influenza A/H5N1 viruses. Especially for these children vaccines should be used 
that do induce heterosubtypic immunity. However, ideally our results obtained in this study should 
be confirmed with larger groups of children without differences in underlying disease, although we 
observed no differences in the immune response between healthy control children and vaccinated 
children with CF to other antigens.  In the Netherlands, vaccination is only recommended for chil-
dren with a high risk to develop severe disease upon infection with an influenza virus, so it was not 
possible to compare young healthy children vaccinated annually with unvaccinated children.
Development of universal vaccines
Findings presented in this thesis highlight the importance of the development of vaccines that do 
induce heterosubtypic immunity (121). The elucidation of the role of various components of the 
adaptive immune system  in heterosubtypic immunity is important to establish the exact correlates 
of protection (40). It has been demonstrated both in mice and humans that the number of virus-
specific CD8+ T cells correlates with reduced virus shedding and T cell immunity correlates with pro-
tection in children (50, 77, 212). Therefore, focussing on the vaccines that induce virus-specific CD8+ 
T cell immunity might be a valid route for the development vaccines that induce of heterosubtypic 
immunity (218). It has been shown that live attenuated vaccines induce virus specific CD8+ T cell 
responses in contrast to the frequently used subunit, split virion or whole inactivated virus vaccines 
and therefore may confer some degree of protection against heterosubtypic influenza virus strains 
(105, 120). Indeed in animal models it has been shown that live attenuated vaccines induced broad 
protective immune responses (134, 291, 292).  In addition, novel generations of influenza vaccines, 
like viral vector vaccines, may be attractive alternatives since they also can induce virus specific CD8+ 
T cell responses directed to conserved viral proteins like the matrix protein and the nucleoprotein, 
in addition to antibodies directed against the HA of seasonal influenza virus strains (293-298). Exam-
ples of vector vaccine production platforms are the recombinant replication deficient adenoviruses, 
poxviruses and the Newcastle disease virus vector, which have been shown to induce protective 
immunity to influenza viruses efficiently (171, 299-304). Another conserved viral protein is the M2 
protein that can induce cross-reactive antibodies. Using M2-based candidate vaccines protective im-
munity could be induced against influenza A viruses of various subtype (96, 172). Furthermore, it has 
been demonstrated recently that a vaccine that is able to provoke an antibody response against the 
relatively conserved stalk region of the hemagglutinin can also provide protection against multiple 
influenza A virus subtypes (173). These vaccine candidates not only may afford protection against 
seasonal influenza viruses but also against future pandemic strains and can be used even if they 
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provide only partial protection against these strains as they may reduce the morbidity and mortality 
during the first months of the pandemic until virus-specific vaccines become available.  
Development of a novel influenza A/H5N1 vaccine 
An example of a vaccine that has been developed to be used as an adequate future pandemic vac-
cine against the highly pathogenic influenza A/H5N1 virus, is the MDCK-grown whole inactivated 
influenza A/H5N1 vaccine in combination with the novel adjuvant CoVaccine HT™. Key issues for the 
development of pandemic influenza A virus vaccines are the time required that vaccines become 
available after the start of a pandemic, optimal use of the existing (limited) production capacity 
of viral antigen and effectiveness against viruses that are antigenetically distinct. Ideally, a single 
administration of a low dose of antigen would be sufficient to induce protective immunity against 
the homologous strain and heterologous antigenic variant strains. Therefore, the use of safe and 
effective adjuvants in the vaccine is considered an efficient strategy to induce dose-sparing and 
to broaden the specificity of the induced antibody responses. During the last years, multiple adju-
vanted vaccines have been tested and licensed against seasonal and pandemic influenza viruses 
but for all these vaccines it has been demonstrated that two vaccinations are necessary to provide 
protection against influenza A/H5N1 viruses (68, 252, 305). In chapters 8 and 9 experiments are 
described in mice and ferrets in which it is demonstrated that a single administration of a low dose 
of H5N1-antigen in combination with the CoVaccine HT™ induces antibody responses against ho-
mologous and heterologous influenza A/H5N1 viruses. In addition, it is demonstrated in ferrets that 
this vaccine-adjuvant combination is able to provide complete protection against homologous and 
partial protection against heterologous challenge. Furthermore, it is shown that CoVaccine HT™ in-
duces the maturation and secretion of cytokines by human dendritic cells and that this effect was 
mediated by binding of CoVaccine HT™ to Toll like receptor-4. The latter most likely is facilitated 
by the most important component of CoVaccine HT™, the synthetic sucrose fatty acid sulphate es-
ter (SFASE), which may mimic the lipopolysaccharide present on gram negative bacteria. Based on 
these promising results and data collected during in a study in rabbits and macaques (306), it can 
be concluded that this vaccine candidate will fulfill a number of the key criteria for the develop-
ment of an ideal pandemic influenza A/H5N1 vaccine, as low doses of MDCK-grown antigen and a 
broad-protective potential. Before it can be used and that it was also effective against antigenitically 
distinct viruses. However, before it can be used in humans, of course this vaccine candidate needs 
to be tested in clinical trials. 
Pathogenesis of influenza A/H5N1 virus in ferrets 
The use of an appropriate animal model is crucial for the testing of vaccines and to study the patho-
genesis of viruses. For influenza A viruses, ferrets are currently regarded as the golden standard 
animal model. In chapter 10, the intranasal route (used in chapter 5) and intratracheal route (used 
in chapter 6) of inoculation of ferrets with influenza A/Indonesia/5/05 (H5N1) were compared. Intra-
tracheal inoculation results primarily in disease of the lower respiratory tract, which is also the most 
prominent cause of death of the reported human H5N1 influenza cases (24, 264). In contrast, intra-
nasal inoculation induces primarily in disease of the central nervous system and only in a proportion 
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of the inoculated ferrets in a bronchopneumonia. These findings in combination with the character 
of the CNS lesions also suggest that intranasal inoculation of influenza A/H5N1 virus in ferrets may 
lead to direct spread of virus from the nasal cavity, via olfactory nerves through the ethmoidal plate, 
to the olfactory bulb. Based on the results of chapter 10, intranasal inoculation would be the route 
of choice to study influenza A/H5N1-virus-induced CNS disease, while intratracheal inoculation may 
be more appropriate to study influenza A/H5N1-virus-induced lower respiratory tract disease.
Concluding remarks
Studies presented in this thesis provide information which may aid decision making for the im-
plementation of vaccination strategies that aim at achieving optimal protective immunity against 
seasonal and pandemic influenza. It is demonstrated that the use of inactivated influenza vaccines 
against seasonal influenza has an negative impact on the development of heterosubtypic immu-
nity, which highlights the importance of the development of vaccines that induce heterosubtypic 
immunity. By no means, results presented in this thesis suggest that children or other people with 
underlying disease should not be vaccinated against seasonal influenza virus infection. In addition, 
the effect of vaccination on the development of heterosubtypic immunity is typically for influenza 
viruses and our considerations are not intended for all other viruses and vaccines that are currently 
implemented in the (Dutch) governmental vaccination programs. However, results presented in this 
thesis can provide information for a balanced discussion if children should be vaccinated against 
influenza until vaccines that induce heterosubtypic immunity are available or until techniques are 
used for the production of vaccines that allow the very fast production of hundreds of millions of 
vaccines when an influenza A virus of a novel subtype is introduced into the human population. 
In table 1, possible advantages and possible disadvantages of vaccination of children against sea-
sonal influenza viruses are listed. Especially for children with underlying disease, the risk of devel-
oping severe disease upon infection with a seasonal influenza virus is much higher than the risk of 
reduction of heterosubtypic immunity due to vaccination. Therefore, vaccination is recommended 
for these children. In addition, children without underlying disease that are older than six years of 
age will have been infected with an influenza A virus at least once as is demonstrated in chapter 6, 
so they will most likely have developed virus-specific CD8+ T cell immunity and antibodies as is dem-
onstrated in chapter 7. Reasons to recommend vaccination of these children include the prevention 
of morbidity and mortality of children and the elderly but also economical aspects (183, 213). For 
these children, both inactivated and live attenuated influenza virus vaccines can be used. However, 
it is currently unknown if vaccination with inactivated antigens also reduces the presence of virus-
specific CD8+ T cell immunity in children when administered for a number of years but it has been 
demonstrated in adults that during years with only mild influenza activity also the CTL immunity 
declined (217). Therefore, vaccination of children of these ages with live attenuated vaccines might 
be an alternative, because these vaccines do induce CD8+ T cell responses and are effective (62, 281). 
For children under 6 years of age, the situation is different as a proportion of them has not been in-
fected with an influenza A virus previously. Especially for these children the effect of vaccination on 
the prevention of sometimes severe disease due to infection with seasonal influenza viruses should 
be weighed against the possible prevention of the development of heterosubtypic immunity as 
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demonstrated in this thesis and in a recent epidemiological study (59, 207). In addition, the number 
of hospitalizations and deaths attributable to influenza virus infection in very young children should 
be evaluated in the Netherlands before vaccination of these children is recommended as differences 
in health care systems between countries might influence these results. Furthermore, live attenuated 
vaccines are licensed recently in Europe, but only for children older than two years of age. Children 
below two years of age could be vaccinated against seasonal influenza viruses in combination with 
components that induce immunity against multiple influenza viruses. These vaccines are currently 
in various stages of development (218).  A novel approach would be to decide if children should be 
vaccinated based on an individual serological profile. Children with virus-specific antibodies in their 
serum samples have been infected previously with a seasonal influenza virus and can be vaccinated 
against influenza without affecting the presence of heterosubtypic immunity, while children with-
out antibodies should ideally not be vaccinated or vaccinated with live attenuated influenza virus 
vaccines. However, another option is testing if these children have antibodies against the predicted 
epidemic influenza A viruses as vaccination of children that already have antibodies against these 
strains is of limited value. This service might be of interest to parents as an optional self-pay service 
that do not want to have their children vaccinated frequently.
Table 1. Possible advantages and possible disadvantages of vaccination of all healthy children with 
inactivated antigens against seasonal influenza A viruses.
Possible advantages Possible Disadvantages
• Less morbidity due to infection with sea-
sonal influenza viruses in children.
• Lower hospitalization rates of children and 
elderly.
• Lower absenteeism of parents due to sick-
ness of children.
• Prevention of induction of CTL immunity 
and heterosubtypic immunity against fu-
ture pandemic strains
• Mild side effects induced by vaccination.
• Reduced antibody responses after vacci-
nation against pandemic viruses
In the face of an possible pandemic, studies in this thesis demonstrate that a single vaccination with 
the novel adjuvant CoVaccine HT™ in combination with influenza A/H5N1 viral antigen can protect 
ferrets against challenge with influenza A/H5N1 viruses. As there is still concern about the continu-
ous spread of the highly pathogenic influenza A/H5N1 viruses among poultry and the occasional 
spread to humans, a pandemic with this virus is still feared. However, as the first human infections 
with this virus have already been described more than a decade ago, it is at present unclear if this 
virus will adapt to humans in the future. However, the unexpected emergence and rapid spread of 
the influenza A/H1N1(2009) virus has demonstrated that the introduction of a novel influenza A virus 
into humans has to be expected in the future. The multiple pandemics during the 20th century con-
firm this. Therefore, screening of birds, pigs and other animal species for the presence of influenza 
viruses, research to elucidate the pathogenesis of influenza A viruses and the development and 
adjustment of influenza virus vaccines are of crucial importance to prevent high mortality rates dur-
ing a future influenza pandemic. In addition, the development of influenza vaccines that are able to 
protect against influenza viruses of various subtypes, should be considered a high priority.
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Influenza virussen zijn de veroorzakers van influenza, ook wel ‘griep’ genoemd. Dit is in het alge-
meen een ziekte van de bovenste luchtwegen, die gedurende ongeveer een week klinische ver-
schijnselen als verkoudheid, hoesten, koorts, spierpijn en hoofdpijn veroorzaakt. Influenza virussen 
behoren tot de familie van de orthomyxoviridae en worden onderverdeeld in influenza A, B en C 
virussen. Influenza A virussen worden verder van elkaar onderscheiden op basis van twee eiwitten 
die aan de buitenkant van het influenza virus partikel zitten, het hemagglutinine (HA) en het neur-
aminidase (NA). Er zijn 16 verschillende subtypen van het HA en 9 van het NA bekend. Influenza 
virussen circuleren in het algemeen gedurende de wintermaanden van zowel het noordelijk als 
het zuidelijk halfrond rond bij mensen. Ondanks dat infectie met influenza virussen bij de meeste 
mensen met milde klinische verschijnselen gepaard gaat, schat de wereldgezondheidsorganisatie 
(WHO) dat er jaarlijks tussen de 250.000 en 500.000 mensen overlijden als gevolg van ernstige lon-
gontsteking na infectie met het influenza virus. Dit zijn voornamelijk ouderen of mensen met een 
ernstige onderliggende aandoening. 
Naast de jaarlijkse seizoensgriepepidemie, wordt er zo nu en dan een ‘nieuw’ influenza virus geïn-
troduceerd in de humane populatie, waartegen het merendeel van de bevolking geen bescher-
mende antistoffen heeft. Zo’n influenza virus kan dan een influenza virus pandemie veroorzaken, 
het recente influenza A/H1N1(2009) virus dat de Mexicaanse grieppandemie veroorzaakte is hier 
een voorbeeld van. De introductie van een ‘nieuw’ influenza A virus in de humane populatie is mo-
gelijk doordat er maar een beperkt aantal verschillende influenza A virus subtypen circuleren in 
mensen (H1N1 en H3N2), terwijl wilde vogels het reservoir van alle influenza virus subtypes vor-
men. Door aanpassing aan de mens of door recombinatie met een ander influenza virus afkomstig 
uit mensen of bijvoorbeeld varkens, kan een influenza virus ontstaan dat zich goed kan verspreiden 
onder mensen en waartegen het merendeel van de bevolking niet beschermd is. Een voorbeeld 
van een influenza virus waarvan op dit moment wordt gevreesd dat het zich in de toekomst onder 
mensen kan verspreiden, is het vogelgriepvirus (influenza A/H5N1 virus). Dit virus circuleert op dit 
moment voornamelijk in Zuidoost-Azië onder pluimvee en heeft daar al miljoenen kippen gedood 
sinds 1997. Daarnaast zijn er ook meer dan 500 mensen geïnfecteerd met dit virus waarvan on-
geveer 60% is overleden. Echter, dit virus is op dit moment nog niet in staat om zich goed onder 
mensen te verspreiden, maar de angst bestaat dat dit virus zich in de toekomst zo aanpast dat het 
wel efficiënt van mens tot mens kan worden overgedragen en op die manier voor miljoenen slach-
toffers zorgt. Deze angst heeft er toe geleid dat er veel onderzoek is en wordt gedaan naar dit in-
fluenza virus. Door goede surveillering van wilde vogels, het onderzoeken van de wijze waarop 
mensen ziek worden door infectie met dit virus of een influenza A virus van een ander subtype en 
door de zoektocht naar nieuwe vaccines en antivirale middelen wordt getracht te voorkomen dat 
dit virus in de toekomst miljoenen mensen doodt. 
In dit proefschrift worden twee onderdelen van het onderzoek naar de mogelijkheden van bes-
cherming van mensen tegen het influenza A/H5N1 virus beschreven. In hoofdstuk 2 wordt aan-
getoond in muizen dat eerdere infectie met een seizoensgriepvirus (influenza A/H3N2 virus) 
gedeeltelijke bescherming biedt tegen infectie met een vogelgriepvirus. Naar deze bescherming, 
die heterosubtypische immuniteit genoemd wordt, is al vele jaren onderzoek gedaan door middel 
van experimenten met proefdieren, maar ook in mensen zijn er duidelijke aanwijzingen dat deze 
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bescherming een rol van betekenis speelt. Verder is gebleken dat deze heterosubtypische immu-
niteit niet leidt tot steriele immuniteit. Dit betekent dat het virus nog wel in staat is om de cellen 
van de gastheer te infecteren en te repliceren, en dus ziekte niet voorkomen kan worden, maar dat 
de ziekteverschijnselen wel veel minder ernstig zijn. Voornamelijk van een bepaald celtype van het 
immuunsysteem, de cytotoxische T cellen (CTL), wordt gedacht dat ze een belangrijke rol spelen 
in de bescherming tegen dit virus aangezien ze de geconserveerde onderdelen van het influenza 
virus kunnen herkennen dat gepresenteerd wordt door cellen die door het virus geïnfecteerd zijn. 
Door deze cellen op te herkennen en op te ruimen kunnen ze voorkomen dat het virus zich verder 
verspreidt. Ook de in hoofdstuk 2 beschreven heterosubtypische immuniteit correleerde met de 
aanwezigheid van virus-specifieke CTL, terwijl geen antilichamen tegen het influenza A/H5N1 virus 
werden gevonden. In grote lijnen werden dezelfde resultaten waargenomen in fretten, een dier-
soort waarvan wordt gedacht dat de wijze van ziekteverwekken van influenza A virussen vergeli-
jkbaar is met die van de mens. Deze studie staat beschreven in hoofdstuk 5. Naar aanleiding van 
de bevindingen in hoofdstukken 2 en 5 en studies gedaan door andere onderzoekers is in hoofd-
stukken 3, 4 en 5 gekeken of vaccinatie met een geïnactiveerd vaccin mogelijk zou interfereren 
met de heterosubtypische immuniteit opgewerkt door infectie met een seizoensgriepvirus. Dit is 
van groot belang aangezien het sinds een paar jaar door volksgezondheidsinstituten van een aan-
tal landen (waaronder de Verenigde Staten en een aantal Europese landen) wordt aanbevolen om 
alle gezonde kinderen te vaccineren tegen seizoensgriep, om te voorkomen dat kinderen ernstig 
ziek worden als gevolg van infectie met het seizoensgriepvirus. Deze vaccinatie kan een toege-
voegde waarde hebben voor de gezondheid van alle kinderen, maar in theorie zou het ook kunnen 
zijn dat vaccinatie de ontwikkeling van goede CTL reacties en dus heterosubtypische immuniteit 
voorkomt. Dit zou belangrijke implicaties kunnen hebben met het oog op een toekomstige pand-
emie van bijvoorbeeld het vogelgriepvirus. In hoofdstuk 3 en 4 worden studies beschreven in het 
muismodel waarin wordt aangetoond wordt dat vaccineren met een vaccin tegen seizoensgriep de 
ontwikkeling van heterosubtypische immuniteit tegen influenza A/H5N1 virussen voorkomt. Ook 
het voorkomen van deze heterosubtypische immuniteit correleerde met de afwezigheid van CTL 
immuniteit in de niet beschermde dieren. Naar aanleiding van deze studies in muizen is er ook in 
fretten een vergelijkbare studie gedaan zoals beschreven in hoofdstuk 5. Aangezien fretten gevoe-
lig zijn voor humane influenza virussen en klinische verschijnselen ontwikkelen die lijken op die 
van de mens na infectie, wordt aan het frettenmodel veel waarde gehecht. Ook in deze diersoort 
werd aangetoond dat vaccinatie tegen seizoensgriep de ontwikkeling van heterosubtypische im-
muniteit door infectie met een seizoensgriepvirus in een deel van de dieren voorkwam. 
De resultaten beschreven in hoofstukken 2-5 laten zien dat het doormaken van een natuurlijke in-
fectie een grote invloed heeft op de ontwikkeling van heterosubtypische immuniteit. Daarom, en 
om een goed vaccinatiebeleid voor kinderen te kunnen bepalen, is het van groot belang om te 
weten op welke leeftijd kinderen een infectie met een influenza virus doormaken. Om dit te onder-
zoeken, is er gebruik gemaakt van bloedmonsters van kinderen die verzameld zijn tijdens het een 
landelijke studie van het RIVM, het Pienter2-project. Door middel van het uitvoeren van de hemag-
glutinatie remmingstest is de aanwezigheid van antilichamen tegen verschillende stammen van 
het influenza A en B virus in bloedmonsters van kinderen tussen de 0 en 7 jaar oud beoordeeld in 
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hoofdstuk 6. Een relatief groot gedeelte van de kinderen tussen de 1 en 6 maanden oud bezat an-
tilichamen tegen een of meerdere influenzavirussen, waarschijnlijk antilichamen afkomstig van de 
moeder aangezien relatief hoge titers waargenomen tegen influenza virusstammen van enkele jar-
en geleden die circuleerden toen de kinderen nog niet geboren waren. Lagere percentages werden 
gevonden in kinderen van 7 maanden tot 1 jaar oud. Vanaf een leeftijd van 1 jaar werden geleidelijk 
hogere seroprevalenties van antilichamen tegen influenza virussen gevonden totdat in alle mon-
sters van kinderen van 6 jaar oud antilichamen werden gevonden tegen minimaal één influenza A 
virus subtype. Dit geeft aan dat een relatief groot aandeel van de jonge kinderen nog geen infectie 
met een influenza virus heeft doorgemaakt, wat belangrijke gevolgen kan hebben voor de aan-
wezigheid van heterosubtypische immuniteit in deze kwetsbare leeftijdsgroep. 
Na de verkregen resultaten in proefdieren is het natuurlijk van belang om vast te stellen of het-
zelfde effect ook in mensen aanwezig is. Daarom worden in hoofdstuk 7 van dit proefschrift de 
influenza A  virus-specifieke antilichamen en T cel reacties van kinderen met cystic fibrosis (taaisli-
jmziekte) die jaarlijks zijn gevaccineerd tegen influenza vergeleken met die van ongevaccineerde 
gezonde kinderen. Uit dit onderzoek werd duidelijk dat gevaccineerde kinderen met cystic fibrosis 
een wat bredere antilichaamrespons hadden en een vergelijkbare respons van T helper cellen. Ech-
ter, de leeftijdsafhankelijke stijging van de virus-specifieke CTL respons die waargenomen werd in 
gezonde kinderen, was niet aanwezig in de gevaccineerde kinderen. Hoewel niet uitgesloten kan 
worden dat dit veroorzaakt zou kunnen worden door een verschil in het immuunsysteem van deze 
twee groepen kinderen, is dit onwaarschijnlijk aangezien geen verschillen tussen de T helper cel 
responsen en de respons van CTL tegen een ‘superantigeen’ is waargenomen in kinderen ouder 
dan 5 jaar. De resultaten uit dit onderzoek bevestigen dus eerdere conclusies uit de studies met 
muizen en tonen aan dat ook in kinderen vaccinatie de ontwikkeling van virus-specifieke CTL reac-
ties remt. Dit betekent dat er een mogelijk nadeel kleeft aan de aanbeveling van een aantal volks-
gezondheidsinstituten om alle gezonde kinderen te vaccineren tegen seizoensgriep. Echter, voor 
gesteld kan worden dat vaccinatie daadwerkelijk een negatief effect heeft op de aanwezigheid van 
heterosubtypische immuniteit zijn grotere epidemiologische studies met twee groepen gezonde 
kinderen noodzakelijk. Duidelijk is wel dat het belangrijk is dat er onderzoek wordt gedaan naar de 
ontwikkeling van vaccins die bescherming bieden tegen meerdere subtypen van het influenza A 
virus, al was het maar om te gebruiken in de tijd tussen de start van een pandemie en het moment 
dat er adequate vaccines beschikbaar zijn. Omdat deze vaccines (nog) niet beschikbaar zijn, is het 
gebruik van levend geattenueerde vaccins mogelijk een goed alternatief. Dat dit onderzoek niet 
bedoeld is om het vaccineren van kinderen met een onderliggende aandoening te af te wijzen mag 
duidelijk zijn, het risico dat deze kinderen ernstig ziek worden van de seizoensgriep is vele malen 
groter dan het risico dat deze kinderen minder goed beschermd zijn tegen een nieuw pandemisch 
virus. Ook zijn onze bevindingen specifiek van toepassing voor het influenza virus en gelden dus 
niet voor alle andere virussen uit het rijksvaccinatieprogramma. Voor het advies om kinderen te 
vaccineren is de leeftijd van groot belang, aangezien uit hoofdstuk 6 blijkt dat alle kinderen ouder 
dan zes jaar antilichamen hebben tegen seizoensgriepvirussen en ook CTL immuniteit hebben 
ontwikkeld zoals blijkt uit hoofdstuk 7. Vooral voor jonge kinderen, die nog niet eerder een infectie 
hebben doorgemaakt is het goed afwegen van de voor- en nadelen dus van groot belang.
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Naast dit onderzoek naar de rol van vaccinatie op de aanwezigheid van heterosubtypische immu-
niteit, hebben we ook onderzoek gedaan naar vaccins die immuniteit tegen het influenza A/H5N1 
virus induceren. Een aantal zaken zijn erg belangrijk bij de ontwikkeling van vaccins tegen het in-
fluenza A/H5N1 virus. Ze moeten in staat zijn om te beschermen tegen meerdere varianten van het 
influenza A/H5N1 virus bij voorkeur door middel van een enkele vaccinatie, ze moeten veilig zijn en 
weinig tot geen bijwerkingen geven. Om bescherming door middel van een enkele vaccinatie mo-
gelijk te maken en om de immuunrespons te verbreden, wordt er op dit moment veel onderzoek 
gedaan naar hulpstoffen die het immuunsysteem aspecifiek stimuleren om toe te voegen aan vac-
cins, de zogenaamde adjuvans. In hoofdstukken 8 en 9 worden studies beschreven waarin de im-
munogeniciteit en de beschermende werking van een heel geïnactiveerde influenza A/H5N1 virus 
vaccin in combinatie met het nieuwe adjuvant CoVaccine HT™ wordt geëvalueerd. Uit deze studies 
blijkt dat het nieuwe vaccine immunogeen is in zowel muizen als fretten en dat het in staat is om 
al na één vaccinatie met een lage dosis antigeen fretten te beschermen tegen twee verschillende 
varianten van het influenza A/H5N1 virus. Verder blijkt ook dat het adjuvans CoVaccine HT™ in vitro 
bij humane dendritische cellen de secretie van cytokines stimuleert door middel van het binden 
aan Toll like receptor-4. Aangezien dendritische cellen een belangrijke rol spelen in het immuunsys-
teem, zou dit er op kunnen wijzen dat dit adjuvant ook in mensen het immuunsysteem zou kunnen 
stimuleren. Meer onderzoek is echter noodzakelijk om dit aan te tonen.
Onderzoek naar nieuwe vaccins of naar de gevolgen van vaccinatie is onmogelijk zonder proefdie-
ren. Voor onderzoek naar influenza virussen worden verschillende proefdiermodellen gebruikt die 
ook in dit proefschrift worden beschreven, zoals de muis en de fret. Aangezien fretten gevoelig zijn 
voor humane influenza virussen en klinische verschijnselen ontwikkelen die lijken op die van de 
mens na infectie, wordt vooral aan het frettenmodel veel waarde gehecht. In hoofstuk 10 worden 
twee manieren waarop fretten experimenteel geïnfecteerd kunnen worden met een influenza A/
H5N1 virus met elkaar vergeleken. Uit de resultaten van dit onderzoek blijkt dat infectie van fretten 
met een influenza A/H5N1 virus via de neus voornamelijk tot ziekte van de hersenen leidt, terwijl 
infectie van fretten met hetzelfde virus in de luchtpijp voornamelijk leidt tot  ziekte van de longen. 
Aangezien influenza A/H5N1 virussen bij mensen vooral ziekte van de longen veroorzaken, is het 
wellicht beter voor vaccinonderzoek om fretten te infecteren via de luchtpijp dan via de neus. 
Samenvattend tonen we in dit proefschrift aan dat vaccinatie tegen seizoensgriep mogelijk een 
negatief effect heeft op de ontwikkeling van heterosubtypische immuniteit tegen influenza A/
H5N1 virussen en dat een enkele vaccinatie met het nieuwe adjuvans CoVaccine HT™ in combina-
tie met een influenza A/H5N1 vaccin goede bescherming biedt tegen challenge-infectie in fretten. 
Beide bevindingen zijn van belang voor de voorbereiding op een eventuele nieuwe pandemie 
veroorzaakt door het influenza A/H5N1 virus of een ander influenza A virus.
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Workshops
Workshop Writing Succesful Grant Proposals (MolMed)     
Masterclass Prof. Rino Rappuoli (Novartis Vaccines & Diagnostics)  AMC, Amsterdam  
(Inter)national conferences
Symposium Post-Infectious Diseases (Oct 4-5)     
12th MolMed day, Rotterdam (Feb 6)
Dutch Annual Virology Symposium, Amsterdam  (March 7)    
3th European Influenza Conference (ESWI), Villamoura, Portugal (Sept 14-17)   
13th MolMed day, Rotterdam (Feb 5)      
Dutch Annual Virology Symposium, Amsterdam (March 6)    
5th Orthomyxovirus Conference, Freiburg, Germany (Sept 9-12)     
Vaccine symposium, Utrecht (Nov 19)      
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Rogier Bodewes was born on March 10, 1981 in Delft, the Netherlands. In 
1999, he finished high school (VWO) at the I.S. Westland in ‘s-Gravenzande 
and started to study Veterinary Medicine at Utrecht University from which he 
graduated as a doctor in veterinary medicine in 2007. During this study, he 
did an extended research project at the Department of Virology, ErasmusMC, 
Rotterdam entitled “Crossprotection mediated by cytototoxic T cells in and 
influenza-mouse model” and performed an externship at the Virology Divi-
sion of the Faculty of Veterinary Medicine, Utrecht University and clinical rotations  at the Depart-
ment of Pathology, UC Davis School of Veterinary Medicine, USA. During the last year of his clinical 
rotations, he focused on companion animals medicine. In 2007 he started as a PhD student at the 
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Pienter 2 project: resultaten tot nu toe, Bilthoven (March 30)   
Vaccine symposium, Utrecht (Nov 26)      
Presentations
In vitro analysis of the human immune response to inactivated influenza vaccine and Co-
Vaccine HT™ (EU-project FluVac meeting , London, United Kingdom, 2008)   
Evaluation of WIV influenza A/H5N1 virus vaccine and CoVaccine HT™ in vitro and in vivo 
(EU-project FluVac meeting , London, United Kingdom, 2009)   
Primary infection with influenza A/H3N2 induces heterosubtypic immunity against lethal 
challenge with influenza A/H5N1 in mice (3th European Influenza Conference, 2008)  
Cytotoxic T lymphocytes in heterosubtypic immunity against influenza A viruses (13th 
MolMed Day, 2009) 
Vaccination against human influenza A/H3N2 virus prevents the induction of hetero-
subtypic immunity against lethal infection with avian influenza A/H5N1 virus (5th Ortho-
myxovirus Conference, 2009)  
Vaccination against human influenza A/H3N2 virus prevents the induction of heterosub-
typic immunity against lethal infection with avian influenza A/H5N1 virus (Vaccine sym-
posium, 2009)   
Seroprevalentie van influenza in kinderen tijdens niet-pandemische seizoenen (Pienter 2 
middag, 2010) 
Impact of vaccination against seasonal influenza on the development of heterosubtypic 
immunity against influenza A/H5N1 (Masterclass Prof. Rino Rappuoli, 2010)   
Effect of annual vaccination against influenza on the development of virus-specific CD8+ 
T  cell immunity (Vaccine symposium, 2010) 
Travel grants
ESWI Young Scientist travel grant (3th European Influenza Conference)
FEMS Travel grant for Young scientists (5th Orthomyxovirus Conference)
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